

Global burden of NAFLD and NASH: trends, predictions

Nature Reviews Gastroenterology and Hepatology
15, 11-20

DOI: [10.1038/nrgastro.2017.109](https://doi.org/10.1038/nrgastro.2017.109)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Long-range hypoxia signaling in NAFLD. <i>Nature Medicine</i> , 2017, 23, 1251-1252.	15.2	2
2	The Stomach as an Endocrine Organ: Expression of Key Modulatory Genes and Their Contribution to Obesity and Non-alcoholic Fatty Liver Disease (NAFLD). <i>Current Gastroenterology Reports</i> , 2018, 20, 24.	1.1	4
3	NRF2 Induction for NASH Treatment: A New Hope Rises. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 422-423.	2.3	6
4	Reply. <i>Hepatology</i> , 2018, 68, 390-390.	3.6	0
5	Genecriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 301-311.	1.9	95
6	Time to step up the fight against NAFLD. <i>Hepatology</i> , 2018, 67, 2068-2071.	3.6	29
7	Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. <i>Liver International</i> , 2018, 38, 47-51.	1.9	297
8	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 166-170.	1.3	52
9	Two drinks per day does not take your fatty liver away. <i>Hepatology</i> , 2018, 67, 2072-2073.	3.6	2
10	Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. <i>International Journal of Cardiology</i> , 2018, 265, 162-168.	0.8	41
11	Dietary carbohydrates and fatty liver disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2018, 21, 277-282.	1.3	51
12	The epidemiology of nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2018, 11, 92-94.	1.0	64
13	Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States. <i>Liver Transplantation</i> , 2018, 24, 1398-1410.	1.3	35
15	Systematic evaluation of phenolic compounds and protective capacity of a new mulberry cultivar J33 against palmitic acid-induced lipotoxicity using a simulated digestion method. <i>Food Chemistry</i> , 2018, 258, 43-50.	4.2	67
16	Editorial: NAFLD in Asia—clinical associations with advanced disease become clearer. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1035-1036.	1.9	1
17	NAFLD and cancer: More cause for concern?. <i>Journal of Hepatology</i> , 2018, 68, 10-12.	1.8	5
18	The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. <i>Journal of Hepatology</i> , 2018, 68, 251-267.	1.8	116
20	The evolving role of liver biopsy in non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2018, 17, 899-902.	0.6	21

#	ARTICLE	IF	CITATIONS
21	Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. <i>Annals of Hepatology</i> , 2018, 17, 11-13.	0.6	4
22	Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 262-279.	1.8	160
23	miR-122-regulated metabolic circuits: micro-management of lipid metabolism in the human liver. <i>Non-coding RNA Investigation</i> , 2018, 2, 45-45.	0.6	1
24	Non-alcoholic fatty liver disease and the risk of urolithiasis. <i>Medicine (United States)</i> , 2018, 97, e12092.	0.4	17
26	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1736-1788.	6.3	4,989
27	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1789-1858.	6.3	8,569
28	Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2018, 9, 2418.	2.2	31
29	Genomic and Transcriptomic Analysis of Hypercholesterolemic Rabbits: Progress and Perspectives. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3512.	1.8	11
30	Serotonin signals through a gut-liver axis to regulate hepatic steatosis. <i>Nature Communications</i> , 2018, 9, 4824.	5.8	98
31	BET Inhibition Improves NASH and Liver Fibrosis. <i>Scientific Reports</i> , 2018, 8, 17257.	1.6	27
32	Suppressing NLRP2 expression accelerates hepatic steatosis: A mechanism involving inflammation and oxidative stress. <i>Biochemical and Biophysical Research Communications</i> , 2018, 507, 22-29.	1.0	13
33	Surgical treatment of obesity. <i>F1000Research</i> , 2018, 7, 617.	0.8	26
34	Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in <i>Gynostemma pentaphylla</i> (Thunb.) Makino treated mice. <i>Nutrition and Metabolism</i> , 2018, 15, 86.	1.3	26
35	Exogenous (Pomegranate Juice) or Endogenous (Paraoxonase1) Antioxidants Decrease Triacylglycerol Accumulation in Mouse Cardiovascular Disease-Related Tissues. <i>Lipids</i> , 2018, 53, 1031-1041.	0.7	6
36	Modulation of Gut Microbiota by <i>Lonicera caerulea</i> L. Berry Polyphenols in a Mouse Model of Fatty Liver Induced by High Fat Diet. <i>Molecules</i> , 2018, 23, 3213.	1.7	76
37	Oncogenic Activation of Nrf2, Though as a Master Antioxidant Transcription Factor, Liberated by Specific Knockout of the Full-Length Nrf1 that Acts as a Dominant Tumor Repressor. <i>Cancers</i> , 2018, 10, 520.	1.7	42
38	You are what you wheat: effects of a whole-wheat diet compared with a refined-wheat diet on hepatic steatosis. <i>American Journal of Clinical Nutrition</i> , 2018, 108, 1162-1163.	2.2	0
39	Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. <i>Hepatology Communications</i> , 2018, 2, 1227-1234.	2.0	20

#	ARTICLE	IF	CITATIONS
40	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1109-1116.	1.9	88
41	Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3655-3667.	1.8	18
42	Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress. <i>British Journal of Pharmacology</i> , 2018, 175, 4480-4495.	2.7	21
43	Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study. <i>PLoS ONE</i> , 2018, 13, e0204308.	1.1	17
44	Dissociation of Fatty Liver and Insulin Resistance in I148M PNPLA3 Carriers: Differences in Diacylglycerol (DAG) FA18:1 Lipid Species as a Possible Explanation. <i>Nutrients</i> , 2018, 10, 1314.	1.7	33
45	Non-Alcoholic Fatty Liver Disease in Overweight Children: Role of Fructose Intake and Dietary Pattern. <i>Nutrients</i> , 2018, 10, 1329.	1.7	48
46	Treatment of NASH with Gastric Bypass. <i>Current Gastroenterology Reports</i> , 2018, 20, 49.	1.1	10
47	An update on the recent advances in antifibrotic therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1143-1152.	1.4	60
48	The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality. <i>Current Hepatology Reports</i> , 2018, 17, 336-344.	0.4	2
49	When to Initiate Weight Loss Medications in the NAFLD Population. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 91.	1.0	11
50	Insulin Resistance in HIV-Patients: Causes and Consequences. <i>Frontiers in Endocrinology</i> , 2018, 9, 514.	1.5	34
51	Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. <i>Endocrine Reviews</i> , 2018, 39, 629-663.	8.9	154
52	DNA methylation biomarkers for hepatocellular carcinoma. <i>Cancer Cell International</i> , 2018, 18, 140.	1.8	47
53	Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. <i>Frontiers in Physiology</i> , 2018, 9, 1256.	1.3	24
54	Hypothyroidism and nonalcoholic fatty liver disease – a chance association?. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	15
55	Hypoxia-Inducible Factor Prolyl 4-Hydroxylases and Metabolism. <i>Trends in Molecular Medicine</i> , 2018, 24, 1021-1035.	3.5	34
56	The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. <i>Current Hepatology Reports</i> , 2018, 17, 345-349.	0.4	3
58	Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. <i>Pharmaceuticals</i> , 2018, 11, 104.	1.7	60

#	ARTICLE	IF	CITATIONS
59	A Modular Ionophore Platform for Liver-Directed Copper Supplementation in Cells and Animals. <i>Journal of the American Chemical Society</i> , 2018, 140, 13764-13774.	6.6	40
60	Editorial: hepatocellular carcinoma in non- ϵ irrhotic <sc>NASH</sc>â€”a troubling reality. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1021-1023.	1.9	1
61	SRY-Box Containing Gene 4 Promotes Liver Steatosis by Upregulation of SREBP-1c. <i>Diabetes</i> , 2018, 67, 2227-2238.	0.3	13
62	Obesity-induced upregulation of miR-361-5p promotes hepatosteatosis through targeting Sirt1. <i>Metabolism: Clinical and Experimental</i> , 2018, 88, 31-39.	1.5	12
63	Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. <i>Scientific Reports</i> , 2018, 8, 13638.	1.6	14
64	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. <i>Atherosclerosis</i> , 2018, 278, 82-90.	0.4	27
65	Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. <i>Annals of Gastroenterology</i> , 2018, 31, 288-295.	0.4	54
66	Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. <i>Frontiers in Endocrinology</i> , 2018, 9, 485.	1.5	49
67	High-fat diet consumption reduces hepatic folate transporter expression via nuclear respiratory factor-1. <i>Journal of Molecular Medicine</i> , 2018, 96, 1203-1213.	1.7	15
68	Emerging therapeutic potential of glycine in cardiometabolic diseases: dual benefits in lipid and glucose metabolism. <i>Current Opinion in Lipidology</i> , 2018, 29, 428-432.	1.2	15
69	High-Content Screening of a Taiwanese Indigenous Plant Extract Library Identifies <i>Syzygium simile</i> leaf Extract as an Inhibitor of Fatty Acid Uptake. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2130.	1.8	11
70	Statins in liver disease: not only prevention of cardiovascular events. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 743-744.	1.4	5
71	Morbid obesity: potential effects of hormonal contraception. <i>Contraception</i> , 2018, 98, 174-180.	0.8	7
72	Towards a definite mouse model of NAFLD. <i>Journal of Hepatology</i> , 2018, 69, 272-274.	1.8	23
73	Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-9.	0.8	14
74	Reduction of Liver Span and Parameters of Inflammation in Nonalcoholic Fatty Liver Disease Patients Treated with Lycosome Formulation of Phosphatidylcholine: A Preliminary Report. <i>International Journal of Chronic Diseases</i> , 2018, 2018, 1-7.	1.9	3
75	Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 87, 1-12.	1.5	80
76	Secretory Malfunction. , 2018, , 117-154.		0

#	ARTICLE	IF	CITATIONS
77	IRE1 β aggravates ischemia reperfusion injury of fatty liver by regulating phenotypic transformation of kupffer cells. <i>Free Radical Biology and Medicine</i> , 2018, 124, 395-407.	1.3	32
78	Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 831-841.	1.5	20
79	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. <i>Cell Death and Disease</i> , 2018, 9, 620.	2.7	90
80	Recent advances in understanding and managing non-alcoholic fatty liver disease. <i>F1000Research</i> , 2018, 7, 720.	0.8	37
81	Ideal Cardiovascular Health Is Inversely Associated with Nonalcoholic Fatty Liver Disease: A Prospective Analysis. <i>American Journal of Medicine</i> , 2018, 131, 1515.e1-1515.e10.	0.6	26
82	Impaired Adipogenesis and Dysfunctional Adipose Tissue in Human Hypertrophic Obesity. <i>Physiological Reviews</i> , 2018, 98, 1911-1941.	13.1	285
83	Plasma trans-fatty acid and risk of nonalcoholic fatty liver disease: New data from National Health and Nutrition Examination Survey (NHANES). <i>International Journal of Cardiology</i> , 2018, 272, 329-330.	0.8	3
84	Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. <i>Hepatology</i> , 2018, 68, 2405-2412.	3.6	39
85	Key Inflammatory Processes in Human NASH Are Reflected in Ldlr $^{-/-}$.Leiden Mice: A Translational Gene Profiling Study. <i>Frontiers in Physiology</i> , 2018, 9, 132.	1.3	35
86	Bile Acids Activated Receptors Regulate Innate Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 1853.	2.2	334
87	Link between plasma trans-fatty acid and fatty liver is moderated by adiposity. <i>International Journal of Cardiology</i> , 2018, 272, 316-322.	0.8	16
88	Ablation of carotenoid cleavage enzymes (BCO1 and BCO2) induced hepatic steatosis by altering the farnesoid X receptor/miR-34a/sirtuin 1 pathway. <i>Archives of Biochemistry and Biophysics</i> , 2018, 654, 1-9.	1.4	27
89	Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 47.	0.7	18
90	The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. <i>Medical Sciences (Basel)</i> , 2018, 5, 15.	1.3	15
91	Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease. <i>Methods and Protocols</i> , 2018, 1, 21.	0.9	14
92	Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation. <i>Journal of Physiology and Biochemistry</i> , 2018, 74, 503-510.	1.3	27
93	Future trends in the treatment of non-alcoholic steatohepatitis. <i>Pharmacological Research</i> , 2018, 134, 289-298.	3.1	54
94	Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2018, 28, 588-604.e5.	7.2	180

#	ARTICLE	IF	CITATIONS
95	Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers. <i>Scientific Reports</i> , 2018, 8, 10606.	1.6	52
96	miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. <i>PLoS ONE</i> , 2018, 13, e0200847.	1.1	44
97	Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease. <i>Toxicology</i> , 2018, 410, 199-213.	2.0	38
98	Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	15
99	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018, 69, 1365-1370.	1.8	51
100	The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). <i>Non-coding RNA</i> , 2018, 4, 18.	1.3	42
101	Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Thyroid</i> , 2018, 28, 1270-1284.	2.4	87
102	Curative effect of arjunolic acid from <i>Terminalia arjuna</i> in non-alcoholic fatty liver disease models. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 979-988.	2.5	24
103	Increased Serum Uric Acid over five years is a Risk Factor for Developing Fatty Liver. <i>Scientific Reports</i> , 2018, 8, 11735.	1.6	31
104	Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release. <i>Cellular Immunology</i> , 2018, 332, 111-120.	1.4	87
105	Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. <i>Scientific Reports</i> , 2018, 8, 11874.	1.6	54
106	Simple Scores of Fibrosis and Mortality in Patients with NAFLD: A Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2018, 7, 219.	1.0	28
107	Inflexion of the curve: Hepatitis C's waning role in liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 727-728.	1.3	0
108	Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 536-554.	8.2	158
109	B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD). <i>Free Radical Biology and Medicine</i> , 2018, 124, 249-259.	1.3	81
110	Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region. <i>Hepatology</i> , 2019, 69, 498-512.	3.6	40
111	Pediatric nonalcoholic fatty liver disease. <i>Jornal De Pediatria</i> , 2019, 95, 4-6.	0.9	4
112	Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. <i>Medicinal Research Reviews</i> , 2019, 39, 328-348.	5.0	105

#	ARTICLE	IF	CITATIONS
113	The role of IFN in the development of NAFLD and NASH. <i>Cytokine</i> , 2019, 124, 154519.	1.4	31
114	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	2.4	559
115	ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. <i>Hepatology</i> , 2019, 69, 1075-1086.	3.6	174
116	Reappraisal of attenuated insulin sensitivity in the evolution of non-alcoholic fatty liver disease. <i>European Journal of Clinical Nutrition</i> , 2019, 73, 770-775.	1.3	3
117	Scoparone alleviates inflammation, apoptosis and fibrosis of non-alcoholic steatohepatitis by suppressing the TLR4/NF- κ B signaling pathway in mice. <i>International Immunopharmacology</i> , 2019, 75, 105797.	1.7	47
118	Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	3
119	DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2791.	1.2	11
120	iPla2 β Deficiency Suppresses Hepatic ER UPR, Fxr, and Phospholipids in Mice Fed with MCD Diet, Resulting in Exacerbated Hepatic Bile Acids and Biliary Cell Proliferation. <i>Cells</i> , 2019, 8, 879.	1.8	6
121	Are Lifestyle Therapies Effective for NAFLD Treatment?. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 701-709.	3.1	103
122	A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation. <i>Lab on A Chip</i> , 2019, 19, 3022-3031.	3.1	35
123	NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 877.	1.6	86
124	miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. <i>Molecular Metabolism</i> , 2019, 29, 40-54.	3.0	35
125	Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 497-505.	0.4	24
126	Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. <i>Journal of the American College of Nutrition</i> , 2019, 38, 633-639.	1.1	13
127	Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 1422-1437.	1.2	37
128	A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1900487.	1.5	32
129	The acidic pathway of bile acid synthesis: Not just an alternative pathway. <i>Liver Research</i> , 2019, 3, 88-98.	0.5	88
130	Recomendaciones para la detección, diagnóstico y seguimiento de los pacientes con enfermedad por hígado graso no alcohólico en atención primaria y hospitalaria. <i>Medicina Clínica</i> , 2019, 153, 169-177.	0.3	18

#	ARTICLE	IF	CITATIONS
131	Independent Association of Physical Activity with Nonalcoholic Fatty Liver Disease and Alanine Aminotransferase Levels. <i>Journal of Clinical Medicine</i> , 2019, 8, 1013.	1.0	13
132	YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15184-15193.	3.3	24
133	Sex, Age, and BMI Modulate the Association of Physical Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994 Cases Observed at Shuguang Hospital, China. <i>BioMed Research International</i> , 2019, 2019, 1-7.	0.9	15
134	Daily Aspirin Use Reduces Risk of Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease, Providing New Uses for an Old Drug. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2651-2653.	2.4	3
135	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 802-810.	1.8	39
136	Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice. <i>Marine Drugs</i> , 2019, 17, 391.	2.2	43
137	Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. <i>Hepatology</i> , 2019, 70, 1424-1436.	3.6	73
138	Lutein attenuates oxidative stress and inhibits lipid accumulation in free fatty acids-induced HepG2 cells by activating the AMPK pathway. <i>Journal of Functional Foods</i> , 2019, 60, 103445.	1.6	23
139	Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. <i>Journal of Hepatology</i> , 2019, 71, 823-833.	1.8	120
140	Influence of Fat on Differential Receptor Interacting Serine/Threonine Protein Kinase 1 Activity Leading to Apoptotic Cell Death in Murine Liver Ischemia Reperfusion Injury Through Caspase 8. <i>Hepatology Communications</i> , 2019, 3, 925-942.	2.0	6
141	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 1012-1021.	1.8	128
142	Associations Between Body Fat, Muscle Mass, and Nonalcoholic Fatty Liver Disease: A Population-Based Study. <i>Hepatology Communications</i> , 2019, 3, 1061-1072.	2.0	27
143	Obesity and Hepatocarcinogenesis. , 2019, , 87-102.		0
144	Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review. <i>Antioxidants</i> , 2019, 8, 229.	2.2	127
145	Health Benefits of Carotenoids: A Role of Carotenoids in the Prevention of Non-Alcoholic Fatty Liver Disease. <i>Preventive Nutrition and Food Science</i> , 2019, 24, 103-113.	0.7	41
146	Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression. <i>Frontiers in Endocrinology</i> , 2019, 10, 434.	1.5	23
147	<i>Dendrobii Officinalis</i> , a traditional Chinese edible and officinal plant, accelerates liver recovery by regulating the gut-liver axis in NAFLD mice. <i>Journal of Functional Foods</i> , 2019, 61, 103458.	1.6	27
148	An interaction between MKL1, BRG1, and C/EBP β mediates palmitate induced CRP transcription in hepatocytes. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2019, 1862, 194412.	0.9	36

#	ARTICLE	IF	CITATIONS
149	The combination of Ilexhainanoside D and Ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease. <i>Phytomedicine</i> , 2019, 63, 153039.	2.3	19
150	Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 723-730.	0.4	46
151	Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease. <i>JAMA Internal Medicine</i> , 2019, 179, 1262.	2.6	159
152	Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481985847.	1.4	22
153	Treatment of Fatty Liver Disease—Time to Implement Common Sense Measures. <i>JAMA Internal Medicine</i> , 2019, 179, 1272.	2.6	1
154	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	3.6	197
155	Assessing the disease burden of non-alcoholic fatty liver disease in the real world — big data and big numbers. <i>BMC Medicine</i> , 2019, 17, 123.	2.3	4
156	The Effects of Hepatic Steatosis on the Natural History of HBV Infection. <i>Clinics in Liver Disease</i> , 2019, 23, 433-450.	1.0	22
157	The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 793-801.	1.8	1,253
158	NAFLD in children: new genes, new diagnostic modalities and new drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 517-530.	8.2	199
159	Augmented intelligence with natural language processing applied to electronic health records for identifying patients with non-alcoholic fatty liver disease at risk for disease progression. <i>International Journal of Medical Informatics</i> , 2019, 129, 334-341.	1.6	29
160	Melatonin safeguards against fatty liver by antagonizing TRAFs-mediated ASK1 deubiquitination and stabilization in a $\text{I}^2\text{A}^{\text{R}}$ -dependent manner. <i>Journal of Pineal Research</i> , 2019, 67, e12611.	3.4	39
161	Creosote bush-derived NDGA attenuates molecular and pathological changes in a novel mouse model of non-alcoholic steatohepatitis (NASH). <i>Molecular and Cellular Endocrinology</i> , 2019, 498, 110538.	1.6	8
162	Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-12.	1.9	43
163	Acanthosis Nigrans in the Knuckles of Infants: A Novel Clinical Marker of High Metabolic Risk. <i>Diabetes Therapy</i> , 2019, 10, 2169-2181.	1.2	3
164	Prevalence and risk factors of non-alcoholic fatty liver disease in southwest Iran: a population-based case-control study. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 224-231.	0.6	16
165	A Lipidomic Analysis of Docosahexaenoic Acid (22:6, $\text{I}^{\%}\text{3}$) Mediated Attenuation of Western Diet Induced Nonalcoholic Steatohepatitis in Male Ldlr $^{-/-}$ Mice. <i>Metabolites</i> , 2019, 9, 252.	1.3	19
166	Hepatocellular carcinoma and non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2019, 13, 688-694.	1.9	56

#	ARTICLE	IF	CITATIONS
167	Characterization of the Therapeutic Profile of Albiflorin for the Metabolic Syndrome. <i>Frontiers in Pharmacology</i> , 2019, 10, 1151.	1.6	11
168	Potential link between sugar consumption and ectopic fat. , 2019, , 73-90.		0
169	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4334.	1.2	21
170	Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. <i>Hepatology Communications</i> , 2019, 3, 1472-1481.	2.0	26
171	Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2019, 394, 2012-2024.	6.3	401
172	Proteomics—a new approach to identify targets and biomarkers for hepatocellular carcinoma?. <i>Biotarget</i> , 2019, 3, 6-6.	0.5	0
173	Sequential drug delivery for liver diseases. <i>Advanced Drug Delivery Reviews</i> , 2019, 149-150, 72-84.	6.6	7
174	NAFLD Histology: a Critical Review and Comparison of Scoring Systems. <i>Current Hepatology Reports</i> , 2019, 18, 473-481.	0.4	8
175	Mining Public Toxicogenomic Data Reveals Insights and Challenges in Delineating Liver Steatosis Adverse Outcome Pathways. <i>Frontiers in Genetics</i> , 2019, 10, 1007.	1.1	14
176	Multiple extraction conditions to produce phytochemical- and antioxidant-rich <i>Alternanthera sessilis</i> (red) extracts that attenuate lipid accumulation in steatotic HepG2 cells. <i>Food Bioscience</i> , 2019, 32, 100489.	2.0	14
177	Unravelling fibrosis using single-cell transcriptomics. <i>Current Opinion in Pharmacology</i> , 2019, 49, 71-75.	1.7	8
178	FoxO3 regulates hepatic triglyceride metabolism via modulation of the expression of sterol regulatory-element binding protein 1c. <i>Lipids in Health and Disease</i> , 2019, 18, 197.	1.2	14
179	Characterization of Cellular Sources and Circulating Levels of Extracellular Vesicles in a Dietary Murine Model of Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2019, 3, 1235-1249.	2.0	40
180	Self-Healing Properties of PDMS Elastomers via Guanine and Cytosine Base Pairs. <i>Macromolecular Chemistry and Physics</i> , 2019, 220, 1900280.	1.1	11
181	The association between clinically determined periodontal disease and prostate-specific antigen concentration in men without prostate cancer: the 2009–2010 National Health and Nutrition Examination Survey. <i>Cancer Causes and Control</i> , 2019, 30, 1293-1300.	0.8	4
182	Hepatic PKA inhibition accelerates the lipid accumulation in liver. <i>Nutrition and Metabolism</i> , 2019, 16, 69.	1.3	10
183	Modeling the natural history of fatty liver using lifestyle-related risk factors: Effects of body mass index (BMI) on the life-course of fatty liver. <i>PLoS ONE</i> , 2019, 14, e0223683.	1.1	5
184	The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. <i>Nutrients</i> , 2019, 11, 2543.	1.7	51

#	ARTICLE	IF	CITATIONS
185	Incidental hepatic steatosis in radiology reports: a survey of emergency department clinicians's™ perspectives and current practice. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 573-579.	0.9	4
186	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1100-1111.	1.9	27
187	Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH). <i>Cells</i> , 2019, 8, 1277.	1.8	27
188	Mastiha (<i>Pistacia lentiscus</i>) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1900927.	1.5	22
189	KLF15-activating Twist2 ameliorated hepatic steatosis by inhibiting inflammation and improving mitochondrial dysfunction via NF- κ B-FGF21 or SREBP1c-FGF21 pathway. <i>FASEB Journal</i> , 2019, 33, 14254-14269.	0.2	17
190	Tomatidine Reduces Palmitate-Induced Lipid Accumulation by Activating AMPK via Vitamin D Receptor-Mediated Signaling in Human HepG2 Hepatocytes. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1801377.	1.5	18
191	Body Mass Index and Unenhanced CT as a Predictor of Hepatic Steatosis in Potential Liver Donors. <i>Transplantation Proceedings</i> , 2019, 51, 2373-2378.	0.3	5
192	Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3104.	1.2	135
193	A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post-liver transplant patient. <i>Clinical Transplantation</i> , 2019, 33, e13700.	0.8	22
194	Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study. <i>PLoS ONE</i> , 2019, 14, e0221524.	1.1	26
195	Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-10.	0.6	18
196	Indole-3-Acetic Acid Alleviates Nonalcoholic Fatty Liver Disease in Mice via Attenuation of Hepatic Lipogenesis, and Oxidative and Inflammatory Stress. <i>Nutrients</i> , 2019, 11, 2062.	1.7	132
197	Obesity and liver cancer. <i>Annals of Hepatology</i> , 2019, 18, 810-815.	0.6	58
198	n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231987211.	1.1	17
199	Non-alcoholic fatty liver disease in lean individuals. <i>JHEP Reports</i> , 2019, 1, 329-341.	2.6	98
200	New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease. <i>Cells</i> , 2019, 8, 1062.	1.8	17
201	A Low Iron Diet Protects from Steatohepatitis in a Mouse Model. <i>Nutrients</i> , 2019, 11, 2172.	1.7	7
202	Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987804.	1.4	47

#	ARTICLE	IF	CITATIONS
203	Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2019, 13, 662-664.	1.9	10
204	A Changing Etiologic Scenario in Liver Transplantation: A Single-Center Cohort Study From Turkey. <i>Transplantation Proceedings</i> , 2019, 51, 2416-2419.	0.3	6
205	Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	44
206	Extracellular Matrix Remodeling of Adipose Tissue in Obesity and Metabolic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4888.	1.8	149
207	Hepatoprotective and anti-inflammatory effects of total flavonoids of Qu Zhi Ke (peel of Citrus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 58 <i>Phytomedicine</i> , 2019, 64, 153082.	2.3	65
208	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 169-177.	0.1	7
209	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3415.	1.2	90
210	A computationally designed binding mode flip leads to a novel class of potent tri-vector cyclophilin inhibitors. <i>Chemical Science</i> , 2019, 10, 542-547.	3.7	17
211	Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis. <i>Hepatology</i> , 2019, 70, 812-823.	3.6	30
212	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 23-30.	1.8	16
213	Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR- β) agonist and a glucagon-like peptide-1 analogue. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 926-933.	2.5	14
214	Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model. <i>Poultry Science</i> , 2019, 98, 2509-2521.	1.5	37
215	Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1036-1042.	0.4	36
216	Endoplasmic reticulum stress and liver diseases. <i>Liver Research</i> , 2019, 3, 55-64.	0.5	114
217	Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. <i>Liver International</i> , 2019, 39, 758-769.	1.9	75
218	Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation. <i>Nutrients</i> , 2019, 11, 1132.	1.7	21
219	Pediatric nonalcoholic fatty liver disease. <i>Jornal De Pediatria (Versão Em Português)</i> , 2019, 95, 4-6.	0.2	0
220	Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. <i>Handbook of Experimental Pharmacology</i> , 2019, 256, 325-357.	0.9	43

#	ARTICLE	IF	CITATIONS
221	A Human Liver-on-a-Chip Platform for Modeling Nonalcoholic Fatty Liver Disease. <i>Advanced Biology</i> , 2019, 3, e1900104.	3.0	50
222	Erythropoietin suppresses hepatic steatosis and obesity by inhibiting endoplasmic reticulum stress and upregulating fibroblast growth factor 21. <i>International Journal of Molecular Medicine</i> , 2019, 44, 469-478.	1.8	7
223	TNF α -Mediated Necroptosis Aggravates Ischemia-Reperfusion Injury in the Fatty Liver by Regulating the Inflammatory Response. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-14.	1.9	29
224	Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 257.	1.8	76
225	Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. <i>Scientific Reports</i> , 2019, 9, 9046.	1.6	35
226	Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1255.	2.2	58
227	Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr $^{-/-}$.Leiden mice. <i>PLoS ONE</i> , 2019, 14, e0218459.	1.1	30
228	Redox regulation of metabolic syndrome: recent developments in skeletal muscle insulin resistance and non-alcoholic fatty liver disease (NAFLD). <i>Current Opinion in Physiology</i> , 2019, 9, 79-86.	0.9	8
229	Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019, 3, 1050-1060.	2.0	44
230	Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans. <i>FASEB Journal</i> , 2019, 33, 9974-9989.	0.2	20
231	Transcriptional Repression of CYP3A4 by Increased miR-200a-3p and miR-150-5p Promotes Steatosis in vitro. <i>Frontiers in Genetics</i> , 2019, 10, 484.	1.1	15
232	Non-Alcoholic Fatty Liver Disease in Non-Obese Individuals: Prevalence, Pathogenesis and Treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 638-645.	0.7	33
233	Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2019, 42, 1481-1488.	4.3	202
234	Adipokine Signatures in Obese Mouse Models Reflect Adipose Tissue Health and Are Associated with Serum Lipid Composition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2559.	1.8	17
235	Genetic Insights for Drug Development in NAFLD. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 506-516.	4.0	52
236	The Combination of Mulberry Extracts and Silk Amino Acids Alleviated High Fat Diet-Induced Nonalcoholic Hepatic Steatosis by Improving Hepatic Insulin Signaling and Normalizing Gut Microbiome Dysbiosis in Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-17.	0.5	9
237	Toward More Accurate Nomenclature for Fatty Liver Diseases. <i>Gastroenterology</i> , 2019, 157, 590-593.	0.6	75
238	Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2351-2358.	1.1	35

#	ARTICLE	IF	CITATIONS
239	Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 317-328.	1.9	52
240	ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2700.	1.8	72
241	Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet. <i>Molecular and Cellular Endocrinology</i> , 2019, 493, 110480.	1.6	19
242	Alcoholic/Non-Alcoholic Digestive Diseases. , 2019, , .		0
243	Association between non-alcoholic fatty liver disease and colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 633-641.	1.4	19
244	The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH). <i>Frontiers in Physiology</i> , 2019, 10, 770.	1.3	27
245	Ets-1 deficiency alleviates nonalcoholic steatohepatitis via weakening TGF- β 1 signaling-mediated hepatocyte apoptosis. <i>Cell Death and Disease</i> , 2019, 10, 458.	2.7	18
246	Chronic exposure to tetrabromodiphenyl ether (BDE-47) aggravates hepatic steatosis and liver fibrosis in diet-induced obese mice. <i>Journal of Hazardous Materials</i> , 2019, 378, 120766.	6.5	36
247	Systematic Evaluation of the Safety Threshold for Allograft Macrovesicular Steatosis in Cadaveric Liver Transplantation. <i>Frontiers in Physiology</i> , 2019, 10, 429.	1.3	16
248	Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. <i>JHEP Reports</i> , 2019, 1, 30-43.	2.6	176
249	Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. <i>Hepatology</i> , 2019, 70, 1119-1133.	3.6	355
250	LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPAR β axis in non-alcoholic fatty liver disease. <i>Bioscience Reports</i> , 2019, 39, .	1.1	59
251	Ultrasound imaging in nonalcoholic liver disease: current applications and future developments. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 546-551.	1.1	18
252	Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2215.	1.8	42
253	Ameliorative effect of dieckol-enriched extraction from <i>Laminaria japonica</i> on hepatic steatosis induced by a high-fat diet via β -oxidation pathway in ICR mice. <i>Journal of Functional Foods</i> , 2019, 58, 44-55.	1.6	18
254	Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro. <i>Cells</i> , 2019, 8, 457.	1.8	16
255	Impact of different ectopic fat depots on cardiovascular and metabolic diseases. <i>Journal of Cellular Physiology</i> , 2019, 234, 21630-21641.	2.0	128
256	Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. <i>Diabetes and Metabolism</i> , 2019, 45, 536-544.	1.4	25

#	ARTICLE	IF	CITATIONS
257	Human Liver Regeneration: An Etiology Dependent Process. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2332.	1.8	31
258	Liver Zonation in Health and Disease: Hypoxia and Hypoxia-Inducible Transcription Factors as Concert Masters. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2347.	1.8	56
259	Risk of atrial fibrillation in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 818-820.	1.9	0
260	Editorial: collagen proportionate area as a prognostic indicator in NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1452-1454.	1.9	1
261	<i>Nigella sativa</i> and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial. <i>Complementary Therapies in Medicine</i> , 2019, 44, 204-209.	1.3	26
262	Silybin Modulates Collagen Turnover in an In Vitro Model of NASH. <i>Molecules</i> , 2019, 24, 1280.	1.7	8
263	Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2093-2100.e3.	2.4	33
264	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.	2.4	65
265	Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. <i>Annals of Hepatology</i> , 2019, 18, 466-471.	0.6	42
266	Lipid Droplet Formation and Lipophagy in Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2019, 39, 283-290.	1.8	30
267	Association between <i>Helicobacter pylori</i> infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 56-65.	1.5	38
268	Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption. <i>Journal of Lipid Research</i> , 2019, 60, 1284-1292.	2.0	27
269	Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders. , 2019, , 245-274.		0
270	Bile Acids as Metabolic Regulators and Nutrient Sensors. <i>Annual Review of Nutrition</i> , 2019, 39, 175-200.	4.3	233
271	From NASH to HCC: current concepts and future challenges. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 411-428.	8.2	872
272	Vinyl chloride-induced interaction of nonalcoholic and toxicant-associated steatohepatitis: Protection by the ALDH2 activator Alda-1. <i>Redox Biology</i> , 2019, 24, 101205.	3.9	29
273	Missense Mutant Patatin-Like Phospholipase Domain Containing 3 Alters Lipid Droplet Turnover in Partnership With CGL58. <i>Hepatology</i> , 2019, 69, 2323-2325.	3.6	2
274	Value Assessment of Health Losses Caused by PM2.5 Pollution in Cities of Atmospheric Pollution Transmission Channel in the Beijing-Tianjin-Hebei Region, China. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1012.	1.2	15

#	ARTICLE	IF	CITATIONS
275	The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines (Basel, Switzerland), 2019, 6, 41.	0.7	80
276	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999â€“2019: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2019, 4, 389-398.	3.7	616
277	Noninvasive Evaluation of Liver Function in Morbidly Obese Patients. Gastroenterology Research and Practice, 2019, 2019, 1-7.	0.7	12
278	Current Management Strategy of Non-Alcoholic Fatty Liver Disease. Journal of Enam Medical College, 2019, 9, 46-56.	0.1	0
279	A Pathophysiological Model of Non-Alcoholic Fatty Liver Disease Using Precision-Cut Liver Slices. Nutrients, 2019, 11, 507.	1.7	13
280	Dietary Sources of Fructose and Its Association with Fatty Liver in Mexican Young Adults. Nutrients, 2019, 11, 522.	1.7	18
281	A Comprehensive Study of High Cholesterol Diet-Induced Larval Zebrafish Model: A Short-Time <i>In Vivo</i> Screening Method for Non-Alcoholic Fatty Liver Disease Drugs. International Journal of Biological Sciences, 2019, 15, 973-983.	2.6	27
282	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology, 2019, 70, 1457-1469.	3.6	547
283	Global liver disease burdens and research trends: Analysis from a Chinese perspective. Journal of Hepatology, 2019, 71, 212-221.	1.8	327
284	Sixâ€“Week Highâ€“Fat Diet Alters the Gut Microbiome and Promotes Cecal Inflammation, Endotoxin Production, and Simple Steatosis without Obesity in Male Rats. Lipids, 2019, 54, 119-131.	0.7	28
285	Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide. Australian and New Zealand Journal of Public Health, 2019, 43, 267-273.	0.8	31
286	Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers, 2019, 11, 486.	1.7	82
287	Understanding lipid metabolism through hepatic steat-omics. Nature Reviews Endocrinology, 2019, 15, 321-322.	4.3	1
288	From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proceedings of the Nutrition Society, 2019, 78, 290-304.	0.4	36
289	A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nature Communications, 2019, 10, 1406.	5.8	218
290	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clinical Gastroenterology and Hepatology, 2019, 17, 2085-2092.e1.	2.4	79
291	<p>Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 357-367.	1.1	34
292	Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease. Frontiers in Physiology, 2019, 10, 279.	1.3	48

#	ARTICLE	IF	CITATIONS
293	Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations. <i>Journal of Hepatology</i> , 2019, 71, 366-370.	1.8	41
294	Implantable Vascularized Liver Chip for Cross-validation of Disease Treatment with Animal Model. <i>Advanced Functional Materials</i> , 2019, 29, 1900075.	7.8	28
295	<i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy. <i>Helicobacter</i> , 2019, 24, e12588.	1.6	16
296	The Inhibitory T Cell Receptors PD1 and 2B4 Are Differentially Regulated on CD4 and CD8 T Cells in a Mouse Model of Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2019, 10, 244.	1.6	6
297	Testosterone Levels in Women: Implications for Fatty Liver and Beyond. <i>Journal of Women's Health</i> , 2019, 28, 1015-1016.	1.5	3
298	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1148-1156.e4.	2.4	71
299	A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease. <i>Diabetes</i> , 2019, 68, 1073-1083.	0.3	41
300	Nonalcoholic Fatty Liver Disease and the Heart. <i>Journal of the American College of Cardiology</i> , 2019, 73, 948-963.	1.2	259
301	Inhibition of TREM1 attenuates inflammation and lipid accumulation in diet-induced nonalcoholic fatty liver disease. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 11867-11877.	1.2	17
302	Role of gut microbiota in the development of non-alcoholic fatty liver disease. <i>Liver Research</i> , 2019, 3, 25-30.	0.5	10
303	Body mass index in early pregnancy and future risk of severe liver disease: a population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 789-796.	1.9	5
304	Association between Sleep Disturbances and Liver Status in Obese Subjects with Nonalcoholic Fatty Liver Disease: A Comparison with Healthy Controls. <i>Nutrients</i> , 2019, 11, 322.	1.7	29
305	Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum. <i>Proceedings of the Nutrition Society</i> , 2019, 78, 362-371.	0.4	5
306	iPl21 ² deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 677-687.	1.2	13
307	Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 702-713.	1.9	28
308	Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice. <i>EBioMedicine</i> , 2019, 41, 62-72.	2.7	46
309	Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. <i>Clinical Diabetes</i> , 2019, 37, 65-72.	1.2	77
310	YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role. <i>International Journal of Molecular Sciences</i> , 2019, 20, 638.	1.8	44

#	ARTICLE	IF	CITATIONS
311	Spirulina supplementation in a mouse model of diet-induced liver fibrosis reduced the pro-inflammatory response of splenocytes. <i>British Journal of Nutrition</i> , 2019, 121, 748-755.	1.2	15
312	Clinicopathological impact of anti-smooth muscle antibodies in patients with non-alcoholic fatty liver disease. <i>British Journal of Biomedical Science</i> , 2019, 76, 101-103.	1.2	2
313	Genome-Based Nutrition in Chronic Liver Disease. , 2019, , 3-14.		1
314	Critical Role of Hepatic Fatty-Acyl Phospholipid Remodeling in Obese and Nonobese Fatty Liver Mouse Models. , 2019, , 239-256.		0
315	Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease. , 2019, , 357-372.		3
316	Dietary Management of Nonalcoholic Fatty Liver Disease (NAFLD) by n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation. , 2019, , 373-389.		2
317	Protective Actions of Polyphenols in the Development of Nonalcoholic Fatty Liver Disease. , 2019, , 91-99.		3
318	Barriers and Facilitators to Mediterranean Diet Adoption by Patients With Nonalcoholic Fatty Liver Disease in Northern Europe. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1364-1371.e3.	2.4	42
319	Non-alcoholic fatty liver disease (NAFLD) and the quest for effective treatments. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 77-79.	0.7	11
320	Environmental Risk Factors for Liver Cancer and Nonalcoholic Fatty Liver Disease. <i>Current Epidemiology Reports</i> , 2019, 6, 50-66.	1.1	48
321	Emerging awareness on the importance of skeletal muscle in liver diseases: time to dig deeper into mechanisms!. <i>Clinical Science</i> , 2019, 133, 465-481.	1.8	51
322	Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. <i>Drug Safety</i> , 2019, 42, 701-711.	1.4	19
323	Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH. <i>Scientific Reports</i> , 2019, 9, 2045.	1.6	51
324	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2019, 45, 480-487.	1.4	36
325	The dawn of a new era for nonalcoholic fatty liver disease?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 629-631.	0.7	2
326	Association between Hemoglobin Glycation Index and NAFLD in Chinese Nondiabetic Individuals. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-8.	0.8	10
327	Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism. <i>Scientific Reports</i> , 2019, 9, 16810.	1.6	34
328	Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. <i>Gene Expression</i> , 2019, 19, 175-185.	0.5	20

#	ARTICLE	IF	CITATIONS
329	Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis. Expert Review of Precision Medicine and Drug Development, 2019, 4, 283-297.	0.4	1
330	4-methylumbelliferone Prevents Liver Fibrosis by Affecting Hyaluronan Deposition, FSTL1 Expression and Cell Localization. International Journal of Molecular Sciences, 2019, 20, 6301.	1.8	21
331	Sarcopoterium spinosum Inhibited the Development of Non-Alcoholic Steatosis and Steatohepatitis in Mice. Nutrients, 2019, 11, 3044.	1.7	6
332	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. Nutrients, 2019, 11, 3048.	1.7	29
333	Intestinal Absorption of Bile Acids in Health and Disease. , 2019, 10, 21-56.		117
334	Fat and Sugarâ€”A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease. Nutrients, 2019, 11, 2871.	1.7	14
335	Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?. Nutrients, 2019, 11, 2878.	1.7	47
336	In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells. Advanced Healthcare Materials, 2019, 8, e1901379.	3.9	30
337	Plasticity of histone modifications around Cidea and Cidec genes with secondary bile in the amelioration of developmentally-programmed hepatic steatosis. Scientific Reports, 2019, 9, 17100.	1.6	7
339	Obeticholic acid: towards first approval for NASH. Lancet, The, 2019, 394, 2131-2133.	6.3	30
341	The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. , 0, , .		9
342	Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports, 2019, 18, 444-454.	0.4	1
343	Association of leukocyte telomere length with non-alcoholic fatty liver disease in patients with type 2 diabetes. Chinese Medical Journal, 2019, 132, 2927-2933.	0.9	6
344	Nonalcoholic Fatty Liver Disease. Gastroenterology Nursing, 2019, 42, 428-434.	0.2	16
345	Senescent cells in the development of cardiometabolic disease. Current Opinion in Lipidology, 2019, 30, 177-185.	1.2	7
346	Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease according to Different Menstrual Status Groups. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-7.	0.8	16
347	Topics on quantitative liver magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery, 2019, 9, 1840-1890.	1.1	31
348	NAFLD in Women: Unique Pathways, Biomarkers, and Therapeutic Opportunities. Current Hepatology Reports, 2019, 18, 425-432.	0.4	8

#	ARTICLE	IF	CITATIONS
349	Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1121-1128.	0.8	49
350	Ischemia reperfusion injury promotes recurrence of hepatocellular carcinoma in fatty liver via ALOX12-12HETE-GPR31 signaling axis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 489.	3.5	40
351	Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis. <i>Transplantation</i> , 2019, 103, e345-e354.	0.5	76
352	Deep learning enables pathologist-like scoring of NASH models. <i>Scientific Reports</i> , 2019, 9, 18454.	1.6	61
353	Thyroid-stimulating hormone is associated with nonalcoholic steatohepatitis in patients with chronic hepatitis B. <i>Medicine (United States)</i> , 2019, 98, e17945.	0.4	7
354	Alpha-fetoprotein to transaminase ratio is related to higher diagnostic efficacy for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, e15414.	0.4	14
355	Serum Soluble Receptor for AGE (sRAGE) Levels Are Associated With Unhealthy Lifestyle and Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00040.	1.3	10
356	Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00042.	1.3	28
357	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , 2019, 11, 2971.	1.7	57
358	The Impact of Obesity and Type 2 Diabetes on Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 1714-1715.	0.2	25
359	Fermented Korean Red Ginseng Extract Enriched in Rd and Rg3 Protects against Non-Alcoholic Fatty Liver Disease through Regulation of mTORC1. <i>Nutrients</i> , 2019, 11, 2963.	1.7	18
360	Traditional Chinese Medicine and Intestinal Microbiota. <i>Holistic Nursing Practice</i> , 2019, 33, 259-265.	0.3	13
361	Vitamin D and nonalcoholic fatty liver disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2019, 22, 449-458.	1.3	38
362	High Protein Diet and Metabolic Plasticity in Non-Alcoholic Fatty Liver Disease: Myths and Truths. <i>Nutrients</i> , 2019, 11, 2985.	1.7	26
363	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 313-324.	5.5	566
364	Generic chemoprevention of hepatocellular carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2019, 1440, 23-35.	1.8	16
365	Hepatocellular carcinoma in Australia 1982-2014: Increasing incidence and improving survival. <i>Liver International</i> , 2019, 39, 522-530.	1.9	45
366	Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. <i>Molecular Aspects of Medicine</i> , 2019, 65, 37-55.	2.7	628

#	ARTICLE	IF	CITATIONS
367	MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF- κ B-TNF α pathway. <i>Journal of Hepatology</i> , 2019, 70, 87-96.	1.8	129
368	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	3.6	1,203
369	Multicentre study of the prognostic impact of preoperative bodyweight on long-term prognosis of hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2019, 106, 276-285.	0.1	15
370	Extract from <i>Aronia melanocarpa</i> L. Berries Prevents Cadmium-Induced Oxidative Stress in the Liver: A Study in A Rat Model of Low-Level and Moderate Lifetime Human Exposure to this Toxic Metal. <i>Nutrients</i> , 2019, 11, 21.	1.7	31
371	Hepatic microcirculation and mechanisms of portal hypertension. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 221-234.	8.2	148
372	Enhanced hepatic glycogen synthesis and suppressed adenosine deaminase activity by lithium attenuates hepatic triglyceride accumulation in nicotine-exposed rats. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 1417-1427.	2.5	16
373	Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. <i>Advanced Science</i> , 2019, 6, 1801585.	5.6	110
374	A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 80-82.	8.2	29
375	Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 933-940.	1.9	17
376	Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD. <i>Cell Reports</i> , 2019, 26, 192-208.e6.	2.9	202
377	Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi. <i>Molecular Metabolism</i> , 2019, 20, 128-137.	3.0	86
378	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. <i>Transplantation</i> , 2019, 103, 22-27.	0.5	296
379	Systematic review with meta-analysis: nonalcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 375-388.	1.9	45
380	Prevalence and outcomes of nonalcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. <i>Liver International</i> , 2019, 39, 748-757.	1.9	46
381	The role of gut microbiota in intestinal and liver diseases. <i>Laboratory Animals</i> , 2019, 53, 271-280.	0.5	19
382	The role of the microbiome in <sc>NAFLD</sc> and <sc>NASH</sc>. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	368
383	Fa(s)t assessment of the liver graft: Is it relevant?. <i>Journal of Hepatology</i> , 2019, 70, 346-347.	1.8	5
384	Lessons learnt from pathologic imaging correlation in the liver: an historical perspective. <i>British Journal of Radiology</i> , 2019, 92, 20180701.	1.0	2

#	ARTICLE	IF	CITATIONS
385	Editorial: Cytokines in liver diseases. <i>Cytokine</i> , 2019, 124, 154608.	1.4	1
386	A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2019, 29, 983-989.	1.1	8
387	Non-alcoholic fatty liver disease – A global public health perspective. <i>Journal of Hepatology</i> , 2019, 70, 531-544.	1.8	1,345
388	Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey. <i>Atherosclerosis</i> , 2019, 284, 129-135.	0.4	12
389	Nonalcoholic Fatty Liver Disease and Bone Mineral Density in Children and Adolescents: Specific Considerations for Future Studies. <i>Digestive Diseases and Sciences</i> , 2019, 64, 898-900.	1.1	1
390	Steatosis in Liver Transplantation: Current Limitations and Future Strategies. <i>Transplantation</i> , 2019, 103, 78-90.	0.5	71
391	Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function. <i>Metabolic Engineering</i> , 2019, 52, 263-272.	3.6	37
392	High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population. <i>PLoS ONE</i> , 2019, 14, e0208926.	1.1	28
393	NASH in Lean Individuals. <i>Seminars in Liver Disease</i> , 2019, 39, 086-095.	1.8	161
394	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G462-G472.	1.6	162
395	Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 597-618.	2.3	32
396	Genetic depletion of Soat2 diminishes hepatic steatosis via genes regulating de novo lipogenesis and by GLUT2 protein in female mice. <i>Digestive and Liver Disease</i> , 2019, 51, 1016-1022.	0.4	8
397	Thioacetamide potentiates high cholesterol and high fat diet induced steato-hepatic changes in livers of C57BL/6J mice: A novel eight weeks model of fibrosing NASH. <i>Toxicology Letters</i> , 2019, 304, 21-29.	0.4	18
398	Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2019, 45, 347-355.	1.4	47
399	Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 342-352.	1.9	38
400	Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA. <i>Digestive Diseases and Sciences</i> , 2019, 64, 698-707.	1.1	26
401	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. <i>Journal of Hepatology</i> , 2019, 70, 494-500.	1.8	67
402	Quantification of Liver Function with MRI: Is It Ready?. <i>Radiology</i> , 2019, 290, 134-135.	3.6	3

#	ARTICLE	IF	CITATIONS
403	Potential mechanisms linking gut microbiota and portal hypertension. <i>Liver International</i> , 2019, 39, 598-609.	1.9	34
404	Tieing Up Angiogenesis to Treat Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 937-939.	3.6	1
405	A higher flavonoid intake is associated with less likelihood of nonalcoholic fatty liver disease: results from a multiethnic study. <i>Journal of Nutritional Biochemistry</i> , 2019, 65, 66-71.	1.9	30
406	Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. <i>Biochemical Pharmacology</i> , 2019, 160, 34-45.	2.0	50
407	Reproductive Endocrinology of Nonalcoholic Fatty Liver Disease. <i>Endocrine Reviews</i> , 2019, 40, 417-446.	8.9	73
408	LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics. <i>Analytical Chemistry</i> , 2019, 91, 836-845.	3.2	33
409	Clinical workup of fatty liver for the primary care provider. <i>Postgraduate Medicine</i> , 2019, 131, 19-30.	0.9	4
410	Isosteviol Protects Free Fatty Acid- and High Fat Diet-Induced Hepatic Injury via Modulating PKC- β /p66Shc/ROS and Endoplasmic Reticulum Stress Pathways. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 1949-1968.	2.5	15
411	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 82-97.	1.5	679
412	Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. <i>FASEB Journal</i> , 2019, 33, 2809-2822.	0.2	40
413	The future R&D landscape in non-alcoholic steatohepatitis (NASH). <i>Drug Discovery Today</i> , 2019, 24, 560-566.	3.2	8
414	Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 2494-2505.	5.4	47
415	Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 163-183.	2.5	107
416	Role of long non-coding RNAs in metabolic control. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2020, 1863, 194348.	0.9	22
417	Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 320-329.	0.9	34
418	Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis. <i>Gut</i> , 2020, 69, 551-563.	6.1	142
419	The Role of Senescence in the Development of Nonalcoholic Fatty Liver Disease and Progression to Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 363-374.	3.6	131
420	Sestrin 3 Protects Against Diet-Induced Nonalcoholic Steatohepatitis in Mice Through Suppression of Transforming Growth Factor β Signal Transduction. <i>Hepatology</i> , 2020, 71, 76-92.	3.6	44

#	ARTICLE	IF	CITATIONS
421	Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPAR α pathway. <i>Applied Physiology, Nutrition and Metabolism</i> , 2020, 45, 227-239.	0.9	47
422	The influence of dietary fatty acids on liver fat content and metabolism. <i>Proceedings of the Nutrition Society</i> , 2020, 79, 30-41.	0.4	46
423	Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 89-96.	0.8	29
424	Moderate consumption of fermented alcoholic beverages diminishes diet-induced non-alcoholic fatty liver disease through mechanisms involving hepatic adiponectin signaling in mice. <i>European Journal of Nutrition</i> , 2020, 59, 787-799.	1.8	7
425	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24.	1.8	123
426	Multi-drug approaches to NASH: what are the challenges in the development pipeline?. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 143-150.	1.9	18
427	Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. <i>Journal of Gastroenterology</i> , 2020, 55, 330-341.	2.3	20
428	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <i>Endocrine Reviews</i> , 2020, 41, 66-117.	8.9	134
429	Quantitative Proteomics and Mechanistic Modeling of Transporter-Mediated Disposition in Nonalcoholic Fatty Liver Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1128-1137.	2.3	51
430	Yes-Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 72, 72-87.	3.6	64
431	Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease. <i>Gastroenterology</i> , 2020, 158, 200-214.	0.6	121
432	Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice. <i>Hepatology</i> , 2020, 71, 1609-1625.	3.6	44
433	Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 40-52.	8.2	203
434	Adaptive immunity: an emerging player in the progression of NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 81-92.	8.2	227
435	Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 106-113.	1.1	19
436	Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 245-254.	0.4	24
437	Epidemiology of chronic liver diseases in the USA in the past three decades. <i>Gut</i> , 2020, 69, 564-568.	6.1	321
438	Atropselective Disposition of 2,2',3,4',6-Pentachlorobiphenyl (PCB 91) and Identification of Its Metabolites in Mice with Liver-Specific Deletion of Cytochrome P450 Reductase. <i>Chemical Research in Toxicology</i> , 2020, 33, 1328-1338.	1.7	11

#	ARTICLE	IF	CITATIONS
439	Deficiency of glutathione peroxidase-1 and catalase attenuated diet-induced obesity and associated metabolic disorders. <i>Acta Diabetologica</i> , 2020, 57, 151-161.	1.2	6
440	Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. <i>Translational Behavioral Medicine</i> , 2020, 10, 1016-1030.	1.2	34
441	Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 539-548.	3.6	128
442	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020, 71, 1213-1227.	3.6	209
443	Carbon monoxide releasing molecule-A1 improves nonalcoholic steatohepatitis via Nrf2 activation mediated improvement in oxidative stress and mitochondrial function. <i>Redox Biology</i> , 2020, 28, 101314.	3.9	57
444	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020, 88, 105889.	0.8	80
445	Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 808-819.	3.6	170
446	Creatinine-to-bodyweight ratio is a predictor of incident non-alcoholic fatty liver disease: A population-based longitudinal study. <i>Hepatology Research</i> , 2020, 50, 57-66.	1.8	16
447	Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 362-369.	1.4	21
448	Risk of chemotherapy-associated liver injury (CALI) in PNPLA3 p.148M allele carriers: Preliminary results of a transient elastography-based study. <i>Digestive and Liver Disease</i> , 2020, 52, 102-106.	0.4	1
449	The modulatory effect of triclosan on the reversion of the activated phenotype of LX-2 hepatic stellate cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2020, 34, e22413.	1.4	3
450	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1592-1599.e8.	2.4	21
451	Temporal trends in utilization and outcomes of steatotic donor livers in the United States. <i>American Journal of Transplantation</i> , 2020, 20, 855-863.	2.6	19
452	Nonalcoholic fatty liver disease and use of folate. , 2020, , 323-343.		2
453	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 1953-1966.	3.6	66
454	Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features. <i>Nutrition</i> , 2020, 71, 110620.	1.1	28
455	Hepatocellular carcinoma in non-alcohol fatty liver disease – changing trends and specific challenges. <i>Current Medical Research and Opinion</i> , 2020, 36, 235-243.	0.9	18
456	Minimizing Risks of Liver Transplantation With Steatotic Donor Livers by Preferred Recipient Matching. <i>Transplantation</i> , 2020, 104, 1604-1611.	0.5	18

#	ARTICLE	IF	CITATIONS
457	Investigating fibrosis and inflammation in an ex vivo NASH murine model. American Journal of Physiology - Renal Physiology, 2020, 318, G336-G351.	1.6	12
458	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 1917-1925.	0.9	11
459	Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality. Liver International, 2020, 40, 815-824.	1.9	26
460	Baicalein reduces hepatic fat accumulation by activating AMPK in oleic acid-induced HepG2 cells and high-fat diet-induced non-insulin-resistant mice. Food and Function, 2020, 11, 711-721.	2.1	40
461	T1 mapping, T2 mapping and MR elastography of the liver for detection and staging of liver fibrosis. Abdominal Radiology, 2020, 45, 692-700.	1.0	57
462	Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. Digestive Diseases and Sciences, 2020, 65, 2712-2718.	1.1	4
463	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events: A Prospective Study. Clinical Gastroenterology and Hepatology, 2020, 18, 2324-2331.e4.	2.4	136
464	ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation. Journal of Hepatology, 2020, 72, 976-989.	1.8	36
465	Copper modulates sex-specific fructose hepatotoxicity in nonalcoholic fatty liver disease (NALFD) Wistar rat models. Journal of Nutritional Biochemistry, 2020, 78, 108316.	1.9	12
466	Therapeutic potential of targeting mixed lineage kinases in cancer and inflammation. , 2020, 207, 107457.		12
467	Programming of hepatic lipid metabolism in a rat model of postnatal nicotine exposure – Sex-related differences. Environmental Pollution, 2020, 258, 113781.	3.7	7
468	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2020, 5, 167-228.	3.7	320
469	Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results From the Third National Health and Nutrition Examination Survey With 27 Years of Follow-up. Hepatology, 2020, 72, 430-440.	3.6	48
470	Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology. Journal of Clinical and Experimental Hepatology, 2020, 10, 296-303.	0.4	18
471	Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Digestive Diseases and Sciences, 2020, 65, 2112-2119.	1.1	68
472	Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharmaceutica Sinica B, 2020, 10, 3-18.	5.7	121
473	Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function. Clinical Pharmacology in Drug Development, 2020, 9, 699-708.	0.8	10
474	Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. American Journal of Gastroenterology, 2020, 115, 562-574.	0.2	29

#	ARTICLE	IF	CITATIONS
475	Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. <i>Journal of Gastroenterology</i> , 2020, 55, 142-158.	2.3	105
476	Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 80-86.	0.8	7
477	The Prevalence of Lean/Nonobese Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 378-387.	1.1	64
478	STING expression in monocyte-derived macrophages is associated with the progression of liver inflammation and fibrosis in patients with nonalcoholic fatty liver disease. <i>Laboratory Investigation</i> , 2020, 100, 542-552.	1.7	64
479	Drug-Induced Liver Injury in the Setting of Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2020, 24, 89-106.	1.0	13
480	Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 627-635.	1.8	84
481	The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 291-304.	1.9	37
482	Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis. <i>Liver International</i> , 2020, 40, 622-637.	1.9	32
483	Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 2079-2090.	2.4	52
484	Accuracy of common proton density fat fraction thresholds for magnitude- and complex-based chemical shift-encoded MRI for assessing hepatic steatosis in patients with obesity. <i>Abdominal Radiology</i> , 2020, 45, 661-671.	1.0	16
485	The effect of a Mediterranean diet on metabolic parameters in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , 2020, 35, 40-46.	0.5	35
486	Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population. <i>Cytokine</i> , 2020, 126, 154927.	1.4	15
487	Adolescent exposure to environmental level of PCBs (Aroclor 1254) induces non-alcoholic fatty liver disease in male mice. <i>Environmental Research</i> , 2020, 181, 108909.	3.7	15
488	Lipid droplet-associated kinase STK25 regulates peroxisomal activity and metabolic stress response in steatotic liver. <i>Journal of Lipid Research</i> , 2020, 61, 178-191.	2.0	23
489	Readiness for the epidemic: The adult nonalcoholic fatty liver disease toolkit for primary care nurse practitioners. <i>Journal of the American Association of Nurse Practitioners</i> , 2020, 32, 323-331.	0.5	6
490	Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 101-109.	0.8	7
491	One-Carbon Metabolism and Nonalcoholic Fatty Liver Disease: The Crosstalk between Nutrients, Microbiota, and Genetics. <i>Lifestyle Genomics</i> , 2020, 13, 53-63.	0.6	29
492	Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. <i>Cells</i> , 2020, 9, 37.	1.8	85

#	ARTICLE	IF	CITATIONS
493	From NAFLD to MAFLD: a redefining moment for fatty liver disease. <i>Chinese Medical Journal</i> , 2020, 133, 2271-2273.	0.9	79
494	Associations between <i>Helicobacter pylori</i> with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. <i>Helicobacter</i> , 2020, 25, e12756.	1.6	16
495	Effect of Walking on Sand with Dietary Intervention in Overweight Type 2 Diabetes Mellitus Patients: A Randomized Controlled Trial. <i>Healthcare (Switzerland)</i> , 2020, 8, 370.	1.0	1
496	A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. <i>Microorganisms</i> , 2020, 8, 1526.	1.6	8
497	Microbiota, Fiber, and NAFLD: Is There Any Connection?. <i>Nutrients</i> , 2020, 12, 3100.	1.7	34
498	Oleate acid-stimulated HMMR expression by CEBP β is associated with nonalcoholic steatohepatitis and hepatocellular carcinoma. <i>International Journal of Biological Sciences</i> , 2020, 16, 2812-2827.	2.6	16
499	GPR91 antagonist and TGF- β 2 inhibitor suppressed collagen production of high glucose and succinate induced HSC activation. <i>Biochemical and Biophysical Research Communications</i> , 2020, 530, 362-366.	1.0	14
500	Triose Kinase Controls the Lipogenic Potential of Fructose and Dietary Tolerance. <i>Cell Metabolism</i> , 2020, 32, 605-618.e7.	7.2	32
501	Updates in non-alcoholic fatty liver disease (NAFLD). <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2020, 50, 100844.	0.8	5
502	Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 1571-1573.	1.8	18
503	Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 112, 154355.	1.5	23
504	Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity. <i>Journal of Lipid Research</i> , 2020, 61, 1400-1409.	2.0	17
505	Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. <i>Redox Biology</i> , 2020, 37, 101710.	3.9	58
506	MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. <i>Liver International</i> , 2020, 40, 3018-3030.	1.9	274
507	Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients. <i>Medicina (Lithuania)</i> , 2020, 56, 544.	0.8	16
508	Hepatic steatosis is highly prevalent but is not correlated with stiffness in autoimmune hepatitis. <i>Medicine (United States)</i> , 2020, 99, e22805.	0.4	5
509	Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 160-171.	1.9	20
510	Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling. <i>Frontiers in Endocrinology</i> , 2020, 11, 572490.	1.5	47

#	ARTICLE	IF	CITATIONS
511	The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults. <i>Lipids in Health and Disease</i> , 2020, 19, 218.	1.2	47
512	Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. <i>Annals of Hepatology</i> , 2020, 19, 622-626.	0.6	23
513	Lifestyle interventions affecting hepatic fatty acid metabolism. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2020, 23, 373-379.	1.3	6
514	Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Liver International</i> , 2020, 40, 2906-2916.	1.9	74
515	Week 2020 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2020, 8, 144-887.	1.6	7
516	miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease. <i>Frontiers in Medicine</i> , 2020, 7, 527059.	1.2	22
517	A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study. <i>Contemporary Clinical Trials</i> , 2020, 98, 106170.	0.8	53
518	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	0.8	71
519	The role of stress kinases in metabolic disease. <i>Nature Reviews Endocrinology</i> , 2020, 16, 697-716.	4.3	46
521	The Burden of NAFLD Worldwide. , 2020, , 15-24.		0
522	Low-dose trans-resveratrol induce poly(ADP)-ribosylation-dependent increase of the PPAR- β protein expression level in the in vitro model of non-alcoholic fatty liver disease. <i>Molecular Biology Reports</i> , 2020, 47, 8331-8337.	1.0	2
523	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 996-1007.	3.7	22
524	The multi-faces of Angptl8 in health and disease: Novel functions beyond lipoprotein lipase modulation. <i>Progress in Lipid Research</i> , 2020, 80, 101067.	5.3	48
525	Automated thermal imaging for the detection of fatty liver disease. <i>Scientific Reports</i> , 2020, 10, 15532.	1.6	17
526	A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-15.	1.0	5
527	Effect and mechanism of ginsenoside Rg1-regulating hepatic steatosis in HepG2 cells induced by free fatty acid. <i>Bioscience, Biotechnology and Biochemistry</i> , 2020, 84, 2228-2240.	0.6	12
528	Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?. <i>Advances in Nutrition</i> , 2020, 11, 1696-1711.	2.9	36
529	Nonalcoholic fatty liver disease burden: Australia, 2019-2030. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1628-1635.	1.4	68

#	ARTICLE	IF	CITATIONS
530	NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 60.	1.2	321
531	Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. <i>Cells</i> , 2020, 9, 1638.	1.8	76
532	Accuracy of a Semi-Quantitative Ultrasound Method to Determine Liver Fat Infiltration in Early Adulthood. <i>Diagnostics</i> , 2020, 10, 431.	1.3	6
533	Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease. <i>Metabolites</i> , 2020, 10, 283.	1.3	23
534	The Interplay between Oxidative Stress and miRNAs in Obesity-Associated Hepatic and Vascular Complications. <i>Antioxidants</i> , 2020, 9, 607.	2.2	9
535	The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease. <i>Journal of Traditional and Complementary Medicine</i> , 2020, 10, 268-274.	1.5	38
536	Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH. <i>Redox Biology</i> , 2020, 36, 101634.	3.9	68
537	Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1297-1305.	1.0	19
538	An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 985-998.	1.4	3
539	Adult obesity complications: challenges and clinical impact. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882093495.	1.4	57
540	Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis. <i>Annals of Hepatology</i> , 2020, 19, 472-481.	0.6	12
541	Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. <i>Hepatology Communications</i> , 2020, 4, 1263-1278.	2.0	57
542	Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00134.	1.0	11
543	Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 72, 1556-1568.	3.6	70
544	Breath Metabolomics Provides an Accurate and Noninvasive Approach for Screening Cirrhosis, Primary, and Secondary Liver Tumors. <i>Hepatology Communications</i> , 2020, 4, 1041-1055.	2.0	32
545	Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. <i>Hepatology Communications</i> , 2020, 4, 1136-1148.	2.0	56
546	Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. <i>JGH Open</i> , 2020, 4, 808-817.	0.7	20
547	Neddylation: A Versatile Pathway Takes on Chronic Liver Diseases. <i>Frontiers in Medicine</i> , 2020, 7, 586881.	1.2	17

#	ARTICLE	IF	CITATIONS
548	Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Nutrients</i> , 2020, 12, 3472.	1.7	27
549	Sleep disorder in patients with chronic liver disease: a narrative review. <i>Journal of Thoracic Disease</i> , 2020, 12, S248-S260.	0.6	21
550	AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. <i>Cell Reports Medicine</i> , 2020, 1, 100057.	3.3	72
551	Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. <i>Frontiers in Endocrinology</i> , 2020, 11, 597583.	1.5	42
552	Effect of Sheng-Jiang Powder on Gut Microbiota in High-Fat Diet-Induced NAFLD. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-15.	0.5	7
553	ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. <i>Hepatology Communications</i> , 2020, 4, 1624-1636.	2.0	21
554	Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China. <i>Medicine (United States)</i> , 2020, 99, e23360.	0.4	8
555	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. <i>Journal of Clinical Medicine</i> , 2020, 9, 3817.	1.0	27
556	Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101580.	0.7	6
558	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	205
559	MicroRNA-20a-5p Ameliorates Non-alcoholic Fatty Liver Disease via Inhibiting the Expression of CD36. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 596329.	1.8	24
560	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8838.	1.8	22
561	Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1185-1194.	1.9	37
562	An Algorithmic Approach to NAFLD Screening: From PCP to Specialist. <i>ACG Case Reports Journal</i> , 2020, 7, e00473.	0.2	2
563	Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1209-1219.	3.2	29
564	Evaluation of NAFLD and fibrosis in obese patients – a comparison of histological and clinical scoring systems. <i>BMC Gastroenterology</i> , 2020, 20, 254.	0.8	25
565	Detecting liver disease via an endogenous pigment. <i>Nature Biomedical Engineering</i> , 2020, 4, 761-762.	11.6	2
566	Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease. <i>PLoS Genetics</i> , 2020, 16, e1008955.	1.5	32

#	ARTICLE	IF	CITATIONS
567	NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. <i>Endocrinology</i> , 2020, 161, .	1.4	94
568	Effects of surface-deacetylated chitin nanofibers on non-alcoholic steatohepatitis model rats and their gut microbiota. <i>International Journal of Biological Macromolecules</i> , 2020, 164, 659-666.	3.6	11
569	Circulating Neutrophils of Nonalcoholic Steatohepatitis Patients Show an Activated Phenotype and Suppress T Lymphocytes Activity. <i>Journal of Immunology Research</i> , 2020, 2020, 1-15.	0.9	19
570	Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. <i>Hepatology</i> , 2020, 72, 1864-1872.	3.6	221
571	Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154318.	1.5	28
572	Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1387-1398.	1.9	50
573	Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 2057-2073.	1.2	16
574	β-Glucan ameliorates nonalcoholic steatohepatitis induced by methionine and choline-deficient diet in mice. <i>Journal of Food Biochemistry</i> , 2020, 44, e13408.	1.2	6
575	Visceral adiposity and liver fat as mediators of the association between cardiorespiratory fitness and plasma glucose-insulin homeostasis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 319, E548-E556.	1.8	10
576	The effects of <i>Bacillus coagulans</i> supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. <i>Clinical Nutrition ESPEN</i> , 2020, 39, 53-60.	0.5	40
577	Hepatic steatosis as an independent risk factor for severe disease in patients with COVID -19: A computed tomography study. <i>JGH Open</i> , 2020, 4, 1102-1107.	0.7	22
578	Nature or Nurture? The Answer Is “Both” in Nonalcoholic Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 641-642.	2.3	0
579	Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. <i>BMJ Open</i> , 2020, 10, e036663.	0.8	108
580	Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus. <i>Medicine (United States)</i> , 2020, 99, e21568.	0.4	3
581	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020, 2, 100142.	2.6	53
583	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1289-1292.	0.2	9
584	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2020, 10, 579.	1.3	21
585	Consumption of Spinach and Tomato Modifies Lipid Metabolism, Reducing Hepatic Steatosis in Rats. <i>Antioxidants</i> , 2020, 9, 1041.	2.2	10

#	ARTICLE	IF	CITATIONS
586	<p>Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 3861-3872.	1.1	20
587	Regulatory Connections between Iron and Glucose Metabolism. International Journal of Molecular Sciences, 2020, 21, 7773.	1.8	26
588	Extracellular vesicle-associated proteins as potential biomarkers. Advances in Clinical Chemistry, 2020, 99, 1-48.	1.8	6
589	CKIP-1 augments autophagy in steatotic hepatocytes by inhibiting Akt/mTOR signal pathway. Experimental Cell Research, 2020, 397, 112341.	1.2	6
590	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. Journal of Medical Ultrasonics (2001), 2020, 47, 511-520.	0.6	20
591	Chinese Medicinal Herbs Targeting the Gutâ€œLiver Axis and Adipose Tissueâ€œLiver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. Frontiers in Endocrinology, 2020, 11, 572729.	1.5	15
592	The regulatory state of nonalcoholic steatohepatitis and metabolism. Endocrinology, Diabetes and Metabolism, 2020, 3, e00113.	1.0	4
593	Extracellular Vesicles in the Development of the Non-Alcoholic Fatty Liver Disease: An Update. Biomolecules, 2020, 10, 1494.	1.8	20
594	Whatâ€™s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. Metabolites, 2020, 10, 397.	1.3	6
595	Involvement of the Autophagy-ER Stress Axis in High Fat/Carbohydrate Diet-Induced Nonalcoholic Fatty Liver Disease. Nutrients, 2020, 12, 2626.	1.7	14
596	Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical. Nutrients, 2020, 12, 2627.	1.7	14
597	Metabolite profiling of mice under long-term fructose drinking and vitamin D deficiency: increased risks for metabolic syndrome and nonalcoholic fatty liver disease. Journal of Physiology and Biochemistry, 2020, 76, 587-598.	1.3	4
598	Long Non-Coding RNAs in Liver Cancer and Nonalcoholic Steatohepatitis. Non-coding RNA, 2020, 6, 34.	1.3	11
599	The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise. Hepatology International, 2020, 14, 652-666.	1.9	34
600	Nonâ€œalcoholic fatty liver disease (NAFLD) in Asiaâ€œMore efforts are needed. Liver International, 2020, 40, 3144-3144.	1.9	1
601	Exercise-Induced Improvements to Whole Body Glucose Metabolism in Type 2 Diabetes: The Essential Role of the Liver. Frontiers in Endocrinology, 2020, 11, 567.	1.5	22
602	Rescue of Hepatic Phospholipid Remodeling Defect in iPLA2Î²-Null Mice Attenuates Obese but Not Non-Obese Fatty Liver. Biomolecules, 2020, 10, 1332.	1.8	8
603	Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output. Cell, 2020, 183, 76-93.e22.	13.5	237

#	ARTICLE	IF	CITATIONS
604	Scoparone as a therapeutic drug in liver diseases: Pharmacology, pharmacokinetics and molecular mechanisms of action. <i>Pharmacological Research</i> , 2020, 160, 105170.	3.1	43
605	A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. <i>Scientific Reports</i> , 2020, 10, 15308.	1.6	31
606	Liver Steatosis Categorization on Contrast-Enhanced CT Using a Fully Automated Deep Learning Volumetric Segmentation Tool: Evaluation in 1204 Healthy Adults Using Unenhanced CT as a Reference Standard. <i>American Journal of Roentgenology</i> , 2021, 217, 359-367.	1.0	31
607	LPCN 1144 Resolves NAFLD in Hypogonadal Males. <i>Hepatology Communications</i> , 2020, 4, 1430-1440.	2.0	8
608	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. <i>Hepatology Communications</i> , 2020, 4, 1637-1650.	2.0	32
609	Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. <i>Journal of Clinical Medicine</i> , 2020, 9, 2648.	1.0	93
611	Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5927.	1.8	31
612	Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity. <i>Scientific Reports</i> , 2020, 10, 13671.	1.6	17
613	The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). <i>Journal of Diabetes Research</i> , 2020, 2020, 1-16.	1.0	196
614	Si-Wu-Tang Alleviates Nonalcoholic Fatty Liver Disease via Blocking TLR4-JNK and Caspase-8-GSDMD Signaling Pathways. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-11.	0.5	5
615	Neurotrophin Inhibits Lipid Accumulation by Maintaining Mitochondrial Function in Hepatocytes via AMPK Activation. <i>Frontiers in Physiology</i> , 2020, 11, 950.	1.3	3
616	Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3456-3462.	1.1	10
617	Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. <i>Liver International</i> , 2020, 40, 3061-3070.	1.9	13
618	Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers. <i>Disease Markers</i> , 2020, 2020, 1-16.	0.6	26
619	Very Low-Carbohydrate Ketogenic Diet for the Treatment of Severe Obesity and Associated Non-Alcoholic Fatty Liver Disease: The Role of Sex Differences. <i>Nutrients</i> , 2020, 12, 2748.	1.7	36
620	Mitochondrial Transfer by Human Mesenchymal Stromal Cells Ameliorates Hepatocyte Lipid Load in a Mouse Model of NASH. <i>Biomedicines</i> , 2020, 8, 350.	1.4	19
622	A Novel Combination of Fruits and Vegetables Prevents Diet-Induced Hepatic Steatosis and Metabolic Dysfunction in Mice. <i>Journal of Nutrition</i> , 2020, 150, 2950-2960.	1.3	5
623	Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice. <i>Hepatology Communications</i> , 2020, 4, 1441-1458.	2.0	23

#	ARTICLE	IF	CITATIONS
624	Dietary Intervention Accelerates NASH Resolution Depending on Inflammatory Status with Minor Additive Effects on Hepatic Injury by Vitamin E Supplementation. <i>Antioxidants</i> , 2020, 9, 808.	2.2	6
625	Internalization of Garlic-Derived Nanovesicles on Liver Cells is Triggered by Interaction With CD98. <i>ACS Omega</i> , 2020, 5, 23118-23128.	1.6	49
626	Reduction of Polyunsaturated Fatty Acids with Tumor Progression in a Lean Non-Alcoholic Steatohepatitis-Associated Hepatocellular Carcinoma Mouse Model. <i>Journal of Cancer</i> , 2020, 11, 5536-5546.	1.2	12
627	Liver biopsy reliability in clinical trials: Thoughts from a liver pathologist. <i>Journal of Hepatology</i> , 2020, 73, 1310-1312.	1.8	12
628	Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1329-1338.	1.1	5
629	Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. <i>Medicine (United States)</i> , 2020, 99, e21463.	0.4	3
630	The Emerging Relevance of AIM2 in Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6535.	1.8	21
631	Microbial Metabolites: Critical Regulators in NAFLD. <i>Frontiers in Microbiology</i> , 2020, 11, 567654.	1.5	51
632	Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. <i>PLoS ONE</i> , 2020, 15, e0236977.	1.1	29
633	The Protective Effect of <i>Myristica fragrans</i> Houtt. Extracts Against Obesity and Inflammation by Regulating Free Fatty Acids Metabolism in Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020, 12, 2507.	1.7	16
634	Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). <i>Clinical Epigenetics</i> , 2020, 12, 126.	1.8	20
635	Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5999.	1.8	13
636	Cytokines™ Involvement in Periodontal Changes. , 0, , .		0
637	Differences in multi-echo chemical shift encoded MRI proton density fat fraction estimation based on multifrequency fat peaks selection in non-alcoholic fatty liver disease patients. <i>Clinical Radiology</i> , 2020, 75, 880.e5-880.e12.	0.5	1
638	Pluripotent Stem Cell-Derived Hepatocytes Phenotypic Screening Reveals Small Molecules Targeting the CDK2/4-C/EBP1±/DGAT2 Pathway Preventing ER-Stress Induced Lipid Accumulation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9557.	1.8	8
639	Metabolic drivers of non-alcoholic fatty liver disease. <i>Molecular Metabolism</i> , 2021, 50, 101143.	3.0	99
640	Aging and Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2020, 40, 373-384.	1.8	21
641	The Role of Thyroid Hormones and Autoantibodies in Metabolic Dysfunction Associated Fatty Liver Disease: TgAb May Be a Potential Protective Factor. <i>Frontiers in Endocrinology</i> , 2020, 11, 598836.	1.5	10

#	ARTICLE	IF	CITATIONS
642	FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. <i>Frontiers in Endocrinology</i> , 2020, 11, 601290.	1.5	111
643	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	1.2	2
644	New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. <i>Frontiers in Pediatrics</i> , 2020, 8, 603654.	0.9	23
645	Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9646.	1.8	40
646	Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet. <i>Nutrients</i> , 2020, 12, 3886.	1.7	15
647	The Phospholipid Research Center: Current Research in Phospholipids and Their Use in Drug Delivery. <i>Pharmaceutics</i> , 2020, 12, 1235.	2.0	67
648	The Association and Interaction of Aldehyde Dehydrogenase 2 Polymorphisms with Food Group Intake and Probability of Having Non-Alcoholic Fatty Liver Disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 5049-5057.	1.1	9
649	Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2020, 11, 592373.	1.5	42
650	Learning steatosis staging with two-dimensional Convolutional Neural Networks: comparison of accuracy of clinical B-mode with a co-registered spectrogram representation of RF Data. , 2020, , .		1
651	The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100097.	1.3	10
652	Bone morphogenetic protein 4 (BMP4) promotes hepatic glycogen accumulation and reduces glucose level in hepatocytes through mTORC2 signaling pathway. <i>Genes and Diseases</i> , 2021, 8, 531-544.	1.5	14
653	Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies. <i>Liver Research</i> , 2020, 4, 180-190.	0.5	6
654	Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis. <i>Advanced Science</i> , 2020, 7, 2002997.	5.6	10
655	National and Global Ethnicity Differences in Non-alcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2020, 19, 429-436.	0.4	1
656	The influence of dietary conditions in the effects of resveratrol on hepatic steatosis. <i>Food and Function</i> , 2020, 11, 9432-9444.	2.1	6
657	Effect of Adult Weight Gain on Non-Alcoholic Fatty Liver Disease and Its Association with Anthropometric Parameters in the Lean Japanese Population. <i>Diagnostics</i> , 2020, 10, 863.	1.3	1
658	Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. <i>Nutrients</i> , 2020, 12, 3379.	1.7	30
659	Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NF- κ B Signaling Pathway and Restores Gut Microbiota in High-Fat-Diet-Fed Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-20.	1.9	53

#	ARTICLE	IF	CITATIONS
660	Brown-Algae Polysaccharides as Active Constituents against Nonalcoholic Fatty Liver Disease. <i>Planta Medica</i> , 2022, 88, 9-19.	0.7	15
661	A Nomogram Model Based on Noninvasive Bioindicators to Predict 3-Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	14
662	Eating quickly is associated with a low aspartate aminotransferase to alanine aminotransferase ratio in middle-aged adults: a large-scale cross-sectional survey in Japan. <i>Archives of Public Health</i> , 2020, 78, 101.	1.0	4
663	Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?. <i>Nutrients</i> , 2020, 12, 3363.	1.7	16
664	Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882095829.	1.4	17
665	Causative and Sanative dynamicity of ChREBP in Hepato-Metabolic disorders. <i>European Journal of Cell Biology</i> , 2020, 99, 151128.	1.6	6
666	Association between serum β -carotene-to-retinol ratio and severity of hepatic steatosis in non-alcoholic fatty liver disease in Japan: A cross-sectional study. <i>Nutrition</i> , 2020, 79-80, 110984.	1.1	3
667	NPY stimulates cholesterol synthesis acutely by activating the SREBP2-HMGR pathway through the Y1 and Y5 receptors in murine hepatocytes. <i>Life Sciences</i> , 2020, 262, 118478.	2.0	20
668	Diagnostic accuracy of B-Mode ultrasound and Hepatorenal Index for graduation of hepatic steatosis in patients with chronic liver disease. <i>PLoS ONE</i> , 2020, 15, e0231044.	1.1	24
669	Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00165.	1.3	4
670	Danger signals in liver injury and restoration of homeostasis. <i>Journal of Hepatology</i> , 2020, 73, 933-951.	1.8	54
671	Cypenositides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis. <i>Nutrition and Metabolism</i> , 2020, 17, 34.	1.3	26
672	Immune modulating effects of additional supplementation of estradiol combined with testosterone in murine testosterone-deficient NAFLD model. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G989-G999.	1.6	18
673	Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites. <i>Nutrients</i> , 2020, 12, 1434.	1.7	39
674	Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT2 inhibitors in a real-world setting. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00131.	1.0	6
675	Relationships between Very Low-Density Lipoproteins, Ceramides, Diacylglycerols, and Triacylglycerols in Insulin-Resistant Men. <i>Lipids</i> , 2020, 55, 387-393.	0.7	15
676	Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 1353-1362.	1.9	17
677	Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?. <i>Scientific Reports</i> , 2020, 10, 8161.	1.6	97

#	ARTICLE	IF	CITATIONS
678	A Diet Rich in Saturated Fat and Cholesterol Aggravates the Effect of Bacterial Lipopolysaccharide on Alveolar Bone Loss in a Rabbit Model of Periodontal Disease. <i>Nutrients</i> , 2020, 12, 1405.	1.7	8
679	Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway. <i>BMC Immunology</i> , 2020, 21, 28.	0.9	25
680	Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 321-330.	1.0	5
681	Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD. <i>Nutrients</i> , 2020, 12, 1316.	1.7	40
682	An Update on the Role of the Microbiome in Non-alcoholic Fatty Liver Disease Pathogenesis, Diagnosis, and Treatment. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 270-280.	0.3	8
683	Alternative Splicing in Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 699-712.	2.3	37
684	Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. <i>Journal of Hepatology</i> , 2020, 73, 896-905.	1.8	119
685	Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. <i>Scientific Reports</i> , 2020, 10, 7440.	1.6	8
686	Pemafibrate, a selective PPAR α modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. <i>Scientific Reports</i> , 2020, 10, 7818.	1.6	60
687	Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. <i>Journal of Digestive Diseases</i> , 2020, 21, 372-384.	0.7	34
688	Interface Hepatitis over Grade 2 May Differentiate Chronic Inflammation Associated with CHB from NAFLD in the Early Stage. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-7.	0.7	1
689	Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease. <i>Endocrine</i> , 2020, 69, 294-302.	1.1	19
690	Epigenome environment interactions accelerate epigenomic aging and unlock metabolically restricted epigenetic reprogramming in adulthood. <i>Nature Communications</i> , 2020, 11, 2316.	5.8	43
691	Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1305-1320.	1.9	103
692	Non-invasive diagnosis of nonalcoholic fatty liver disease: impact of age and other risk factors. <i>Aging Male</i> , 2020, 23, 1275-1282.	0.9	5
693	Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice. <i>Biochemical and Biophysical Research Communications</i> , 2020, 528, 305-310.	1.0	34
694	Sirtuin-6 in Hepatic Fibrosis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 420-421.	2.3	0
695	Comparison of MAFLD and NAFLD diagnostic criteria in real world. <i>Liver International</i> , 2020, 40, 2082-2089.	1.9	362

#	ARTICLE	IF	CITATIONS
696	Quantification of liver fat content with ultrasonographic attenuation measurement function: Correlation with unenhanced multidimensional computerized tomography. <i>Clinical Imaging</i> , 2020, 65, 85-93.	0.8	21
697	Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1149-1159.	1.9	101
698	Magnesium isoglycyrrhizinate prevents the nonalcoholic hepatic steatosis via regulating energy homeostasis. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7201-7213.	1.6	15
699	Kefir in the Prevention and Treatment of Obesity and Metabolic Disorders. <i>Current Nutrition Reports</i> , 2020, 9, 184-192.	2.1	19
700	Sexâ€opposed inflammatory effects of 27â€hydroxycholesterol are mediated via differences in estrogen signaling. <i>Journal of Pathology</i> , 2020, 251, 429-439.	2.1	9
701	Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis. <i>Nature Metabolism</i> , 2020, 2, 413-431.	5.1	131
702	Combined alcoholic and non-alcoholic steatohepatitis. <i>JHEP Reports</i> , 2020, 2, 100101.	2.6	42
703	The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 284-290.	0.5	2
704	Regional difference in the susceptibility of non-alcoholic fatty liver disease in China. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001311.	1.2	3
705	Decreased Quality of Life Is Significantly Associated With Body Composition in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2980-2988.e4.	2.4	19
706	Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis. <i>Liver Research</i> , 2020, 4, 47-63.	0.5	100
707	Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154291.	1.5	20
708	Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non-alcoholic steatohepatitis in rats. <i>Toxicology and Applied Pharmacology</i> , 2020, 401, 115101.	1.3	16
709	Automatic segmentation of liver/kidney area with double-layered fuzzy C-means and the utility of hepatorenal index for fatty liver severity classification. <i>Journal of Intelligent and Fuzzy Systems</i> , 2020, 39, 925-936.	0.8	3
710	Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin. <i>Nature Biomedical Engineering</i> , 2020, 4, 801-813.	11.6	34
711	Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Nonobese Postmenopausal Women: A Cross-sectional Study. <i>Scientific Reports</i> , 2020, 10, 10072.	1.6	18
712	Effectiveness and safety of traditional Chinese medicines for non-alcoholic fatty liver disease. <i>Medicine (United States)</i> , 2020, 99, e20699.	0.4	1
713	Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. <i>Hepatology Communications</i> , 2020, 4, 1293-1301.	2.0	70

#	ARTICLE	IF	CITATIONS
714	The prevalence and correlates of T-wave inversion in lead III in non-obese men. <i>Journal of Electrocardiology</i> , 2020, 61, 66-70.	0.4	0
715	Combination of luteolin and lycopene effectively protect against the "two-hit" in NAFLD through Sirt1/AMPK signal pathway. <i>Life Sciences</i> , 2020, 256, 117990.	2.0	39
716	Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver. <i>Hepatology</i> , 2020, 72, 857-872.	3.6	24
717	Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 1030-1036.	1.8	18
718	Delivery of microRNA-33 Antagomirs by Mesoporous Silica Nanoparticles to Ameliorate Lipid Metabolic Disorders. <i>Frontiers in Pharmacology</i> , 2020, 11, 921.	1.6	8
719	The role of AMPK \pm 2 in the HFD-induced nonalcoholic steatohepatitis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165854.	1.8	7
720	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1476-1482.	0.8	16
721	S-petasin inhibits lipid accumulation in oleic acid-induced HepG2 cells through activation of the AMPK signaling pathway. <i>Food and Function</i> , 2020, 11, 5664-5673.	2.1	19
722	Non Alcoholic Fatty Liver Disease and Degree of Steatosis in Diabetic and Non- Diabetic patients. <i>Obesity Medicine</i> , 2020, 19, 100243.	0.5	4
723	<i>Bifidobacterium adolescentis</i> and <i>Lactobacillus rhamnosus</i> alleviate non-alcoholic fatty liver disease induced by a high-fat, high-cholesterol diet through modulation of different gut microbiota-dependent pathways. <i>Food and Function</i> , 2020, 11, 6115-6127.	2.1	47
724	Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 623-632.	1.9	67
725	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	1.9	14
726	Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. <i>Nature Metabolism</i> , 2020, 2, 514-531.	5.1	31
727	Mechanisms for increased risk of diabetes in chronic liver diseases. <i>Liver International</i> , 2020, 40, 2489-2499.	1.9	9
728	The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome. <i>Visceral Medicine</i> , 2020, 36, 198-205.	0.5	14
729	Dyslipidemic Diet Induces Mobilization of Peripheral Neutrophils and Monocytes That Exacerbate Hemorrhagic Brain Injury and Neuroinflammation. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 154.	1.8	8
730	APOC3 rs2854116 , PNPLA3 rs738409, and TM6SF2 rs58542926 polymorphisms might influence predisposition of NAFLD : A meta-analysis. <i>IUBMB Life</i> , 2020, 72, 1757-1764.	1.5	7
731	Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. <i>Journal of Hepatology</i> , 2020, 73, 516-522.	1.8	78

#	ARTICLE	IF	CITATIONS
732	Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study. <i>Lipids in Health and Disease</i> , 2020, 19, 145.	1.2	15
733	Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans. <i>EBioMedicine</i> , 2020, 57, 102849.	2.7	33
734	Beneficial effects of Chinese herbs in the treatment of fatty liver diseases. <i>Journal of Traditional and Complementary Medicine</i> , 2020, 10, 260-267.	1.5	7
735	Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 171.	1.3	139
736	Body mass indexâ€‘based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 32-41.	0.7	27
737	Editorial: choosing an appropriate risk stratification tool for nonalcoholic fatty liver diseaseâ€‘one size does not fit all. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 662-663.	1.9	0
738	Epidemiology of non-alcoholic fatty liver disease in Asia. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 1-8.	0.7	39
739	<p>DHA Protects Against Hepatic Steatosis by Activating Sirt1 in a High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 185-196.	1.1	14
740	Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154203.	1.5	88
741	Relationship Between Ginsenoside Rg3 and Metabolic Syndrome. <i>Frontiers in Pharmacology</i> , 2020, 11, 130.	1.6	32
742	RNA G-quadruplex regulates microRNA-26a biogenesis and function. <i>Journal of Hepatology</i> , 2020, 73, 371-382.	1.8	38
743	Overweight and obesity status from the prenatal period to adolescence and its association with nonâ€‘alcoholic fatty liver disease in young adults: cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1200-1209.	1.1	10
744	A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. <i>Journal of Hepatology</i> , 2020, 72, 1070-1081.	1.8	35
745	Genetic Risk for Hepatic Fat among an Ethnically Diverse Cohort of Youth: The Exploring Perinatal Outcomes among Children Study. <i>Journal of Pediatrics</i> , 2020, 220, 146-153.e2.	0.9	10
746	Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. <i>Gastroenterology</i> , 2020, 158, 1967-1983.e1.	0.6	75
747	Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. <i>Journal of Translational Medicine</i> , 2020, 18, 133.	1.8	22
748	Exercise Combats Hepatic Steatosis: Potential Mechanisms and Clinical Implications. <i>Diabetes</i> , 2020, 69, 517-524.	0.3	55
749	Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1014-1022.	1.1	24

#	ARTICLE	IF	CITATIONS
750	Nonalcoholic Steatohepatitis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1175.	3.8	784
751	The Effect of Moderate Weight Loss on a Non-Invasive Biomarker of Liver Fibrosis: A Randomised Controlled Trial. <i>Obesity Facts</i> , 2020, 13, 144-151.	1.6	3
752	Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990â€2017. <i>Cancer</i> , 2020, 126, 2267-2278.	2.0	79
753	Attenuation of the Hepatoprotective Effects of Ileal Apical Sodium Dependent Bile Acid Transporter (ASBT) Inhibition in Choline-Deficient L-Amino Acid-Defined (CDAA) Diet-Fed Mice. <i>Frontiers in Medicine</i> , 2020, 7, 60.	1.2	12
754	Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1818.	1.2	42
755	Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	5
756	Update on NAFLD genetics: From new variants to the clinic. <i>Journal of Hepatology</i> , 2020, 72, 1196-1209.	1.8	234
757	Sugar-Sweetened Beverages Are Not Associated with Increased Liver Fat Content in Middle-Aged Men and Women. <i>Journal of Nutrition</i> , 2020, 150, 644.	1.3	0
758	<i>PNPLA3</i>148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. <i>Liver International</i> , 2020, 40, 1130-1141.	1.9	33
759	Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. <i>Cells</i> , 2020, 9, 590.	1.8	38
760	Promising therapeutic use of <i>Baccharis trimera</i> (less.) DC. as a natural hepatoprotective agent against hepatic lesions that are caused by multiple risk factors. <i>Journal of Ethnopharmacology</i> , 2020, 254, 112729.	2.0	13
761	Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. <i>Journal of Hepatology</i> , 2020, 73, 1322-1332.	1.8	235
762	Mitochondrial oxidative injury: a key player in nonalcoholic fatty liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G400-G411.	1.6	50
763	Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease. <i>Cancers</i> , 2020, 12, 1714.	1.7	28
764	Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2020, 20, 210.	0.8	47
765	Global epidemiology of lean nonâ€alcoholic fatty liver disease: A systematic review and metaâ€analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2041-2050.	1.4	67
766	Epidemiology, Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4337.	1.8	21
767	The emerging role of ferroptosis in non-cancer liver diseases: hype or increasing hope?. <i>Cell Death and Disease</i> , 2020, 11, 518.	2.7	75

#	ARTICLE	IF	CITATIONS
768	Imaging and immunometabolic phenotyping uncover changes in the hepatic immune response in the early phases of NAFLD. <i>JHEP Reports</i> , 2020, 2, 100117.	2.6	10
769	SHPâ€1 ameliorates nonalcoholic steatohepatitis by inhibiting proinflammatory cytokine production. <i>FEBS Letters</i> , 2020, 594, 2965-2974.	1.3	12
770	Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 527-547.	1.0	5
771	Non-alcoholic fatty liver disease (NAFLD) among underweight adults. <i>Clinical Nutrition ESPEN</i> , 2020, 38, 80-85.	0.5	7
772	A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. <i>Cell Metabolism</i> , 2020, 32, 878-888.e6.	7.2	167
773	Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154305.	1.5	10
774	Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. <i>SAGE Open Medicine</i> , 2020, 8, 205031212093380.	0.7	12
775	Impact of sleeve gastrectomy and dietary change on metabolic and hepatic function in an obesity rat model - Experimental research. <i>International Journal of Surgery</i> , 2020, 75, 139-147.	1.1	7
776	Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2020, 158, 1913-1928.	0.6	346
777	Association between plasminogen activator inhibitorâ€1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. <i>Liver International</i> , 2020, 40, 1111-1120.	1.9	7
778	Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. <i>Disease Markers</i> , 2020, 2020, 1-7.	0.6	10
779	Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?. <i>Hepatology</i> , 2020, 72, 770-771.	3.6	12
780	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0219412.	1.1	17
781	Association of Bone Metabolism with Fatty Liver Disease in the Elderly in Japan: A Community-based Study. <i>Internal Medicine</i> , 2020, 59, 1247-1256.	0.3	8
782	NAFLD and NASH. , 2020, , .		1
783	Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a caseâ€control study. <i>Cancer Causes and Control</i> , 2020, 31, 321-332.	0.8	20
784	The roles of zinc finger proteins in non-alcoholic fatty liver disease. <i>Liver Research</i> , 2020, 4, 35-39.	0.5	4
785	Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 25-44.	1.0	21

#	ARTICLE	IF	CITATIONS
786	Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 105-121.	1.0	4
788	Huang-Qi San improves glucose and lipid metabolism and exerts protective effects against hepatic steatosis in high fat diet-fed rats. <i>Biomedicine and Pharmacotherapy</i> , 2020, 126, 109734.	2.5	21
789	Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease. <i>Liver Research</i> , 2020, 4, 15-22.	0.5	27
790	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
791	Epidemiology of non-alcoholic and alcoholic fatty liver diseases. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 16-16.	1.5	296
792	Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. <i>Gastroenterology</i> , 2020, 158, 1851-1864.	0.6	710
793	NAFLD and autoimmune hepatitis: Do not judge a book by its cover. <i>European Journal of Internal Medicine</i> , 2020, 75, 1-9.	1.0	26
794	Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1899-1912.	0.6	157
795	Emerging therapeutic targets for NASH: key innovations at the preclinical level. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 175-186.	1.5	8
797	Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.. <i>Diabetes Care</i> , 2020, 43, 283-289.	4.3	115
798	Chronic Viral Hepatitis: Current Management and Future Directions. <i>Hepatology Communications</i> , 2020, 4, 329-341.	2.0	32
799	Association of metabolic syndrome and patatin-like phospholipase 3 rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population. <i>Journal of Gene Medicine</i> , 2020, 22, e3160.	1.4	7
800	Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2020, 20, 10.	0.8	93
801	Genecriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905.	3.6	227
802	Targeting alkaline ceramidase 3 alleviates the severity of nonalcoholic steatohepatitis by reducing oxidative stress. <i>Cell Death and Disease</i> , 2020, 11, 28.	2.7	26
803	Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 89-92.	1.9	27
804	A single nucleotide polymorphism of PLIN2 is associated with nonalcoholic steatohepatitis and causes phenotypic changes in hepatocyte lipid droplets: A pilot study. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158637.	1.2	10
805	Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1597-1610.e7.	0.6	123

#	ARTICLE	IF	CITATIONS
806	Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G554-G573.	1.6	175
807	Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006â€“2016. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz509.	0.4	11
808	Combining Ablation and Resection for the Treatment of Hepatocellular Carcinoma: An Attempt to Expand Treatment Options. <i>Annals of Surgical Oncology</i> , 2020, 27, 2125-2126.	0.7	0
809	Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	7
810	Targeting DUSP16/TAK1 signaling alleviates hepatic dyslipidemia and inflammation in high fat diet (HFD)-challenged mice through suppressing JNK MAPK. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 142-149.	1.0	9
811	Association of serum uric acid with visceral, subcutaneous and hepatic fat quantified by magnetic resonance imaging. <i>Scientific Reports</i> , 2020, 10, 442.	1.6	35
812	Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis. <i>Scientific Reports</i> , 2020, 10, 481.	1.6	25
813	NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 191-196.	1.9	14
814	Fatty liver in pregnancy: a narrative review of two distinct conditions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 127-135.	1.4	17
816	Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2073-2080.e7.	2.4	29
818	Complications, morbidity and mortality of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154170.	1.5	278
819	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	3.7	411
820	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	0.6	575
821	Systematic investigation on the chemical basis of antiâ€“NAFLD Qushi Huayu Fang. Part 1: A study of metabolic profiles in vivo and in vitro by highâ€“performance liquid chromatographyâ€“quadrupole timeâ€“ofâ€“flight mass spectrometry. <i>Biomedical Chromatography</i> , 2020, 34, e4805.	0.8	6
822	Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. <i>Scientific Reports</i> , 2020, 10, 1699.	1.6	26
823	Biological Role of Unsaturated Fatty Acid Desaturases in Health and Disease. <i>Nutrients</i> , 2020, 12, 356.	1.7	72
824	A Human REPIN1 Gene Variant: Genetic Risk Factor for the Development of Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00114.	1.3	3
825	Liver gene regulatory networks: Contributing factors to nonalcoholic fatty liver disease. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2020, 12, e1480.	6.6	1

#	ARTICLE	IF	CITATIONS
826	Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 1686-1692.	1.9	21
827	Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. <i>Journal of Hepatology</i> , 2020, 73, 757-770.	1.8	154
828	Redefining fatty liver disease classification in 2020. <i>Liver International</i> , 2020, 40, 1016-1017.	1.9	43
829	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. <i>PLoS Medicine</i> , 2020, 17, e1003100.	3.9	205
830	Pyruvium pamoate attenuates non-alcoholic steatohepatitis: Insight on hedgehog/Gli and Wnt/ β -catenin signaling crosstalk. <i>Biochemical Pharmacology</i> , 2020, 177, 113942.	2.0	24
831	Association of bedtime with the risk of non-alcoholic fatty liver disease among middle-aged and elderly Chinese adults with pre-diabetes and diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3322.	1.7	11
832	Sleeve Gastroplasty Combined with the NLRP3 Inflammasome Inhibitor CY-09 Reduces Body Weight, Improves Insulin Resistance and Alleviates Hepatic Steatosis in Mouse Model. <i>Obesity Surgery</i> , 2020, 30, 3435-3443.	1.1	15
834	Fatty liver diseases, mechanisms, and potential therapeutic plant medicines. <i>Chinese Journal of Natural Medicines</i> , 2020, 18, 161-168.	0.7	9
835	The acute schistosomiasis mansoni ameliorates metabolic syndrome in the C57BL/6 mouse model. <i>Experimental Parasitology</i> , 2020, 212, 107889.	0.5	9
836	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
837	Phytotherapy using blueberry leaf polyphenols to alleviate non-alcoholic fatty liver disease through improving mitochondrial function and oxidative defense. <i>Phytotherapy</i> , 2020, 69, 153209.	2.3	33
838	The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. <i>Trends in Genetics</i> , 2020, 36, 429-441.	2.9	58
839	Hepatoprotective and Anti-Oxidative Effects of Total Flavonoids From Qu Zhi Qiao (Fruit of Citrus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2020, 11, 483.	1.6	24
840	Polymorphisms in Interleukin 13 Signaling and Interacting Genes Predict Advanced Fibrosis and Hepatocellular Carcinoma Development in Non-Alcoholic Steatohepatitis. <i>Biology</i> , 2020, 9, 75.	1.3	13
841	Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cutoff to assess fibrosis stages. <i>Journal of Digestive Diseases</i> , 2020, 21, 279-286.	0.7	6
842	Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. <i>JHEP Reports</i> , 2020, 2, 100099.	2.6	30
843	Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 75-83.	0.7	6
844	Lighter serum copper isotopic composition in patients with early non-alcoholic fatty liver disease. <i>BMC Research Notes</i> , 2020, 13, 225.	0.6	14

#	ARTICLE	IF	CITATIONS
845	SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 341-364.	2.3	45
846	Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice. <i>Journal of Ethnopharmacology</i> , 2020, 258, 112896.	2.0	19
847	What's in a name? Renaming "NAFLD" to "MAFLD". <i>Liver International</i> , 2020, 40, 1254-1261.	1.9	212
848	Combined effects of lifestyle risk factors on fatty liver index. <i>BMC Gastroenterology</i> , 2020, 20, 109.	0.8	13
849	<p>Radix Polygoni Multiflori and Its Main Component Emodin Attenuate Non-Alcoholic Fatty Liver Disease in Zebrafish by Regulation of AMPK Signaling Pathway</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1493-1506.	2.0	36
850	The lncRNA Gm15622 stimulates SREBP-1c expression and hepatic lipid accumulation by sponging the miR-742-3p in mice. <i>Journal of Lipid Research</i> , 2020, 61, 1052-1064.	2.0	37
851	Emergent Properties of the HNF4 α -PPAR β Network May Drive Consequent Phenotypic Plasticity in NAFLD. <i>Journal of Clinical Medicine</i> , 2020, 9, 870.	1.0	18
852	Design, Synthesis, and Biological Evaluation of New Peripheral 5HT _{2A} Antagonists for Nonalcoholic Fatty Liver Disease. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4171-4182.	2.9	8
853	Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta-Activated Kinase 1/ Jun N-terminal Kinase/p38 Signaling. <i>Hepatology</i> , 2021, 73, 104-125.	3.6	40
854	Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH). <i>Hepatology</i> , 2021, 73, 920-936.	3.6	39
855	The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter. <i>Transplantation Proceedings</i> , 2021, 53, 159-165.	0.3	15
856	Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease. <i>Annals of Hepatology</i> , 2021, 21, 100212.	0.6	25
857	From NAFLD to MAFLD: Implications of a Premature Change in Terminology. <i>Hepatology</i> , 2021, 73, 1194-1198.	3.6	266
858	Chronic ingestion of Primex-Z, compared with other common fat sources, drives worse liver injury and enhanced susceptibility to bacterial infections. <i>Nutrition</i> , 2021, 81, 110938.	1.1	4
859	Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 751-757.	1.4	4
860	Evolving Role for Pharmacotherapy in NAFLD/NASH. <i>Clinical and Translational Science</i> , 2021, 14, 11-19.	1.5	86
861	Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. <i>Cell Biology and Toxicology</i> , 2021, 37, 293-311.	2.4	25
862	Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. <i>Digestive and Liver Disease</i> , 2021, 53, 79-85.	0.4	36

#	ARTICLE	IF	CITATIONS
863	Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 947-955.	0.9	45
864	Metabolic Inflammation in Obesity—At the Crossroads between Fatty Acid and Cholesterol Metabolism. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e1900482.	1.5	19
865	Cafeteria diet from birth to adulthood promotes hepatic steatosis and redox imbalance in Wistar rats. <i>Nutrition and Food Science</i> , 2021, 51, 483-493.	0.4	1
866	17 β -Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury. <i>Hepatology</i> , 2021, 73, 1701-1716.	3.6	38
867	<i>Lactobacillus casei</i> YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway. <i>British Journal of Nutrition</i> , 2021, 125, 521-529.	1.2	15
868	The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 893-909.	1.4	13
869	Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1240-1247.e5.	2.4	40
870	Gender-Specific Risk Factors for Reflux Esophagitis in a Predominantly Hispanic Population of a Large Safety-Net Hospital. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1940-1948.	1.1	0
871	The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. <i>Translational Research</i> , 2021, 227, 75-88.	2.2	61
872	Inflammatory Diseases and Vitamin E—What Do We Know and Where Do We Go?. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000097.	1.5	27
873	Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101483.	0.7	9
874	Modifications of IGF2 and EGFR plasma protein concentrations in NAFLD patients after bariatric surgery. <i>International Journal of Obesity</i> , 2021, 45, 374-382.	1.6	1
875	Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. <i>Gastroenterology</i> , 2021, 160, 331-345.e6.	0.6	46
876	Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101526.	0.7	47
877	Seeing the fetus from a DOHaD perspective: discussion paper from the advanced imaging techniques of DOHaD applications workshop held at the 2019 DOHaD World Congress. <i>Journal of Developmental Origins of Health and Disease</i> , 2021, 12, 153-167.	0.7	4
878	Outcomes of Japanese patients with non-alcoholic fatty liver disease according to genetic background and lifestyle-related diseases. <i>Annals of Hepatology</i> , 2021, 21, 100260.	0.6	4
879	Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 82-91.	2.2	11
880	Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice. <i>Metabolism: Clinical and Experimental</i> , 2021, 114, 154349.	1.5	29

#	ARTICLE	IF	CITATIONS
881	Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works. <i>Hepatology Research</i> , 2021, 51, 19-30.	1.8	20
882	Evolutionary conservation of long non-coding RNAs in non-alcoholic fatty liver disease. <i>Life Sciences</i> , 2021, 264, 118560.	2.0	18
883	Maladaptive regeneration – the reawakening of developmental pathways in NASH and fibrosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 131-142.	8.2	64
884	Prevalence of anti-Hepatitis E antibodies and impact on disease severity in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2021, 51, 69-79.	1.8	4
885	NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 734-739.	1.0	34
886	Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus. <i>Journal of Hepatology</i> , 2021, 74, 1028-1037.	1.8	32
887	Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101530.	0.7	4
888	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021, 160, 1608-1619.e13.	0.6	60
889	Role of histone deacetylase on nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 353-361.	1.4	5
890	Osteocalcin and Non-Alcoholic Fatty Liver Disease: Lessons From Two Population-Based Cohorts and Animal Models. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 712-728.	3.1	22
891	The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 65-72.	3.7	108
892	Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing. <i>Medical Hypotheses</i> , 2021, 146, 110379.	0.8	8
893	Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2021, 33, 21-32.	7.2	98
894	Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR- α signaling in obese mice. <i>Life Sciences</i> , 2021, 266, 118868.	2.0	57
895	Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns. <i>Frontiers in Immunology</i> , 2020, 11, 609900.	2.2	16
896	Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. <i>Archives of Medical Research</i> , 2021, 52, 25-37.	1.5	112
897	Gut microbiome, liver immunology, and liver diseases. <i>Cellular and Molecular Immunology</i> , 2021, 18, 4-17.	4.8	182
898	The Importance of Keeping Time in the Liver. <i>Endocrinology</i> , 2021, 162, .	1.4	8

#	ARTICLE	IF	CITATIONS
899	Presence of Liver Steatosis Is Associated With Greater Diabetes Remission After Gastric Bypass Surgery. <i>Diabetes Care</i> , 2021, 44, 321-325.	4.3	14
900	Residual risk of liver disease after hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2021, 74, 952-963.	1.8	22
902	Endocrine disrupting chemicals and metabolic disorders in the liver: What if we also looked at the female side?. <i>Chemosphere</i> , 2021, 268, 129212.	4.2	16
903	A portable single-sided magnetic-resonance sensor for the grading of liver steatosis and fibrosis. <i>Nature Biomedical Engineering</i> , 2021, 5, 240-251.	11.6	21
904	Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: A cohort study. <i>Diabetes and Metabolism</i> , 2021, 47, 101200.	1.4	16
905	Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e34-e44.	1.8	13
906	The mother relationship between insulin resistance and non-alcoholic steatohepatitis: Glucosinolates hydrolysis products as a promising insulin resistance-modulator and fatty liver-preventer. <i>Life Sciences</i> , 2021, 264, 118615.	2.0	2
907	The Prevalence of Nonalcoholic Fatty Liver Disease and Its Risk Factors in Children and Young Adults with Type 1 Diabetes Mellitus. <i>Journal of Pediatrics</i> , 2021, 230, 32-37.e1.	0.9	4
908	Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. <i>Liver International</i> , 2021, 41, 261-270.	1.9	155
909	Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 25-40.	1.4	13
910	Mechanisms of nonalcoholic fatty liver disease and implications for surgery. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 1-17.	0.8	21
911	The role of TLR4/MyD88/NF- κ B pathway in periodontitis-induced liver inflammation of rats. <i>Oral Diseases</i> , 2021, 27, 1012-1021.	1.5	18
912	The Connection between MicroRNAs from Visceral Adipose Tissue and Non-Alcoholic Fatty Liver Disease. <i>Acta Medica (Hradec Kralove)</i> , 2021, 64, 1-7.	0.2	3
913	Emerging Role of Microbiota in Precision Nutrition Approaches. , 2021, , 220-220.		1
914	Carotenoids in Liver and Lung Diseases. , 2021, , 585-608.		0
915	Lean NAFLD: an underrecognized and challenging disorder in medicine. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 351-366.	2.6	40
916	Composite BMI and Waist-to-Height Ratio Index for Risk Assessment of Non-alcoholic Fatty Liver Disease in Adult Populations. <i>Hepatitis Monthly</i> , 2021, 20, .	0.1	2
917	RESULTS OF QUESTIONING PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN THE CONDITIONS OF DENTAL PRACTICE. <i>Wiadomości Lekarskie</i> , 2021, 74, 504-507.	0.1	0

#	ARTICLE	IF	CITATIONS
918	Functional milk fat enriched in conjugated linoleic acid prevented liver lipid accumulation induced by a high-fat diet in male rats. <i>Food and Function</i> , 2021, 12, 5051-5065.	2.1	4
919	Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database. <i>Journal of Gastroenterology</i> , 2021, 56, 274-284.	2.3	19
920	Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. <i>Metabolites</i> , 2021, 11, 73.	1.3	145
921	Non-alcoholic fatty liver disease: digest 2021. <i>Russian Journal of Evidence-Based Gastroenterology</i> , 2021, 10, 27.	0.3	4
922	The Altered Serum Lipidome and its Diagnostic Potential for Non-Alcoholic Fatty Liver (NAFL)-Associated Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
923	Effect of dietary carbohydrate and lipid modification on clinical and anthropometric parameters in nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2021, 79, 1321-1337.	2.6	10
924	NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. <i>Journal of Clinical Medicine</i> , 2021, 10, 467.	1.0	31
925	Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 818.	1.8	147
926	Active phase prebiotic feeding alters gut microbiota, induces weight-independent alleviation of hepatic steatosis and serum cholesterol in high-fat diet-fed mice. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 448-458.	1.9	16
927	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 212-226.	0.7	4
928	Complications of Obesity. , 2021, , 95-116.		1
929	Effect of Kupffer Cells in the Pathogenesis of Primary Liver Cancer. <i>Advances in Clinical Medicine</i> , 2021, 11, 1726-1732.	0.0	0
930	A nutritional intervention that promotes increased vegetable intake in Japanese with non-alcoholic fatty liver disease: a six-month trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2022, 70, 46-53.	0.6	2
931	Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110368.	1.0	15
932	Association between obesity profile and non-alcoholic fatty liver by race/ethnicity. <i>Annals of Clinical Endocrinology and Metabolism</i> , 2021, 5, 001-010.	0.3	1
933	Pterostilbene modifies triglyceride metabolism in hepatic steatosis induced by high-fat high-fructose feeding: a comparison with its analog resveratrol. <i>Food and Function</i> , 2021, 12, 3266-3279.	2.1	12
934	Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of <i>Erysipelotrichales</i> . <i>PLoS ONE</i> , 2021, 16, e0244763.	1.1	30
935	Bioactive lipids in metabolic liver disease. <i>Studies in Natural Products Chemistry</i> , 2021, , 263-297.	0.8	1

#	ARTICLE	IF	CITATIONS
936	H. pylori is related to NAFLD but only in female: A Cross-sectional Study. <i>International Journal of Medical Sciences</i> , 2021, 18, 2303-2311.	1.1	11
937	The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 45-81.	0.4	12
938	Referral Patterns for Patients with Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 404.	1.0	1
939	CD4 derived double negative T cells prevent the development and progression of nonalcoholic steatohepatitis. <i>Nature Communications</i> , 2021, 12, 650.	5.8	17
940	HbA1C as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 1-7.	0.7	5
941	Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110002.	1.4	21
942	Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD. <i>Food and Function</i> , 2021, 12, 3898-3918.	2.1	147
943	Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. <i>Hepatoma Research</i> , 2021, 2021, 11.	0.6	25
944	Short-Term Weight Loss Decreased the Risk of Chronic Kidney Disease in Incident NAFLD Participants: A Prospective Cohort. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
946	Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARM \pm) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 3.	2.0	18
947	Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. <i>Gut</i> , 2021, 70, 2085-2095.	6.1	120
948	The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 583-593.	1.2	8
949	Hepatocyte-specific TAZ deletion downregulates p62/ Sqstm1 expression in nonalcoholic steatohepatitis. <i>Biochemical and Biophysical Research Communications</i> , 2021, 535, 60-65.	1.0	4
950	Therapeutic approaches for non-alcoholic steatohepatitis. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110343.	1.4	7
951	Comparative analysis of metabolic risk factors for progression of non-alcoholic fatty liver disease. <i>Clinical and Experimental Hepatology</i> , 2021, 7, 241-247.	0.6	4
952	CD73 Maintains Hepatocyte Metabolic Integrity and Mouse Liver Homeostasis in a Sex-Dependent Manner. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 141-157.	2.3	11
953	Lactobacillus johnsonii BS15 combined with abdominal massage on intestinal permeability in rats with nonalcoholic fatty liver and cell biofilm repair. <i>Bioengineered</i> , 2021, 12, 6354-6363.	1.4	4
954	Molecular mechanisms and physiological functions of mitophagy. <i>EMBO Journal</i> , 2021, 40, e104705.	3.5	553

#	ARTICLE	IF	CITATIONS
955	Extracellular Vesicles as Drivers of Non-Alcoholic Fatty Liver Disease: Small Particles with Big Impact. <i>Biomedicines</i> , 2021, 9, 93.	1.4	11
956	Association of hepatic steatosis with epicardial fat volume and coronary artery disease in symptomatic patients. <i>Radiologia Medica</i> , 2021, 126, 652-660.	4.7	8
958	Evaluation of Different Anthropometric Indicators for Screening for Nonalcoholic Fatty Liver Disease in Elderly Individuals. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-12.	0.6	11
959	Common Transcriptional Program of Liver Fibrosis in Mouse Genetic Models and Humans. <i>International Journal of Molecular Sciences</i> , 2021, 22, 832.	1.8	4
961	Changing Etiology and Epidemiology of Human Liver Cancer. , 2021, , 13-29.		0
962	Learning from Subjective Ratings Using Auto-Decoded Deep Latent Embeddings. <i>Lecture Notes in Computer Science</i> , 2021, , 270-280.	1.0	1
963	Preparation of Chitin Nanofiber and Its Derivatives from Crab Shell and Their Efficient Biological Properties. <i>Advances in Polymer Science</i> , 2021, , 301-318.	0.4	0
964	Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. <i>Hepatology Communications</i> , 2021, 5, 573-588.	2.0	82
965	A novel immune-related genes signature after bariatric surgery is histologically associated with non-alcoholic fatty liver disease. <i>Adipocyte</i> , 2021, 10, 424-434.	1.3	16
966	Co-Culture of Human Mesenchymal Stromal Cells and Primary Mouse Hepatocytes. <i>Methods in Molecular Biology</i> , 2021, 2269, 151-165.	0.4	2
967	Liver Enzymes Correlate With Metabolic Syndrome, Inflammation, and Endothelial Dysfunction in Prepubertal Children With Obesity. <i>Frontiers in Pediatrics</i> , 2021, 9, 629346.	0.9	15
968	Comparison of hepatic gene expression profiles between three mouse models of Nonalcoholic Fatty Liver Disease. <i>Genes and Diseases</i> , 2022, 9, 201-215.	1.5	8
969	Diagnostic accuracy assessment of molecular prediction model for the risk of NAFLD based on MRI-PDFF diagnosed Chinese Han population. <i>BMC Gastroenterology</i> , 2021, 21, 88.	0.8	7
970	Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma. <i>Biomedicines</i> , 2021, 9, 184.	1.4	23
971	Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. <i>Liver International</i> , 2021, 41, 731-742.	1.9	27
972	Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization. <i>Nutrients</i> , 2021, 13, 599.	1.7	26
973	Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 730.	1.7	35
974	Gegen Qinlian Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats via Oxidative Stress, Inflammation, and the NLRP3 Signal Axis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-11.	0.5	7

#	ARTICLE	IF	CITATIONS
975	Nonalcoholic Fatty Liver Disease and Fibrosis Risk in Patients With Obstructive Sleep Apnea: A Retrospective Analysis. <i>Cureus</i> , 2021, 13, e13623.	0.2	1
976	The metabolic profiles and body composition of lean metabolic associated fatty liver disease. <i>Hepatology International</i> , 2021, 15, 405-412.	1.9	21
977	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	6.1	113
978	From NAFLD to MAFLD: Nurse and allied health perspective. <i>Liver International</i> , 2021, 41, 683-691.	1.9	34
979	Protection of Fatty Liver by the Intake of Fermented Soybean Paste, Miso, and Its Pre-Fermented Mixture. <i>Foods</i> , 2021, 10, 291.	1.9	2
980	Diagnostic Value of Ultrasound in Fatty Liver Disease. <i>Ultraschall in Der Medizin</i> , 2021, 42, 128-153.	0.8	8
981	Dietary and metabolic risk of neuropsychiatric disorders: insights from animal models. <i>British Journal of Nutrition</i> , 2021, 126, 1771-1787.	1.2	8
982	Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0245762.	1.1	61
983	Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. <i>Hepatology International</i> , 2021, 15, 258-282.	1.9	62
984	Dietary approaches to managing nonalcoholic fatty liver disease. <i>Nurse Practitioner</i> , 2021, 46, 19-26.	0.2	2
985	Integrated Analysis of Key Genes and Pathways Involved in Nonalcoholic Steatohepatitis Improvement After Roux-en-Y Gastric Bypass Surgery. <i>Frontiers in Endocrinology</i> , 2020, 11, 611213.	1.5	4
986	Natural Killer Cells: Friend or Foe in Metabolic Diseases?. <i>Frontiers in Immunology</i> , 2021, 12, 614429.	2.2	16
987	Mitochondrial Dysfunction and Oxidative Stress in Liver Transplantation and Underlying Diseases: New Insights and Therapeutics. <i>Transplantation</i> , 2021, 105, 2362-2373.	0.5	13
988	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. <i>Hepatology International</i> , 2021, 15, 366-379.	1.9	71
990	Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 209-219.	0.1	1
991	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00300.	1.3	9
992	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 437-442.	0.6	4
993	Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. <i>World Journal of Gastroenterology</i> , 2021, 27, 609-623.	1.4	24

#	ARTICLE	IF	CITATIONS
994	Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients. <i>Medicine (United States)</i> , 2021, 100, e24557.	0.4	9
995	Association of dietary insulinaemic potential and odds of non-alcoholic fatty liver disease among adults: A case-control study. <i>Journal of Human Nutrition and Dietetics</i> , 2021, 34, 901-909.	1.3	15
996	Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 894-904.	1.9	16
998	Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease—The Union of Two Culprits. <i>Life</i> , 2021, 11, 119.	1.1	2
999	Vegan Diet Advice Might Benefit Liver Enzymes in Nonalcoholic Fatty Liver Disease: an Open Observational Pilot Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 81-87.	0.5	5
1000	Pathophysiological Roles of Mucosal-Associated Invariant T Cells in the Context of Gut Microbiota-Liver Axis. <i>Microorganisms</i> , 2021, 9, 296.	1.6	11
1001	Is the Mediterranean Diet the Best Approach to NAFLD Treatment Today?. <i>Nutrients</i> , 2021, 13, 739.	1.7	7
1002	Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2020, 11, 609135.	1.5	34
1003	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults. <i>Digestive Diseases and Sciences</i> , 2022, 67, 676-688.	1.1	4
1004	Transcriptome analysis reveals the efficacy of ginsenoside-Rg1 in the treatment of nonalcoholic fatty liver disease. <i>Life Sciences</i> , 2021, 267, 118986.	2.0	13
1005	NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response. <i>FASEB Journal</i> , 2021, 35, e21395.	0.2	4
1006	Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 669.	1.0	11
1007	Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine. <i>International Immunopharmacology</i> , 2021, 91, 107308.	1.7	32
1008	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. <i>Life</i> , 2021, 11, 143.	1.1	22
1009	What are the clinical settings and outcomes of lean NAFLD?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 289-290.	8.2	24
1010	Evaluación de fibrosis en pacientes con enfermedad por hígado graso no alcohólico: adherencia a los algoritmos propuestos y barreras para cumplir con ellos. <i>Revista De Gastroenterología De México</i> , 2021, 87, 4-4.	0.4	0
1011	Prevalence of non-alcoholic fatty liver disease and its associated factors in individuals with type 1 diabetes: a cross-sectional study in a tertiary care center in Brazil. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 33.	1.2	9
1012	Risk of Liver Fibrosis According to TSH Levels in Euthyroid Subjects. <i>Journal of Clinical Medicine</i> , 2021, 10, 1350.	1.0	4

#	ARTICLE	IF	CITATIONS
1013	VCAM-1: closing the gap between lipotoxicity and endothelial dysfunction in nonalcoholic steatohepatitis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	13
1015	Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study. <i>Liver International</i> , 2021, 41, 1556-1564.	1.9	16
1017	Association of LDLR rs1433099 with the Risk of NAFLD and CVD in Chinese Han Population. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	2
1018	Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine. <i>Frontiers in Endocrinology</i> , 2021, 12, 601160.	1.5	16
1019	Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 10-14.	2.8	14
1020	Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13519.	1.7	32
1021	Maternal high-fat high-sucrose diet and gestational exercise modulate hepatic fat accumulation and liver mitochondrial respiratory capacity in mothers and male offspring. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154704.	1.5	22
1022	Xiaochaihu decoction for nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2021, 100, e25267.	0.4	2
1023	Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2092-2100.	1.1	30
1024	WW domain-binding protein 2 overexpression prevents diet-induced liver steatosis and insulin resistance through AMPK β 1. <i>Cell Death and Disease</i> , 2021, 12, 228.	2.7	8
1025	Estimation of Apolipoprotein A1, Haptoglobin and Alpha 2macroglobulin with some Biochemical Metabolic Markers in Nonalcoholic Fatty Liver Disease Iraqi Patients. <i>Al-Taqani</i> , 2021, 3, 24-30.	0.2	1
1026	Pentraxin 3 and the TyG Index as Two Novel Markers to Diagnose NAFLD in Children. <i>Disease Markers</i> , 2021, 2021, 1-7.	0.6	9
1027	Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis. <i>Journal of Pancreatic Cancer</i> , 2021, 7, 23-30.	1.6	2
1028	Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1167-1175.	1.1	5
1029	Pyruvate Dehydrogenase as a Therapeutic Target for Nonalcoholic Fatty Liver Disease. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 582-588.	2.5	14
1030	Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	56
1031	The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. <i>Pharmaceuticals</i> , 2021, 14, 215.	1.7	7
1032	Role of Angiogenesis in the Pathogenesis of NAFLD. <i>Journal of Clinical Medicine</i> , 2021, 10, 1338.	1.0	19

#	ARTICLE	IF	CITATIONS
1033	A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?. <i>Cancers</i> , 2021, 13, 1412.	1.7	26
1034	High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	14
1035	Ultrasonographic profile of non-alcoholic fatty liver disease manifestation in patients with hypertension. <i>Ukrainian Therapeutical Journal</i> , 2021, , .	0.0	0
1036	Biochemical assessment of metabolic associated fatty liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 199-208.	0.1	3
1037	Exploring the Causality Between Hypothyroidism and Non-alcoholic Fatty Liver: A Mendelian Randomization Study. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 643582.	1.8	23
1038	Sacran, a sulfated polysaccharide, suppresses the absorption of lipids and modulates the intestinal flora in non-alcoholic steatohepatitis model rats. <i>Life Sciences</i> , 2021, 268, 118991.	2.0	9
1039	Frequency of non-alcoholic fatty liver disease in a series of forensic cases in Mexico. <i>Horizonte Sanitario</i> , 2021, 20, .	0.1	0
1040	Ferulic acid ameliorates intrahepatic triglyceride accumulation in vitro but not in high fat diet-fed C57BL/6 mice. <i>Food and Chemical Toxicology</i> , 2021, 149, 111978.	1.8	11
1041	The role of biofactors in the prevention and treatment of age-related diseases. <i>BioFactors</i> , 2021, 47, 522-550.	2.6	15
1042	Optimising referral pathways for patients with non-alcoholic fatty liver disease in the UK. <i>British Journal of Health Care Management</i> , 2021, 27, 62-70.	0.1	1
1043	The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. <i>Scientific Reports</i> , 2021, 11, 5195.	1.6	25
1044	Red Meat Consumption and Risk of Nonalcoholic Fatty Liver Disease in a Population With Low Meat Consumption: The Golestan Cohort Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 1667-1675.	0.2	27
1045	Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. <i>Human and Experimental Toxicology</i> , 2021, 40, 1496-1509.	1.1	16
1046	Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. <i>Gut</i> , 2022, 71, 778-788.	6.1	132
1047	Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. <i>Liver International</i> , 2021, 41, 1532-1544.	1.9	26
1048	Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. <i>BMC Gastroenterology</i> , 2021, 21, 135.	0.8	8
1050	An insight into the role of telmisartan as PPAR α / β dual activator in the management of nonalcoholic fatty liver disease. <i>Biotechnology and Applied Biochemistry</i> , 2021, , .	1.4	8
1051	Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00321.	1.3	6

#	ARTICLE	IF	CITATIONS
1052	Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes: A Network Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021, 12, 649018.	1.5	13
1053	Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). <i>Mitochondrion</i> , 2021, 57, 119-130.	1.6	40
1054	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2275-2284.	1.4	26
1055	Ectopic fat depots as a factor of cardiovascular risk in patients with nonalcoholic fatty liver disease. <i>Klinicheskaia Meditsina</i> , 2021, 98, 759-765.	0.2	0
1056	Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. <i>Annals of Translational Medicine</i> , 2021, 9, 615-615.	0.7	9
1057	Role of series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non-alcoholic fatty liver disease (Review). <i>International Journal of Molecular Medicine</i> , 2021, 47, .	1.8	22
1058	Controlled Attenuation Parameter in Healthy Individuals Aged 70 Years. <i>Ultrasound International Open</i> , 2021, 07, E6-E13.	0.3	1
1059	Non Alcoholic Fatty Liver Disease Is Positively Associated with Increased Glycated Haemoglobin Levels in Subjects without Diabetes. <i>Journal of Clinical Medicine</i> , 2021, 10, 1695.	1.0	11
1060	The Gene Signature Associated with Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Journal of Oncology</i> , 2021, 2021, 1-9.	0.6	2
1061	GCSF deficiency attenuates nonalcoholic fatty liver disease through regulating GCSFR-SOCS3-JAK-STAT3 pathway and immune cells infiltration. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G531-G542.	1.6	14
1062	Relationship of Vitamin D Deficiency and Fatty Liver in Children as Defined by Multiple Imaging and Histologic Endpoints. <i>JPGN Reports</i> , 2021, 2, e077.	0.2	2
1063	Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00323.	1.3	22
1064	A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2021, 21, 144.	0.8	35
1065	The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, 104-111.	0.8	0
1066	Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996-2016. <i>American Journal of Gastroenterology</i> , 2021, 116, 2060-2067.	0.2	19
1067	Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. <i>Microorganisms</i> , 2021, 9, 957.	1.6	81
1068	Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). <i>Visceral Medicine</i> , 2021, 37, 273-280.	0.5	21
1069	What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0250385.	1.1	1

#	ARTICLE	IF	CITATIONS
1070	Comparison of Liver Recovery After Sleeve Gastrectomy and Roux-en-Y-Gastric Bypass. <i>Obesity Surgery</i> , 2021, 31, 3218-3226.	1.1	6
1071	Vitamins and non-alcoholic fatty liver disease: A molecular insight. <i>Liver Research</i> , 2021, 5, 62-71.	0.5	37
1072	Integrated Action of Autophagy and Adipose Tissue Triglyceride Lipase Ameliorates Diet-Induced Hepatic Steatosis in Liver-Specific PLIN2 Knockout Mice. <i>Cells</i> , 2021, 10, 1016.	1.8	21
1073	Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 639548.	1.5	35
1074	The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice. <i>Nutrients</i> , 2021, 13, 1281.	1.7	16
1075	Non-alcoholic fatty liver diseases: current challenges and future directions. <i>Annals of Translational Medicine</i> , 2021, 9, 726-726.	0.7	16
1076	Foodborne TiO ₂ Nanoparticles Induced More Severe Hepatotoxicity in Fructose-Induced Metabolic Syndrome Mice via Exacerbating Oxidative Stress-Mediated Intestinal Barrier Damage. <i>Foods</i> , 2021, 10, 986.	1.9	16
1077	NAFLD and MAFLD as emerging causes of HCC: A populational study. <i>JHEP Reports</i> , 2021, 3, 100231.	2.6	54
1078	Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis. <i>Endocrine</i> , 2021, 73, 52-64.	1.1	17
1079	Trend for Clinical Use of Metabolic Associated Fatty Liver Disease (MAFLD). , 2021, 4, 99-102.		1
1080	Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review. <i>Biomedicines</i> , 2021, 9, 378.	1.4	27
1081	Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases. <i>Antioxidants</i> , 2021, 10, 660.	2.2	41
1082	Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease 2019. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	7
1083	Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4282.	1.8	5
1084	Î ² -glucan, "the knight of health sector" critical insights on physiochemical heterogeneities, action mechanisms and health implications. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 6908-6931.	5.4	9
1086	Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools—a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 727-727.	0.7	3
1087	Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial. <i>BMJ Open</i> , 2021, 11, e045922.	0.8	1
1088	NAFLD-Associated HCC: Progress and Opportunities. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 223-239.	1.8	33

#	ARTICLE	IF	CITATIONS
1089	The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on COVID-19 Disease Prognosis. <i>Medicina (Lithuania)</i> , 2021, 57, 434.	0.8	11
1090	Parthenolide plays a protective role in the liver of mice with metabolic dysfunction-associated fatty liver disease through the activation of the HIPPO pathway. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	8
1091	Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population. <i>Frontiers in Endocrinology</i> , 2021, 12, 565714.	1.5	4
1092	Effect of Central Corticotropin-Releasing Factor on Hepatic Lipid Metabolism and Inflammation-Related Gene Expression in Rats. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3940.	1.8	5
1094	Mining Gut Microbiota From Bariatric Surgery for MAFLD. <i>Frontiers in Endocrinology</i> , 2021, 12, 612946.	1.5	5
1095	Effects of betaine on non-alcoholic liver disease. <i>Nutrition Research Reviews</i> , 2022, 35, 28-38.	2.1	16
1096	Role of Insulin Resistance in MAFLD. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4156.	1.8	131
1097	The association between cardiorespiratory fitness, liver fat and insulin resistance in adults with or without type 2 diabetes: a cross-sectional analysis. <i>BMC Sports Science, Medicine and Rehabilitation</i> , 2021, 13, 40.	0.7	12
1098	Metabolomics in Advanced Liver Disease. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 380-397.	0.3	1
1099	Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1659.	1.0	12
1100	Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00340.	1.3	15
1101	European "NAFLD Preparedness Index"™ " Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021, 3, 100234.	2.6	27
1102	Effect of <i>Bombyx mori</i> on the Liver Protection of Non-Alcoholic Fatty Liver Disease Based on In Vitro and In Vivo Models. <i>Current Issues in Molecular Biology</i> , 2021, 43, 21-35.	1.0	6
1103	Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. <i>Scientific Reports</i> , 2021, 11, 8593.	1.6	15
1104	Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. <i>Nutrients</i> , 2021, 13, 1442.	1.7	85
1105	Lipotoxic hepatocyte-derived exosomal miR-1297 promotes hepatic stellate cell activation through the PTEN signaling pathway in metabolic-associated fatty liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 1419-1434.	1.4	34
1106	Lingonberry Improves Non-Alcoholic Fatty Liver Disease by Reducing Hepatic Lipid Accumulation, Oxidative Stress and Inflammatory Response. <i>Antioxidants</i> , 2021, 10, 565.	2.2	15
1107	Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2021, 12, 665987.	1.5	17

#	ARTICLE	IF	CITATIONS
1108	Metabolically healthy obesity and risk of non-alcoholic fatty liver disease severity independent of visceral fat. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2903-2910.	1.4	12
1109	Nonalcoholic Fatty Liver Disease Development in Zebrafish upon Exposure to Bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate, a Novel Brominated Flame Retardant. <i>Environmental Science & Technology</i> , 2021, 55, 6926-6935.	4.6	27
1110	Role of Steroid Hormones in the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>Metabolites</i> , 2021, 11, 320.	1.3	26
1111	Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota. <i>Phytomedicine</i> , 2021, 85, 153544.	2.3	26
1112	Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. <i>BMC Gastroenterology</i> , 2021, 21, 212.	0.8	54
1113	Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4 α . <i>Hepatology</i> , 2021, 74, 723-740.	3.6	40
1114	Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. <i>Cureus</i> , 2021, 13, e15141.	0.2	7
1116	Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. <i>Medical Journal of Australia</i> , 2021, 215, 77-82.	0.8	13
1117	Regulation and functional roles of chemokines in liver diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 630-647.	8.2	46
1118	Infections at the nexus of metabolic-associated fatty liver disease. <i>Archives of Toxicology</i> , 2021, 95, 2235-2253.	1.9	14
1119	Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 813-822.	1.8	66
1120	Effect of ω -3 Polyunsaturated Fatty Acids-Derived Bioactive Lipids on Metabolic Disorders. <i>Frontiers in Physiology</i> , 2021, 12, 646491.	1.3	21
1121	Diagnostic Performance of 9 Quantitative Ultrasound Parameters for Detection and Classification of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease. <i>Investigative Radiology</i> , 2022, 57, 23-32.	3.5	15
1122	Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. <i>European Journal of Pharmacology</i> , 2021, 898, 173976.	1.7	31
1123	Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2638-2640.	2.4	5
1124	On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 865-870.	2.4	33
1125	Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. <i>FEBS Journal</i> , 2022, 289, 3024-3057.	2.2	37
1126	Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5227.	1.2	109

#	ARTICLE	IF	CITATIONS
1128	The role of elastography in non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2021, 67, 164-170.	0.3	7
1129	Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5375.	1.8	59
1130	Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. <i>BMJ Open</i> , 2021, 11, e042843.	0.8	60
1131	Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4807.	1.8	44
1132	The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD. <i>Journal of Hepatology</i> , 2021, 74, 1256-1258.	1.8	39
1133	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
1134	Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice. <i>Hepatology International</i> , 2021, 15, 1122-1135.	1.9	22
1135	Kaempferol-3-O-Glucuronide Ameliorates Non-Alcoholic Steatohepatitis in High-Cholesterol-Diet-Induced Larval Zebrafish and HepG2 Cell Models via Regulating Oxidation Stress. <i>Life</i> , 2021, 11, 445.	1.1	9
1136	Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107874.	1.2	8
1137	Nutritional status and energy metabolism in elderly patients with nonalcoholic fatty liver disease. <i>World Chinese Journal of Digestology</i> , 2021, 29, 467-473.	0.0	0
1138	Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 417-429.	1.8	7
1139	Myeloid Nrf2 deficiency aggravates non-alcoholic steatohepatitis progression by regulating YAP-mediated NLRP3 inflammasome signaling. <i>IScience</i> , 2021, 24, 102427.	1.9	17
1140	3D human liver spheroids for translational pharmacology and toxicology. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 5-15.	1.2	25
1141	Current Status of Radiomics and Deep Learning in Liver Imaging. <i>Journal of Computer Assisted Tomography</i> , 2021, 45, 343-351.	0.5	6
1142	Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19. <i>Digestive and Liver Disease</i> , 2021, 53, 525-533.	0.4	27
1143	Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. <i>World Journal of Gastroenterology</i> , 2021, 27, 1864-1882.	1.4	19
1144	Association between toothbrushing and non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2021, 16, e0243686.	1.1	7
1145	Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner. <i>Cell Systems</i> , 2021, 12, 432-445.e7.	2.9	12

#	ARTICLE	IF	CITATIONS
1147	The interplay of Western diet and binge drinking on the onset, progression, and outlook of liver disease. <i>Nutrition Reviews</i> , 2022, 80, 503-512.	2.6	5
1148	Bariatric surgery and the liver—Mechanisms, benefits, and risks. <i>Obesity Reviews</i> , 2021, 22, e13294.	3.1	24
1149	Lipid Droplet Contact Sites in Health and Disease. <i>Trends in Cell Biology</i> , 2021, 31, 345-358.	3.6	88
1150	A call to action for fatty liver disease. <i>Liver International</i> , 2021, 41, 1182-1185.	1.9	10
1151	Exacerbation of liver dysfunction in non-alcoholic steatohepatitis patients during the coronavirus disease 2019 (COVID-19) pandemic. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021, 68, 243-245.	0.6	2
1152	Non-alcoholic fatty liver disease: raising awareness of a looming public health problem. <i>Medical Journal of Australia</i> , 2021, 215, 75-76.	0.8	0
1153	Effects of lifestyle interventions on epigenetic signatures of liver fat: Central randomized controlled trial. <i>Liver International</i> , 2021, 41, 2101-2111.	1.9	15
1154	Liver damage while Covid-19: problems of pathogenesis and treatment. <i>Ekspierimental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 178-185.	0.1	4
1155	The role of SAMM50 in non-alcoholic fatty liver disease: from genetics to mechanisms. <i>FEBS Open Bio</i> , 2021, 11, 1893-1906.	1.0	12
1156	Pathological Crosstalk Between Oxidized LDL and ER Stress in Human Diseases: A Comprehensive Review. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 674103.	1.8	24
1157	Mechanisms and disease consequences of nonalcoholic fatty liver disease. <i>Cell</i> , 2021, 184, 2537-2564.	13.5	757
1158	Hepatocellular carcinoma: a clinical and pathological overview. <i>Pathologica</i> , 2021, 113, 203-217.	1.3	30
1159	Telemedicine as a tool for dietary intervention in NAFLD-HIV patients during the COVID-19 lockdown: A randomized controlled trial. <i>Clinical Nutrition ESPEN</i> , 2021, 43, 329-334.	0.5	20
1160	Liver-Related and Cardiovascular Outcome of Patients Transplanted for Nonalcoholic Fatty Liver Disease: A European Single-Center Study. <i>Transplantation Proceedings</i> , 2021, 53, 1674-1681.	0.3	5
1161	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6485.	1.8	40
1162	The Emerging Role of B Cells in the Pathogenesis of NAFLD. <i>Hepatology</i> , 2021, 74, 2277-2286.	3.6	49
1163	The use of comics to promote health awareness: a template using non-alcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2021, , e13642.	1.7	15
1164	New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3957-e3968.	1.8	10

#	ARTICLE	IF	CITATIONS
1165	Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Liver International</i> , 2021, 41, 1713-1733.	1.9	58
1166	Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH. <i>Scientific Reports</i> , 2021, 11, 11709.	1.6	12
1167	Exploring the Protective Effects and Mechanism of Crocetin From Saffron Against NAFLD by Network Pharmacology and Experimental Validation. <i>Frontiers in Medicine</i> , 2021, 8, 681391.	1.2	8
1168	Key factors and potential drug combinations of NASH: Bioinformatic analysis and experimental validation-based study. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 433-451.	0.6	3
1169	Fructooligosaccharides enhance the therapeutic effect of xiao-zhi-fang on non-alcoholic fatty liver disease via regulating intestinal flora. <i>Liver Research</i> , 2021, 5, 217-223.	0.5	3
1170	Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 964-972.	2.9	28
1171	Fructose Causes Liver Damage, Polyploidy, and Dysplasia in the Setting of Short Telomeres and p53 Loss. <i>Metabolites</i> , 2021, 11, 394.	1.3	3
1172	The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors – A targeted literature review. <i>Endocrine and Metabolic Science</i> , 2021, 3, 100089.	0.7	35
1173	Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021, 17, 484-495.	4.3	224
1174	Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 441-451.	1.1	28
1175	Non-alcoholic fatty liver disease. <i>Lancet</i> , The, 2021, 397, 2212-2224.	6.3	1,035
1176	SCF ^{JFK} is functionally linked to obesity and metabolic syndrome. <i>EMBO Reports</i> , 2021, 22, e52036.	2.0	5
1177	Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation. <i>Scientific Reports</i> , 2021, 11, 13159.	1.6	28
1178	Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study. <i>Diagnostics</i> , 2021, 11, 1083.	1.3	8
1179	^{CB} Based Quantitative ^{R2*} Mapping at 3 Tesla Reflects Hepatic Iron Overload and Pathogenesis in Nonalcoholic Fatty Liver Disease Patients. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 111-125.	1.9	13
1180	Development and initial validation of the nonalcoholic fatty liver disease self-management questionnaire. <i>Research in Nursing and Health</i> , 2021, 44, 844-853.	0.8	3
1181	Serum selenium and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2011–2016. <i>Environmental Research</i> , 2021, 197, 111190.	3.7	48
1182	Dihydromyricetin ameliorates liver fibrosis via inhibition of hepatic stellate cells by inducing autophagy and natural killer cell-mediated killing effect. <i>Nutrition and Metabolism</i> , 2021, 18, 64.	1.3	22

#	ARTICLE	IF	CITATIONS
1183	Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2565.	1.0	7
1184	Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor β . <i>Chinese Journal of Natural Medicines</i> , 2021, 19, 401-411.	0.7	11
1185	Naringenin Attenuates Non-Alcoholic Fatty Liver Disease by Enhancing Energy Expenditure and Regulating Autophagy via AMPK. <i>Frontiers in Pharmacology</i> , 2021, 12, 687095.	1.6	19
1186	Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1438-e1455.	2.4	49
1187	Role of Leptin in Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2021, 9, 762.	1.4	41
1188	Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2. <i>Biochemical and Biophysical Research Communications</i> , 2021, 557, 62-68.	1.0	10
1189	Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China. <i>International Journal of General Medicine</i> , 2021, Volume 14, 2909-2922.	0.8	9
1190	Liver fat content is independently associated with microalbuminuria in a normotensive, euglycaemic Chinese population: a community-based, cross-sectional study. <i>BMJ Open</i> , 2021, 11, e044237.	0.8	0
1191	Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. <i>Metabolism: Clinical and Experimental</i> , 2021, 119, 154770.	1.5	101
1192	Gut microbiota in obesity and nonalcoholic fatty liver disease. <i>Surgery in Practice and Science</i> , 2021, 5, 100030.	0.2	8
1193	A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2806.	1.0	11
1194	Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. <i>Frontiers in Medicine</i> , 2021, 8, 683250.	1.2	34
1195	Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl4-Induced NASH Mice and the Effect of Obeticholic Acid. <i>Metabolites</i> , 2021, 11, 374.	1.3	6
1196	The Alterations of Mitochondrial Function during NAFLD Progression—An Independent Effect of Mitochondrial ROS Production. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6848.	1.8	24
1197	Circulating branch chain amino acids and improvement in liver fat content in response to exercise interventions in NAFLD. <i>Scientific Reports</i> , 2021, 11, 13415.	1.6	7
1198	Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 9053-9075.	5.4	14
1199	Effect of type 2 diabetic mellitus in the prognosis of acute-on-chronic liver failure patients in China. <i>World Journal of Gastroenterology</i> , 2021, 27, 3372-3385.	1.4	5
1200	Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis. <i>JGH Open</i> , 2021, 5, 740-749.	0.7	4

#	ARTICLE	IF	CITATIONS
1201	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. <i>Journal of Medical Ultrasonics</i> (2001), 2021, 48, 481-487.	0.6	11
1202	Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. <i>Metabolism Open</i> , 2021, 10, 100090.	1.4	16
1203	Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2021, 27, 4677-4685.	0.9	7
1204	Diagnosis and management of secondary causes of steatohepatitis. <i>Journal of Hepatology</i> , 2021, 74, 1455-1471.	1.8	56
1205	Impact of vitamin E on redox biomarkers in non-alcoholic fatty liver disease. <i>Redox Biology</i> , 2021, 42, 101937.	3.9	19
1206	Kaempferol Alleviates Steatosis and Inflammation During Early Non-Alcoholic Steatohepatitis Associated With Liver X Receptor Î±-Lysophosphatidylcholine Acyltransferase 3 Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2021, 12, 690736.	1.6	23
1207	Circulating Levels of Pro-Neurotensin and Its Relationship with Nonalcoholic Steatohepatitis and Hepatic Lipid Metabolism. <i>Metabolites</i> , 2021, 11, 373.	1.3	4
1208	Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-6.	0.6	3
1209	Lipoprotein receptor SR-B1 deficiency enhances adipose tissue inflammation and reduces susceptibility to hepatic steatosis during diet-induced obesity in mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 158909.	1.2	6
1210	Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999â€”2016. <i>Chinese Medical Journal</i> , 2021, 134, 1593-1601.	0.9	28
1211	NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?â€”Results From NHANES III. <i>Frontiers in Medicine</i> , 2021, 8, 693507.	1.2	67
1212	Transition of Care Model for Pediatric Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Liver Disease</i> , 2021, 18, 30-36.	1.0	3
1213	Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience. <i>Journal of Hepatology</i> , 2021, 75, 221-222.	1.8	36
1214	The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool?. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 454-466.	0.8	24
1215	Association of Nonalcoholic Hepatic Fibrosis with Body Composition in Female and Male Psoriasis Patients. <i>Life</i> , 2021, 11, 763.	1.1	2
1216	Low testosterone and cardiometabolic risks in a real-world study of US male firefighters. <i>Scientific Reports</i> , 2021, 11, 14189.	1.6	2
1217	Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. <i>World Journal of Gastroenterology</i> , 2021, 27, 3971-3983.	1.4	18
1218	Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. <i>Cancers</i> , 2021, 13, 3473.	1.7	12

#	ARTICLE	IF	CITATIONS
1219	Similarities and Differences: A Comparative Review of the Molecular Mechanisms and Effectors of NAFLD and AFLD. <i>Frontiers in Physiology</i> , 2021, 12, 710285.	1.3	14
1220	The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. <i>American Journal of Gastroenterology</i> , 2021, 116, 2068-2078.	0.2	16
1221	Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 362-371.	0.4	2
1222	Polyploidy control in hepatic health and disease. <i>Journal of Hepatology</i> , 2021, 75, 1177-1191.	1.8	19
1223	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	2.4	49
1224	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	1.4	37
1225	Differential Effects of Dietary Components on Glucose Intolerance and Non-Alcoholic Steatohepatitis. <i>Nutrients</i> , 2021, 13, 2523.	1.7	6
1226	Green Tea and Epigallocatechin Gallate (EGCG) for the Management of Nonalcoholic Fatty Liver Diseases (NAFLD): Insights into the Role of Oxidative Stress and Antioxidant Mechanism. <i>Antioxidants</i> , 2021, 10, 1076.	2.2	51
1227	Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. <i>Journal of Personalized Medicine</i> , 2021, 11, 684.	1.1	12
1228	Phytochemicals from Cocoa Shell Protect Mitochondrial Function and Alleviate Oxidative Stress in Hepatocytes via Regulation of ERK and PI3K-AKT Pathways. <i>Medical Sciences Forum</i> , 2021, 2, .	0.5	1
1229	Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000678.	1.1	6
1230	Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study. <i>Digestive and Liver Disease</i> , 2021, 53, 873-878.	0.4	2
1231	Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 991.	0.8	12
1232	Extracts of Vine Tea Improve Diet-Induced Non-Alcoholic Steatohepatitis Through AMPK-LXR \pm Signaling. <i>Frontiers in Pharmacology</i> , 2021, 12, 711763.	1.6	7
1233	Lupinus angustifolius Protein Hydrolysates Reduce Abdominal Adiposity and Ameliorate Metabolic Associated Fatty Liver Disease (MAFLD) in Western Diet Fed-ApoE $\Delta\Delta$ Mice. <i>Antioxidants</i> , 2021, 10, 1222.	2.2	16
1234	A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. <i>Cells</i> , 2021, 10, 1822.	1.8	24
1235	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.	4.3	30
1236	Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. <i>Journal of Hepatology</i> , 2021, 75, 1034-1041.	1.8	57

#	ARTICLE	IF	CITATIONS
1237	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2960-2966.	1.4	36
1238	Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. <i>Hepatology Communications</i> , 2022, 6, 90-100.	2.0	22
1239	Intestinal MYC modulates obesity-related metabolic dysfunction. <i>Nature Metabolism</i> , 2021, 3, 923-939.	5.1	27
1240	A network pharmacology approach: Inhibition of the NF- κ B signaling pathway contributes to the NASH preventative effect of an <i>Oroxylum indicum</i> seed extract in oleic acid-stimulated HepG2 cells and high-fat diet-fed rats. <i>Phytomedicine</i> , 2021, 88, 153498.	2.3	16
1241	Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 466-474.	0.4	3
1242	The role of RIPK3 in liver mitochondria bioenergetics and function. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13648.	1.7	5
1243	Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7348.	1.8	3
1244	Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1171-1173.e2.	2.4	22
1245	How will NAFLD change the liver transplant landscape in the 2020s?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101759.	0.7	3
1246	Sex hormones abnormalities in non-alcoholic fatty liver disease: pathophysiological and clinical implications. <i>Exploration of Medicine</i> , 0, , .	1.5	0
1247	Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges. <i>Oncogene</i> , 2021, 40, 5155-5167.	2.6	30
1248	Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1181-1189.	1.4	2
1249	A rapid juvenile murine model of nonalcoholic steatohepatitis (NASH): Chronic intermittent hypoxia exacerbates Western diet-induced NASH. <i>Life Sciences</i> , 2021, 276, 119403.	2.0	10
1250	Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S361-S373.	0.6	66
1251	Liver Stiffness Measurement by Using Transient Elastography in Bangladeshi Patients with Type 2 Diabetes Mellitus and Ultrasonography-Diagnosed Nonalcoholic Fatty Liver Disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 3089-3096.	1.1	5
1252	Metabolic Abnormalities in a Cohort of Overweight and Obese Children in an Urban Setting of Sri Lanka. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-10.	0.6	7
1253	The Cytosolic DNA-Sensing cGAS-STING Pathway in Liver Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 717610.	1.8	9
1255	The Role of Bariatric Surgery in Fatty Liver. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1256	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.	0.6	101
1257	Solidroside Activates the AMP-Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice. <i>Hepatology</i> , 2021, 74, 3056-3073.	3.6	35
1258	Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. <i>Hepatology Communications</i> , 2021, 5, 1676-1688.	2.0	38
1259	Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7249.	1.8	30
1260	Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply. <i>Acta Biomaterialia</i> , 2021, 134, 228-239.	4.1	30
1261	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. <i>Seminars in Liver Disease</i> , 2021, 41, 421-434.	1.8	55
1262	Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101769.	0.7	8
1263	Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. <i>Hepatology Communications</i> , 2021, 5, 1833-1847.	2.0	54
1264	Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7702.	1.8	18
1265	Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. <i>Viruses</i> , 2021, 13, 1333.	1.5	2
1266	Interaction of <i>SAMM50-rs738491</i> , <i>PARVB-rs5764455</i> and <i>PNPLA3-rs738409</i> Increases Susceptibility to Nonalcoholic Steatohepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 219-229.	0.7	3
1267	Complement Component C3: A Novel Biomarker Participating in the Pathogenesis of Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2021, 8, 653293.	1.2	5
1268	Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents. <i>Frontiers in Pediatrics</i> , 2021, 9, 667247.	0.9	6
1269	Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 486-498.	4.5	20
1270	±-Lipoic Acid Alleviates Hepatic Lipid Deposition by Inhibiting FASN Expression via miR-3548 in Rats. <i>Nutrients</i> , 2021, 13, 2331.	1.7	8
1271	Adiponectin involved in portal flow hepatic extraction of 13C-methacetin in obesity and non-alcoholic fatty liver. <i>European Journal of Internal Medicine</i> , 2021, 89, 56-64.	1.0	11
1272	Intervention by picroside II on FFAs induced lipid accumulation and lipotoxicity in HepG2 cells. <i>Journal of Ayurveda and Integrative Medicine</i> , 2021, 12, 465-473.	0.9	7
1273	Deep learning for abdominal ultrasound: A computer-aided diagnostic system for the severity of fatty liver. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 842-850.	0.6	22

#	ARTICLE	IF	CITATIONS
1274	Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD. <i>Inflammation Research</i> , 2021, 70, 765-776.	1.6	8
1275	Liver Inflammation and Hepatobiliary Cancers. <i>Trends in Cancer</i> , 2021, 7, 606-623.	3.8	46
1276	The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs. <i>Journal of Hepatology</i> , 2021, 75, S3-S13.	1.8	51
1277	Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review. <i>Advances in Anatomic Pathology</i> , 2021, 28, 408-414.	2.4	15
1278	The Emerging Role of Stress Granules in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9428.	1.8	8
1279	Sirtuin3 rs28365927 functional variant confers to the high risk of non-alcoholic fatty liver disease in Chinese Han population. <i>Lipids in Health and Disease</i> , 2021, 20, 92.	1.2	1
1280	Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice. <i>Journal of Nanobiotechnology</i> , 2021, 19, 230.	4.2	15
1281	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 3257-3270.	1.1	7
1282	Relationship between <i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2021, 100, e26706.	0.4	12
1283	Stress kinases in the development of liver steatosis and hepatocellular carcinoma. <i>Molecular Metabolism</i> , 2021, 50, 101190.	3.0	25
1284	Increased Risk of Nonalcoholic Fatty Liver Disease in Individuals with High Weight Variability. <i>Endocrinology and Metabolism</i> , 2021, 36, 845-854.	1.3	8
1285	Metabolic Changes of Hepatocytes in NAFLD. <i>Frontiers in Physiology</i> , 2021, 12, 710420.	1.3	46
1286	Non-Invasive Assessment of Liver Fibrosis and Steatosis in End-Stage Renal Disease Patients Undergoing Renal Transplant Evaluation. <i>Gastroenterology Research</i> , 2021, 14, 244-251.	0.4	2
1287	Cancer and hepatic steatosis. <i>ESMO Open</i> , 2021, 6, 100185.	2.0	9
1288	Liver-Specific Deletion of Mouse CTCF Leads to Hepatic Steatosis via Augmented PPAR β Signaling. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1761-1787.	2.3	14
1289	FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. <i>Cell Metabolism</i> , 2021, 33, 1671-1684.e4.	7.2	165
1290	Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus. <i>Endocrine</i> , 2021, 74, 538-545.	1.1	19
1291	Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 36, 102430.	1.7	19

#	ARTICLE	IF	CITATIONS
1292	Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication. <i>Cell Metabolism</i> , 2021, 33, 1685-1700.e9.	7.2	73
1293	Antifibrotic Effects of Kangxian Ruangan Capsule on Rats with Nonalcoholic Fatty Liver Fibrosis and Hepatic Stellate Cells through Regulation of TGF- β 2 and TLR4 Signaling Pathways. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-14.	0.5	2
1294	Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update. <i>Frontiers in Medicine</i> , 2021, 8, 689042.	1.2	30
1295	Effect of transient obstructive cholestasis on liver histology: a cross-sectional study. <i>Sao Paulo Medical Journal</i> , 2021, 139, 351-363.	0.4	1
1296	Diet and exercise in NAFLD/NASH: Beyond the obvious. <i>Liver International</i> , 2021, 41, 2249-2268.	1.9	64
1297	Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1065-1078.	1.5	6
1298	A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health. <i>Medical Science Monitor</i> , 2021, 27, e934134.	0.5	11
1299	Significance of Circulating Cell-Free DNA Species in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8849.	1.8	6
1300	Hepatic Meteorin-like and KrÄppel-like Factor 3 are Associated with Weight Loss and Liver Injury. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, 406-414.	0.6	3
1301	Environmental Toxicants and NAFLD: A Neglected yet Significant Relationship. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3497-3507.	1.1	18
1302	Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications. <i>Liver Transplantation</i> , 2021, 27, 1326-1333.	1.3	6
1303	Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling. <i>Hepatology</i> , 2021, 74, 704-722.	3.6	95
1304	Functional multispectral optoacoustic tomography imaging of hepatic steatosis development in mice. <i>EMBO Molecular Medicine</i> , 2021, 13, e13490.	3.3	9
1305	Determining a healthy reference range and factors potentially influencing PRO-C3 â A biomarker of liver fibrosis. <i>JHEP Reports</i> , 2021, 3, 100317.	2.6	18
1306	Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. <i>Hepatology</i> , 2022, 75, 419-429.	3.6	64
1307	NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. <i>Cells</i> , 2021, 10, 2034.	1.8	20
1308	Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100305.	2.6	83
1309	Gut inflammation exacerbates high-fat diet induced steatosis by suppressing VLDL-TG secretion through HNF4 β pathway. <i>Free Radical Biology and Medicine</i> , 2021, 172, 459-469.	1.3	8

#	ARTICLE	IF	CITATIONS
1310	Associations of acrylamide with non-alcoholic fatty liver disease in American adults: a nationwide cross-sectional study. <i>Environmental Health</i> , 2021, 20, 98.	1.7	9
1311	Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study. <i>Lipids in Health and Disease</i> , 2021, 20, 96.	1.2	9
1312	The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2022, 6, 320-333.	2.0	21
1313	Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. <i>World Journal of Gastroenterology</i> , 2021, 27, 4913-4928.	1.4	16
1314	Relationship between serum uric acid level and nonalcoholic fatty liver disease in type 2 diabetes patients. <i>Medicine (United States)</i> , 2021, 100, e26946.	0.4	14
1315	High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study. <i>Endocrinology and Metabolism</i> , 2021, 36, 800-809.	1.3	5
1316	The effects of Ramadan intermittent fasting on liver function in healthy adults: A systematic review, meta-analysis, and meta-regression. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108951.	1.1	31
1317	Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. <i>Hepatology Communications</i> , 2022, 6, 12-35.	2.0	80
1318	Kaempferol and Kaempferide Attenuate Oleic Acid-Induced Lipid Accumulation and Oxidative Stress in HepG2 Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8847.	1.8	36
1319	The Risk of Type 2 Diabetes and Coronary Artery Disease in Non-obese Patients With Non-alcoholic Fatty Liver Disease: A Cohort Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 680664.	1.1	7
1320	Identification of 90 NAFLD GWAS loci and establishment of NAFLD PRS and causal role of NAFLD in coronary artery disease. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100056.	1.0	10
1321	Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	17
1322	Neonatal Exposure to BPA, BDE-99, and PCB Produces Persistent Changes in Hepatic Transcriptome Associated With Gut Dysbiosis in Adult Mouse Livers. <i>Toxicological Sciences</i> , 2021, 184, 83-103.	1.4	10
1323	Upregulation of miR-96-5p by bone marrow mesenchymal stem cells and their exosomes alleviate non-alcoholic steatohepatitis: Emphasis on caspase-2 signaling inhibition. <i>Biochemical Pharmacology</i> , 2021, 190, 114624.	2.0	28
1324	Hepatic microbiome in healthy lean and obese humans. <i>JHEP Reports</i> , 2021, 3, 100299.	2.6	15
1325	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. <i>Nutrients</i> , 2021, 13, 2830.	1.7	27
1326	Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice. <i>MBio</i> , 2021, 12, e0115521.	1.8	17
1327	Lipid accumulation-induced hepatocyte senescence regulates the activation of hepatic stellate cells through the Nrf2-antioxidant response element pathway. <i>Experimental Cell Research</i> , 2021, 405, 112689.	1.2	18

#	ARTICLE	IF	CITATIONS
1328	Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8993.	1.2	10
1329	Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. <i>Physiological Genomics</i> , 2021, 53, 336-348.	1.0	17
1330	Free-breathing multitasking multi-echo MRI for whole-liver water-specific T ₁ , proton density fat fraction, and quantification. <i>Magnetic Resonance in Medicine</i> , 2022, 87, 120-137.	1.9	16
1331	Hepatic sexual dimorphism " implications for non-alcoholic fatty liver disease. <i>Nature Reviews Endocrinology</i> , 2021, 17, 662-670.	4.3	41
1332	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.	1.5	7
1334	In-Hospital Outcomes of Patients With Non-Alcoholic Fatty Liver Disease Who Underwent Percutaneous Coronary Intervention: A Nationwide Inpatient Sample Analysis. <i>Cureus</i> , 2021, 13, e17338.	0.2	1
1335	The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC). <i>Cureus</i> , 2021, 13, e17320.	0.2	3
1336	Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	1
1337	Spatio-Temporal Multiscale Analysis of Western Diet-Fed Mice Reveals a Translationally Relevant Sequence of Events during NAFLD Progression. <i>Cells</i> , 2021, 10, 2516.	1.8	24
1338	Association of Urinary and Dietary Selenium and of Serum Selenium Species with Serum Alanine Aminotransferase in a Healthy Italian Population. <i>Antioxidants</i> , 2021, 10, 1516.	2.2	21
1340	Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics. <i>Frontiers in Pharmacology</i> , 2021, 12, 727636.	1.6	8
1341	Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3768-3778.	5.7	6
1342	The association between urinary bisphenol A levels and nonalcoholic fatty liver disease in Korean adults: Korean National Environmental Health Survey (KoNEHS) 2015-2017. <i>Environmental Health and Preventive Medicine</i> , 2021, 26, 91.	1.4	16
1343	Nuts: Natural Pleiotropic Nutraceuticals. <i>Nutrients</i> , 2021, 13, 3269.	1.7	53
1344	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.	0.6	58
1345	Prevalence and predictors of non-alcoholic fatty liver disease in tertiary care hospital of Taif, Saudi Arabia: A retrospective study. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 4921-4925.	1.8	4
1346	Nanocapsule-mediated sustained H ₂ release in the gut ameliorates metabolic dysfunction-associated fatty liver disease. <i>Biomaterials</i> , 2021, 276, 121030.	5.7	22
1347	Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 742382.	1.1	22

#	ARTICLE	IF	CITATIONS
1348	Correlation of Hepatic Steatosis Among Cohabitants Using Hounsfield Unit From Coronary Computed Tomography. <i>Cureus</i> , 2021, 13, e17834.	0.2	0
1349	Pancreatic β -Cell Dysfunction Is Associated with Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 3139.	1.7	8
1350	Retrospective analysis (2009–2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102261.	1.8	2
1351	Rare sugars: metabolic impacts and mechanisms of action: a scoping review. <i>British Journal of Nutrition</i> , 2022, 128, 389-406.	1.2	8
1352	The Prevalence, Popular Trends, and Associated and Predictive Factors of Non-Obese Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 744710.	1.5	4
1353	Aflatoxin and the aetiology of liver cancer and its implications for Guatemala. <i>World Mycotoxin Journal</i> , 2021, 14, 305-317.	0.8	9
1354	Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. <i>Cells</i> , 2021, 10, 2502.	1.8	28
1355	Early Chronic Kidney Disease (G1-G3a) in Combination with Steatosis as a Predictor of Incident Ischemic Heart Disease: A Longitudinal Study in Non-Diabetic Koreans. <i>Biomedicines</i> , 2021, 9, 1358.	1.4	3
1356	Grape Pomace Reduces the Severity of Non-Alcoholic Hepatic Steatosis and the Development of Steatohepatitis by Improving Insulin Sensitivity and Reducing Ectopic Fat Deposition in Mice. <i>Journal of Nutritional Biochemistry</i> , 2021, 98, 108867.	1.9	7
1357	Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. <i>European Journal of Pharmacology</i> , 2021, 907, 174272.	1.7	14
1358	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 951-963.	2.3	114
1359	Waist and hip circumference are independently associated with the risk of liver disease in population-based studies. <i>Liver International</i> , 2021, 41, 2903-2913.	1.9	10
1360	Blood sugar targets in surgical intensive care—management and special considerations in patients with diabetes. <i>Deutsches & #x0308;rzteblatt International</i> , 2021, 118, 629-636.	0.6	2
1361	Magnetic resonance elastography plus Fibrosis-4 versus FibroScan—aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , 2022, 75, 661-672.	3.6	29
1362	Molecular mechanism of DLBS3733, a bioactive fraction of <i>Lagerstroemia speciosa</i> (L.) Pers., on ameliorating hepatic lipid accumulation in HepG2 cells. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111937.	2.5	2
1363	Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1036-1046.	3.7	23
1364	Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. <i>World Journal of Gastroenterology</i> , 2021, 27, 5502-5519.	1.4	0
1365	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.	1.5	25

#	ARTICLE	IF	CITATIONS
1366	OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways. <i>Hepatology</i> , 2022, 75, 1218-1234.	3.6	13
1367	Maturation of the Visceral (Gut-Adipose-Liver) Network in Response to the Weaning Reaction versus Adult Age and Impact of Maternal High-Fat Diet. <i>Nutrients</i> , 2021, 13, 3438.	1.7	5
1368	Nonalcoholic steatohepatitis: global impact and clinical consequences. <i>Endocrine Connections</i> , 2021, 10, R240-R247.	0.8	18
1369	Changing clinical management of NAFLD in Asia. <i>Liver International</i> , 2022, 42, 1955-1968.	1.9	18
1370	Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 5753-5763.	1.4	21
1371	Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113869.	6.6	111
1372	Non-alcoholic fatty liver disease - a look at diagnostic prospects. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 62-67.	0.1	0
1373	Diverse mitochondrial abnormalities in a new cellular model of TAF11ZIN deficiency are remediated by cardiolipin-interacting small molecules. <i>Journal of Biological Chemistry</i> , 2021, 297, 101005.	1.6	7
1374	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1253-1266.	1.4	9
1375	Activated Natural Killer Cell Promotes Nonalcoholic Steatohepatitis Through Mediating JAK/STAT Pathway. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 257-274.	2.3	20
1376	Exposure to cigarette smoke precipitates simple hepatosteatosis to NASH in high-fat diet fed mice by inducing oxidative stress. <i>Clinical Science</i> , 2021, 135, 2103-2119.	1.8	6
1377	Liver stiffness measurement as a quantitative method for liver fibrosis in children with non-alcoholic fatty liver disease: A meta-analysis. <i>Journal of Paediatrics and Child Health</i> , 2022, 58, 481-490.	0.4	4
1378	Non-Invasive Photothermal Strain Imaging of Non-Alcoholic Fatty Liver Disease in Live Animals. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 2487-2495.	5.4	5
1379	<i>Drosophila melanogaster</i> : A Powerful Tiny Animal Model for the Study of Metabolic Hepatic Diseases. <i>Frontiers in Physiology</i> , 2021, 12, 728407.	1.3	12
1380	Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis. <i>Nutrients</i> , 2021, 13, 3135.	1.7	51
1381	A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non-specialist needs to know. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 3-14.	2.2	56
1382	Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. <i>Pharmaceuticals</i> , 2021, 14, 995.	1.7	9
1383	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Hepatology Research</i> , 2021, 51, 1013-1025.	1.8	58

#	ARTICLE	IF	CITATIONS
1384	Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?. World Journal of Diabetes, 2021, 12, 1479-1493.	1.3	13
1385	Effect of ipragliflozin on metabolic syndrome components and non-alcoholic fatty liver disease. Meditsinskiy Sovet, 2021, , 305-310.	0.1	1
1386	The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. Digestive and Liver Disease, 2022, 54, 461-468.	0.4	10
1387	Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. World Journal of Diabetes, 2021, 12, 1576-1586.	1.3	4
1388	Genome-Wide Association Study of NAFLD Using Electronic Health Records. Hepatology Communications, 2022, 6, 297-308.	2.0	33
1389	Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Digestive and Liver Disease, 2021, , .	0.4	2
1390	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 835-856.	8.2	183
1391	A Retrospective Study of Hospitalizations in the USA: Proportion of Hospitalizations With Non-Alcoholic Fatty Liver Disease in Non-Obese Population. Cureus, 2021, 13, e17869.	0.2	1
1392	Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Frontiers in Nutrition, 2021, 8, 745609.	1.6	22
1393	Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease. Liver Research, 2021, 5, 119-141.	0.5	15
1394	Association between hepatic fat and subclinical vascular disease burden in the general population. BMJ Open Gastroenterology, 2021, 8, e000709.	1.1	2
1395	Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk. American Journal of Physiology - Renal Physiology, 2021, 321, G252-G261.	1.6	4
1396	Screening for nonalcoholic fatty liver disease-when, who and how?. World Journal of Gastroenterology, 2021, 27, 5803-5821.	1.4	18
1397	Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines, 2021, 9, 1346.	1.4	46
1398	Farnesoid X receptor and fibroblast growth factor 15/19 as pharmacological targets. Liver Research, 2021, 5, 142-150.	0.5	8
1399	Lower brown adipose tissue activity is associated with non-alcoholic fatty liver disease but not changes in the gut microbiota. Cell Reports Medicine, 2021, 2, 100397.	3.3	35
1400	Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease. Obesity Surgery, 2021, , 1.	1.1	6
1401	Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, 2014-2022.e4.	2.4	28

#	ARTICLE	IF	CITATIONS
1402	MAFLD: Renovation of clinical practice and disease awareness of fatty liver. <i>Hepatology Research</i> , 2022, 52, 422-432.	1.8	55
1403	Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1047-1056.	3.7	2
1404	An extra virgin olive oil-enriched chocolate spread positively modulates insulin-resistance markers compared with a palm oil-enriched one in healthy young adults: A double-blind, cross-over, randomised controlled trial. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3492.	1.7	11
1405	Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?. <i>Journal of Hepatology</i> , 2021, 75, 987-989.	1.8	35
1406	Oxidized fish oils increased lipid deposition via oxidative stress-mediated mitochondrial dysfunction and the CREB1-Bcl2-Bcln1 pathway in the liver tissues and hepatocytes of yellow catfish. <i>Food Chemistry</i> , 2021, 360, 129814.	4.2	33
1407	Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2172-2181.e6.	2.4	110
1408	Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. <i>Journal of Hepatology</i> , 2021, 75, 795-809.	1.8	94
1409	Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 733507.	1.6	25
1410	Berteroin ameliorates lipid accumulation through AMPK-mediated regulation of hepatic lipid metabolism and inhibition of adipocyte differentiation. <i>Life Sciences</i> , 2021, 282, 119668.	2.0	12
1411	ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100347.	2.6	57
1412	Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 610-622.	0.7	11
1413	A double-edged sword: The Kelch-like ECH-associated protein 1-nuclear factor erythroid-derived 2-related factor 2-antioxidant response element pathway targeted pharmacological modulation in nonalcoholic fatty liver disease. <i>Current Opinion in Pharmacology</i> , 2021, 60, 281-290.	1.7	4
1414	Dairy protein intake is inversely related to development of non-alcoholic fatty liver disease. <i>Clinical Nutrition</i> , 2021, 40, 5252-5260.	2.3	31
1415	Commentary on "Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial". <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 699-701.	0.7	0
1416	Pancreastatin induces hepatic steatosis in type 2 diabetes by impeding mitochondrial functioning. <i>Life Sciences</i> , 2021, 284, 119905.	2.0	5
1417	Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis. <i>Phytomedicine</i> , 2021, 92, 153739.	2.3	34
1418	New dammarane-type triterpenoid saponins from <i>Gynostemma pentaphyllum</i> and their Sirt1 agonist activity. <i>Bioorganic Chemistry</i> , 2021, 116, 105357.	2.0	6
1419	Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021, 124, 154874.	1.5	20

#	ARTICLE	IF	CITATIONS
1420	Regulation of decorin by ursolic acid protects against non-alcoholic steatohepatitis. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112166.	2.5	9
1421	Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101638.	0.7	3
1422	Impedance-based measures of muscle mass can be used to predict severity of hepatic steatosis in pediatric nonalcoholic fatty liver disease. <i>Nutrition</i> , 2021, 91-92, 111447.	1.1	7
1423	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021, 41, 101145.	3.2	14
1424	Proresolving lipid mediators and liver disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 159023.	1.2	11
1425	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. <i>Molecular Metabolism</i> , 2021, 53, 101275.	3.0	22
1426	Genetic risk scores and personalization of care in fatty liver disease. <i>Current Opinion in Pharmacology</i> , 2021, 61, 6-11.	1.7	13
1427	Blood manganese and nonalcoholic fatty liver disease: A cohort-based case-control study. <i>Chemosphere</i> , 2022, 287, 132316.	4.2	9
1428	Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®). <i>Journal of Medical Biochemistry</i> , 2021, 40, 60-66.	0.7	5
1429	Diosmetin Ameliorates Nonalcoholic Steatohepatitis through Modulating Lipogenesis and Inflammatory Response in a STAT1/CXCL10-Dependent Manner. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 655-667.	2.4	15
1430	The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 22-43.	4.5	46
1431	Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice. <i>Adipocyte</i> , 2021, 10, 446-455.	1.3	6
1432	The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study. <i>Frontiers in Microbiology</i> , 2020, 11, 555293.	1.5	27
1433	A nomogram for predicting metabolic steatohepatitis: The combination of NAMPT, RALGDS, GADD45B, FOSL2, RTP3, and RASD1. <i>Open Medicine (Poland)</i> , 2021, 16, 773-785.	0.6	5
1434	The pathophysiology of gut-liver connection. , 2021, , 97-122.		0
1436	Endoscopic Duodenal Mucosal Resurfacing: A Potential Therapeutic Treatment for Metabolic Disease. , 2021, , 153-159.		0
1437	Causes of erectile dysfunction in non-alcoholic fatty liver disease. <i>Hepatology Forum</i> , 2021, , .	0.3	1
1438	Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). <i>Methods in Molecular Biology</i> , 2021, 2310, 201-246.	0.4	11

#	ARTICLE	IF	CITATIONS
1439	The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: a population-based cross-sectional study. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 811-824.	0.7	14
1440	Molecular Imaging of Diabetes. , 2021, , 1415-1431.		0
1441	Magnesium, Little Known But Possibly Relevant: A Link between NASH and Related Comorbidities. <i>Biomedicines</i> , 2021, 9, 125.	1.4	6
1442	Predicting Non-Alcoholic Fatty Liver Disease for Adults Using Practical Clinical Measures: Evidence from the Multi-ethnic Study of Atherosclerosis. <i>Journal of General Internal Medicine</i> , 2021, 36, 2648-2655.	1.3	6
1443	Moderate Exercise Inhibits Age-Related Inflammation, Liver Steatosis, Senescence, and Tumorigenesis. <i>Journal of Immunology</i> , 2021, 206, 904-916.	0.4	20
1444	MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>International Journal of Biological Sciences</i> , 2021, 17, 1851-1863.	2.6	39
1445	Phytocannabinoidsâ€™ A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 393.	1.0	13
1446	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <i>Metabolomics</i> , 2021, 17, 12.	1.4	37
1447	Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2020, 11, 575843.	1.5	43
1448	Global pandemics interconnected â€™ obesity, impaired metabolic health and COVID-19. <i>Nature Reviews Endocrinology</i> , 2021, 17, 135-149.	4.3	326
1449	Cardiometabolic health benefits of dairy-milk polar lipids. <i>Nutrition Reviews</i> , 2021, 79, 16-35.	2.6	18
1450	NAFLD in Lean Asians. <i>Clinical Liver Disease</i> , 2020, 16, 240-243.	1.0	18
1451	Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 59-73.	1.3	55
1452	Psychological Biomarker Profile in NAFLD/NASH with Advanced Fibrosis. , 2020, , 205-223.		8
1453	NAFLD and Insulin Resistance: A Multisystemic Disease. , 2020, , 49-71.		1
1454	Knockout Mouse Models Provide Insight into the Biological Functions of CRL1 Components. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1217, 147-171.	0.8	5
1455	Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH). <i>Current Hepatology Reports</i> , 2020, 19, 63-69.	0.4	7
1456	The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: A population-based longitudinal study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 375-383.	0.7	10

#	ARTICLE	IF	CITATIONS
1457	Gastric banding-associated weight loss diminishes hepatic Tsukushi expression. <i>Cytokine</i> , 2020, 133, 155114.	1.4	7
1458	Pathophysiological mechanisms underlying MAFLD. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1875-1887.	1.8	75
1459	Herbal formulation MIT ameliorates high-fat diet-induced non-alcoholic fatty liver disease. <i>Integrative Medicine Research</i> , 2020, 9, 100422.	0.7	4
1460	Ginsenoside Mc1 improves liver steatosis and insulin resistance by attenuating ER stress. <i>Journal of Ethnopharmacology</i> , 2020, 259, 112927.	2.0	26
1461	NAFLD as a driver of chronic kidney disease. <i>Journal of Hepatology</i> , 2020, 72, 785-801.	1.8	249
1462	Ginsenoside Rg1 protects against d-galactose induced fatty liver disease in a mouse model via FOXO1 transcriptional factor. <i>Life Sciences</i> , 2020, 254, 117776.	2.0	26
1463	Hepatic lipid droplet homeostasis and fatty liver disease. <i>Seminars in Cell and Developmental Biology</i> , 2020, 108, 72-81.	2.3	88
1464	PBPK modeling of impact of nonalcoholic fatty liver disease on toxicokinetics of perchloroethylene in mice. <i>Toxicology and Applied Pharmacology</i> , 2020, 400, 115069.	1.3	4
1465	Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 713-715.	3.7	40
1466	Cytotoxicity, Retention, and Anti-inflammatory Effects of a CeO ₂ Nanoparticle-Based Supramolecular Complex in a 3D Liver Cell Culture Model. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 101-106.	2.5	6
1467	Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. <i>Scientific Reports</i> , 2020, 10, 8496.	1.6	23
1468	C-Jun/C7ORF41/NF- κ B axis mediates hepatic inflammation and lipid accumulation in NAFLD. <i>Biochemical Journal</i> , 2020, 477, 691-708.	1.7	14
1469	HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels. <i>Bioscience Reports</i> , 2020, 40, .	1.1	22
1470	Processes exacerbating apoptosis in non-alcoholic steatohepatitis. <i>Clinical Science</i> , 2019, 133, 2245-2264.	1.8	13
1471	Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. <i>Gastroenterology</i> , 2020, 159, 999-1014.e9.	0.6	59
1472	Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030: a modelling study. <i>International Journal of Epidemiology</i> , 2021, 50, 128-142.	0.9	44
1473	N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPAR α and SCD α 1. <i>FASEB Journal</i> , 2020, 34, 15338-15363.	0.2	15
1474	MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. <i>Chinese Medical Journal</i> , 2021, 134, 8-19.	0.9	57

#	ARTICLE	IF	CITATIONS
1475	Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. <i>Medicine (United States)</i> , 2020, 99, e23506.	0.4	10
1476	Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1298-1306.	0.8	14
1477	A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1420-1426.	0.8	4
1478	Liver fat storage pathways: methodologies and dietary effects. <i>Current Opinion in Lipidology</i> , 2021, 32, 9-15.	1.2	4
1484	Discrepancies between actual weight, weight perception and weight loss intention amongst persons with NAFLD. <i>Journal of Internal Medicine</i> , 2021, 289, 840-850.	2.7	18
1485	The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis. <i>JCI Insight</i> , 2019, 4, .	2.3	39
1486	Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma. <i>JCI Insight</i> , 2019, 4, .	2.3	5
1487	Parental metabolic syndrome epigenetically reprograms offspring hepatic lipid metabolism in mice. <i>Journal of Clinical Investigation</i> , 2020, 130, 2391-2407.	3.9	42
1488	Territorial and Sustainable Healthy Diets. <i>Food and Nutrition Bulletin</i> , 2020, 41, 87S-103S.	0.5	21
1489	Assessment of hepatic fibrosis and steatosis by vibration-controlled transient elastography and controlled attenuation parameter versus non-invasive assessment scores in patients with non-alcoholic fatty liver disease. <i>Egyptian Liver Journal</i> , 2020, 10, .	0.3	8
1491	Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis. <i>F1000Research</i> , 2020, 9, 56.	0.8	18
1492	Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. <i>World Journal of Clinical Cases</i> , 2020, 8, 1361-1384.	0.3	69
1493	Intravital longitudinal imaging of hepatic lipid droplet accumulation in a murine model for nonalcoholic fatty liver disease. <i>Biomedical Optics Express</i> , 2020, 11, 5132.	1.5	17
1494	Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. <i>PLoS ONE</i> , 2020, 15, e0241770.	1.1	20
1495	Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-9.	0.7	43
1496	Association of GCKR Gene Polymorphisms with the Risk of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in a Chinese Northern Han Population. <i>Journal of Clinical and Translational Hepatology</i> , 2019, X, 1-7.	0.7	10
1497	NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 215-221.	0.7	37
1498	Association of TCF7L2 rs7903146 Gene Polymorphism with the Risk of NAFLD and CAD in the Chinese Han Population. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-6.	0.7	3

#	ARTICLE	IF	CITATIONS
1499	Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 000, 1-10.	0.7	13
1500	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021, 116, 984-993.	0.2	25
1501	Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 183-189.	0.5	51
1502	Mouse Models of Hepatocellular Carcinoma. , 0, , 69-94.		8
1503	NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), MORE THAN A LIVER DISEASE. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 243-245.	0.3	5
1504	Effect of folate supplementation on immunological and autophagy markers in experimental nonalcoholic fatty liver disease. <i>European Cytokine Network</i> , 2019, 30, 135-143.	1.1	9
1505	Immunonutritional consequences of different serine-type protease inhibitors in a C57BL/6 hepatocarcinoma model. <i>Oncotarget</i> , 2019, 10, 760-772.	0.8	13
1506	Association of hand-grip strength and non-alcoholic fatty liver disease index in older adults. <i>Journal of Exercise Nutrition & Biochemistry</i> , 2018, 22, 62-68.	1.3	11
1507	Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. <i>Hepatoma Research</i> , 2018, 4, 66.	0.6	98
1508	Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>Hepatoma Research</i> , 2019, 2019, 42.	0.6	31
1509	The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial. <i>JMIR Research Protocols</i> , 2020, 9, e19189.	0.5	5
1510	Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges. <i>Caspian Journal of Internal Medicine</i> , 2020, 11, 346-354.	0.1	3
1511	Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2020, 7, HEP36.	4.2	12
1512	Molecular Genetics of Keratinization Disorders "What's New About Ichthyosis. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00095-185.	0.6	17
1513	Liver fibrosis: which are independent predictors?. <i>Minerva Medica</i> , 2019, 110, 183-184.	0.3	5
1514	Molecular mechanisms of hepatic fibrosis in chronic liver diseases. <i>Minerva Biotechnologica</i> , 2020, 32, .	1.2	33
1515	Diagnostics of progression of liver fibrosis in patients with non-alcoholic steatohepatitis combined with obesity and chronic calculous cholecystitis.. <i>Medicni Perspektivi</i> , 2020, 25, 65-73.	0.1	1
1516	Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-MÎ-Nuclear Factor-ÎB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 558525.	1.6	47

#	ARTICLE	IF	CITATIONS
1517	In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal. <i>Journal of Clinical Medicine</i> , 2021, 10, 36.	1.0	66
1518	Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. <i>Metabolites</i> , 2021, 11, 22.	1.3	72
1519	Dietary Platycodon grandiflorus Attenuates Hepatic Insulin Resistance and Oxidative Stress in High-Fat-Diet Induced Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020, 12, 480.	1.7	20
1520	Application of artificial intelligence in hepatology: Minireview. <i>Artificial Intelligence in Gastroenterology</i> , 2020, 1, 5-11.	0.2	8
1521	Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. , 2020, 1, 51-74.		18
1522	Biomarkers for hepatocellular carcinoma: What's new on the horizon?. <i>World Journal of Gastroenterology</i> , 2018, 24, 3974-3979.	1.4	34
1523	Macrophages in metabolic associated fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 1861-1878.	1.4	37
1524	Medications in type-2 diabetics and their association with liver fibrosis. <i>World Journal of Gastroenterology</i> , 2020, 26, 3249-3259.	1.4	11
1525	Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 279-290.	1.4	12
1526	Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 5919-5943.	1.4	33
1527	Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. <i>World Journal of Gastroenterology</i> , 2020, 26, 6514-6528.	1.4	25
1528	A mixture of blackberry leaf and fruit extracts decreases fat deposition in HepG2 cells, modifying the gut microbiome. <i>Journal of Applied Biological Chemistry</i> , 2019, 62, 229-237.	0.2	1
1529	Correlation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 1681-1686.	0.8	5
1530	Assessment of Liver Fatty Acid Binding Protein (L-FABP) as a Diagnostic Marker in Non-Alcoholic Fatty Liver Disease. <i>Open Journal of Gastroenterology</i> , 2019, 09, 113-124.	0.1	2
1531	Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. <i>World Journal of Hepatology</i> , 2019, 11, 710-718.	0.8	10
1532	High omega arachidonic acid/docosahexaenoic acid ratio induces mitochondrial dysfunction and altered lipid metabolism in human hepatoma cells. <i>World Journal of Hepatology</i> , 2020, 12, 84-98.	0.8	16
1533	Non-alcoholic fatty liver disease is not independent risk factor for cardiovascular disease event: A cohort study. <i>World Journal of Hepatology</i> , 2020, 12, 323-331.	0.8	5
1534	Anti-inflammatory and anti-oxidant effects of aloe vera in rats with non-alcoholic steatohepatitis. <i>World Journal of Hepatology</i> , 2020, 12, 363-377.	0.8	21

#	ARTICLE	IF	CITATIONS
1535	Can gadoteric acid-enhanced magnetic resonance imaging be used to avoid liver biopsy in patients with nonalcoholic fatty liver disease?. World Journal of Hepatology, 2020, 12, 661-671.	0.8	1
1536	Opisthorchis viverrini Infection Augments the Severity of Nonalcoholic Fatty Liver Disease in High-Fat/High-Fructose Diet-Fed Hamsters. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1161-1169.	0.6	7
1537	Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease. World Journal of Gastrointestinal Pathophysiology, 2019, 10, 11-16.	0.5	11
1538	Effects of Alpha-Lipoic Acid Supplementation on Oxidative Stress Status in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double Blind, Placebo-Controlled Clinical Trial. Iranian Red Crescent Medical Journal, 2018, 20, .	0.5	7
1539	Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease. ELife, 2019, 8, .	2.8	93
1540	Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver. ELife, 2020, 9, .	2.8	7
1541	Association between serum uric acid and nonalcoholic fatty liver disease in community patients with type 2 diabetes mellitus. PeerJ, 2019, 7, e7563.	0.9	12
1542	Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH. PeerJ, 2019, 7, e8115.	0.9	11
1543	Lifestyle Intervention Framework for Obese Patients with Non-alcoholic Fatty Liver Disease – a Tool for Health Professionals in Resource Constraint Settings. Cureus, 2019, 11, e5999.	0.2	2
1544	Stereotactic Body Radiation Therapy for Recurrent, Isolated Hepatocellular Carcinoma Lymph Node Metastasis With or Without Prior Liver Transplantation. Cureus, 2020, 12, e9988.	0.2	3
1545	The Association between Nuts Intake and Non-Alcoholic Fatty Liver Disease (NAFLD) Risk: a Case-Control Study. Clinical Nutrition Research, 2020, 9, 195.	0.5	9
1546	A Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Clinical Study to Evaluate the Efficacy and Safety of <i>Artemisia annua</i> L. Extract for Improvement of Liver Function. Clinical Nutrition Research, 2020, 9, 258.	0.5	9
1547	Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study. International Journal of Medical Sciences, 2021, 18, 3624-3630.	1.1	4
1548	Lrp6 Genotype affects Individual Susceptibility to Nonalcoholic Fatty Liver Disease and Silibinin Therapeutic Response via Wnt/ β -catenin-Cyp2e1 Signaling. International Journal of Biological Sciences, 2021, 17, 3936-3953.	2.6	2
1549	Prevalence of Non-alcoholic Fatty Liver Disease among Patients with Diabetes Mellitus Attending Primary Health Care Centers in Bahrain. Oman Medical Journal, 2022, 37, e350.	0.3	1
1550	Emerging roles of PHLPP phosphatases in metabolism. BMB Reports, 2021, 54, 451-457.	1.1	5
1551	Moderation effect of economic status in the association between early-life famine exposure and MAFLD in adulthood. Liver International, 2021, , .	1.9	4
1552	Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. Cells, 2021, 10, 2806.	1.8	39

#	ARTICLE	IF	CITATIONS
1553	Mangiferin Ameliorates HFD-Induced NAFLD through Regulation of the AMPK and NLRP3 Inflammasome Signal Pathways. <i>Journal of Immunology Research</i> , 2021, 2021, 1-17.	0.9	12
1554	Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10858.	1.8	15
1555	Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 10, 128-133.	0.7	5
1556	Genetic predictors and pathophysiological features of non-alcoholic fat liver disease. <i>Meditinskiy Sovet</i> , 2021, , 78-87.	0.1	1
1557	Oxidative Stress Linked Organ Lipid Hydroperoxidation and Dysregulation in Mouse Model of Nonalcoholic Steatohepatitis: Revealed by Lipidomic Profiling of Liver and Kidney. <i>Antioxidants</i> , 2021, 10, 1602.	2.2	8
1558	First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. <i>Cancer Medicine</i> , 2021, 10, 8530-8541.	1.3	12
1559	Synergistic Interaction of Dietary Pattern and Concordance Lifestyle with Abnormal Liver Function among Young Adults in Taiwan: A Population-Based Longitudinal Study. <i>Nutrients</i> , 2021, 13, 3591.	1.7	3
1560	Particulate and drug-induced toxicity assessed in novel quadruple cell human primary hepatic disease models of steatosis and pre-fibrotic NASH. <i>Archives of Toxicology</i> , 2022, 96, 287-303.	1.9	6
1561	Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico. <i>Lipids in Health and Disease</i> , 2021, 20, 136.	1.2	6
1562	Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease. <i>Cells</i> , 2021, 10, 2634.	1.8	13
1563	Liver biopsy complication rates in patients with non-alcoholic fatty liver disease. <i>Canadian Liver Journal</i> , 2022, 5, 106-112.	0.3	1
1564	Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	38
1565	Hepatic p38 Activation Modulates Systemic Metabolism Through FGF21-Mediated Interorgan Communication. <i>Diabetes</i> , 2022, 71, 60-72.	0.3	13
1566	Association between apolipoprotein E gene polymorphism and nonalcoholic fatty liver disease in Southern China: A case-control study. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e24061.	0.9	7
1567	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021, 13, eabe8939.	5.8	17
1568	Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients. <i>Molecular Systems Biology</i> , 2021, 17, e10459.	3.2	22
1569	Dose-response relationships of accelerometer-measured sedentary behaviour and physical activity with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1330-1339.	1.9	15
1570	Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease. <i>American Journal of the Medical Sciences</i> , 2022, 363, 80-83.	0.4	0

#	ARTICLE	IF	CITATIONS
1571	Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 395-403.	1.4	10
1572	Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2021, 20, 97-107.	0.4	2
1573	Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the problem of conjunction and phasing. <i>Obesity and Metabolism</i> , 2021, 18, 313-319.	0.4	4
1574	Involvement of Autophagy in Ageing and Chronic Cholestatic Diseases. <i>Cells</i> , 2021, 10, 2772.	1.8	4
1575	The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. <i>Biomedicines</i> , 2021, 9, 1491.	1.4	14
1576	Recurrent NASH Post-liver Transplant: Implications and Treatment. <i>Current Hepatology Reports</i> , 2021, 20, 108.	0.4	0
1577	Prevalence and predictors of elevated liver enzyme levels in Mexico: The Mexican National Health and Nutrition Survey, 2016. <i>Annals of Hepatology</i> , 2021, 26, 100562.	0.6	5
1578	Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2022, 6, 550-560.	2.0	13
1579	Prevalence and Independent Factors for Fatty Liver and Significant Hepatic Fibrosis Using B-Mode Ultrasound Imaging and Two Dimensional-Shear Wave Elastography in Health Check-up Examinees. <i>Kurume Medical Journal</i> , 2019, 66, 225-237.	0.0	2
1580	HES5-mediated repression of LIGHT transcription may contribute to apoptosis in hepatocytes. <i>Cell Death Discovery</i> , 2021, 7, 308.	2.0	0
1581	Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2021, 12, 751802.	1.5	32
1582	The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease. <i>Lipids in Health and Disease</i> , 2021, 20, 134.	1.2	59
1583	A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men. <i>Scientific Reports</i> , 2021, 11, 19992.	1.6	7
1584	Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 337-342.	2.2	4
1585	Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000780.	1.1	14
1586	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6.	2.4	42
1587	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021, 385, 1547-1558.	13.9	284
1588	Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 134-139.	0.7	11

#	ARTICLE	IF	CITATIONS
1589	Features of saliva diagnostics and threshold gustometry in patients with non-alcoholic fatty liver disease. <i>Modern Gastroenterology</i> , 2021, , .	0.1	0
1590	Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2041-2049.e5.	2.4	6
1591	Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 374-382.	0.7	8
1592	Ferroptosis in liver disease: new insights into disease mechanisms. <i>Cell Death Discovery</i> , 2021, 7, 276.	2.0	107
1593	Non-alcoholic fatty liver disease: modern approaches to diagnosis and treatment. <i>Å¾urno-Rossijskij Å¾urnal TerapevtiÅeskij Praktiki</i> , 2021, 2, 18-29.	0.1	2
1594	Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. <i>Hepatology International</i> , 2021, 15, 1337-1346.	1.9	15
1595	Sarcopenia in Non-alcoholic Steatohepatitis (NASH). <i>Current Hepatology Reports</i> , 0, , 1.	0.4	0
1596	A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic fatty liver disease. <i>IScience</i> , 2021, 24, 103222.	1.9	14
1598	Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms. <i>Vnitri Lekarstvi</i> , 2018, 64, 735-741.	0.1	0
1600	Influence of the intestinal microbiota on the formation and development of non-alcoholic fatty liver disease in children. <i>ZdorovĚe Rebenka</i> , 2018, 13, 776-782.	0.0	0
1601	Dietary Screening-Questioning Adolescent Dietary Trends and Providing Evidence-Based Dietary Recommendations. , 2019, , 21-32.		0
1602	Evaluation of Liver Biopsy Findings and Comparison with Noninvasive Fibrosis Scores in Patients with Non-Alcoholic Steatohepatitis. <i>Medeniyet Medical Journal</i> , 2019, 34, 354-359.	0.4	0
1604	THE INFLUENCE OF ESSENTIAL PHOSPHOLIPIDS ON THE COURSE OF NON-ALCOHOLIC AND ALCOHOLIC FATTY LIVER DISEASES. <i>Hepatology and Gastroenterology</i> , 2019, 3, 5-13.	0.1	1
1605	Dynamics of changes in lipid peroxidation and antioxidant protection under the influence of complex treatment in patients with comorbid course of non-alcoholic steatohepatitis. <i>ZaporoÅ¾skij Medicinskij Å¾urnal</i> , 2019, .	0.0	0
1606	Fructose Consumption is Associated with Non-Alcoholic Fatty Liver Disease Risk: A Case-Control Study from Iran. <i>Hepatitis Monthly</i> , 2019, In Press, .	0.1	1
1609	Fast Food Consumption and the Risk of Non-Alcoholic Fatty Liver in Adults: A Community-Based Case-Control Study. <i>Journal of Occupational Health and Epidemiology</i> , 2019, 8, 176-184.	0.1	3
1610	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 331-332.	4.5	0
1611	Epidemiology and Natural History of Chronic Liver Disease. , 2020, , 1-9.		1

#	ARTICLE	IF	CITATIONS
1614	Effects of p-Hydroxybenzaldehyde and p-Hydroxyacetophenone from Non-centrifuged Cane Sugar, Kokuto, on Serum Corticosterone, and Liver Conditions in Chronically Stressed Mice Fed with a High-fat Diet. <i>Food Science and Technology Research</i> , 2020, 26, 501-507.	0.3	3
1615	PrÄvention der nicht-alkoholischen Steatohepatitis (NASH) und deren Folgeerkrankungen. , 2020, , 173-189.		0
1617	Metabolic comorbidity, the new enemy. <i>Metabolic syndrome and steatohepatitis. Revista Espa±ola De Sanidad Penitenciaria</i> , 2020, 22, 55-57.	0.5	0
1618	Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 883-894.	0.8	4
1620	Anti-inflammatory and anti-oxidant effects of aloe vera in rats with non-alcoholic steatohepatitis. <i>World Journal of Hepatology</i> , 2020, 12, 364-378.	0.8	0
1621	Goals of therapy and concurrent lifestyle interventions to compliment endoscopic bariatric and metabolic interventions. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2020, 22, 126-129.	0.4	0
1622	Downregulation of GNAI3 Promotes the Pathogenesis of Methionine/Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2020, 14, 492-499.	1.4	5
1623	Role of acetylation in nonalcoholic fatty liver disease: a focus on SIRT1 and SIRT3. <i>Exploration of Medicine</i> , 2020, 1, 248-258.	1.5	4
1625	What Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 5019.	1.0	23
1626	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
1627	Role of vitamin E in the treatment of non-alcoholic steatohepatitis. <i>Free Radical Biology and Medicine</i> , 2021, 177, 391-403.	1.3	12
1628	The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. <i>Cells</i> , 2021, 10, 2959.	1.8	18
1629	Longitudinal Associations Between Hand Grip Strength and Non-Alcoholic Fatty Liver Disease in Adults: A Prospective Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 752999.	1.2	4
1630	The associations between coronary artery disease, and non-alcoholic fatty liver disease by computed tomography. <i>Egyptian Heart Journal</i> , 2021, 73, 96.	0.4	5
1631	Association of cardiovascular factors in diabetic patients with non-alcoholic fatty liver disease. <i>Hormones</i> , 2021, , 1.	0.9	4
1632	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. <i>EBioMedicine</i> , 2021, 73, 103661.	2.7	31
1633	Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. <i>World Journal of Clinical Cases</i> , 2021, 9, 9333-9349.	0.3	5
1635	Liver Transplantation and NAFLD/NASH. , 2020, , 343-362.		0

#	ARTICLE	IF	CITATIONS
1637	Pathogenesis of Nonalcoholic Fatty Liver Disease in Children and Adolescents. <i>Advances in Clinical Medicine</i> , 2020, 10, 360-366.	0.0	0
1638	Obesity and NAFLD: Same Problem?. , 2020, , 1-14.		0
1639	Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models. <i>Zoological Research</i> , 2020, 41, 539-551.	0.9	10
1640	Metabolic associated fatty liver disease and cancer risk: causal role or epiphenomenon?. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 774-776.	0.7	0
1641	What Is the Role of Bariatric Surgery in the Treatment of Nonalcoholic Steatohepatitis?. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2021, , 201-211.	0.0	0
1642	Effects of Ademetionine on Liver Fibrosis, Level of Pentraxin-3 and Metabolic Indicators in Patients with Comorbid Course of Non-alcoholic Liver Disease and Arterial Hypertension. <i>Ukrainian Journal of Medicine in Biology and Sport</i> , 2020, 5, 95-101.	0.0	0
1644	Associations between serum trace elements and inflammation in two animal models of nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243179.	1.1	6
1645	The ratio of the main phylotypes of the intestinal microbiota in patients with non-alcoholic fatty liver disease against the background of obesity and its correlation with the stage of hepatic steatosis. <i>Modern Gastroenterology</i> , 2020, .	0.1	0
1646	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243590.	1.1	3
1647	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2021, 70, 2359-2372.	6.1	56
1648	Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based study. <i>Clinical Nutrition</i> , 2020, 39, 3730-3735.	2.3	3
1649	Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. <i>World Journal of Hepatology</i> , 2020, 12, 1258-1167.	0.8	18
1650	Characteristics of Non-Alcoholic Fatty Liver Disease Patients at Dr. M. Djamil General Hospital Padang. <i>The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy</i> , 2020, 21, 171-176.	0.0	0
1651	Free-breathing 3D stack-of-radial MRI quantification of liver fat and R2* in adults with fatty liver disease. <i>Magnetic Resonance Imaging</i> , 2022, 85, 141-152.	1.0	7
1652	A review of environmental metabolism disrupting chemicals and effect biomarkers associating disease risks: Where exposomics meets metabolomics. <i>Environment International</i> , 2022, 158, 106941.	4.8	77
1653	The EMRG Consortium: a gate to identify the burden of metabolic (dysfunction)-associated fatty liver disease in Egypt. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110546.	1.4	0
1654	Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Obese and Overweight Children in the Northwest of Iran. <i>Hepatitis Monthly</i> , 2019, 19, .	0.1	2
1655	CLUSTER ANALYSIS OF THE PATHOGENETIC RELATIONSHIPS OF METABOLIC PARAMETERS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ON THE BACKGROUND OF HYPERTENSION. <i>World Science</i> , 2019, 1, 30-36.	0.0	2

#	ARTICLE	IF	CITATIONS
1656	Applications of Fat Mapping. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2020, 1, 735-777.	0.0	1
1657	Hepatic regeneration in aging: Cell type plasticity and redundancies. <i>Advances in Stem Cells and Their Niches</i> , 2020, , 127-171.	0.1	1
1658	Genes and NAFLD/NASH Progression. , 2020, , 29-47.		0
1659	NAFLD, Diabetes, and Other Endocrine Diseases: Clinical Implications. , 2020, , 147-168.		0
1660	Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea. <i>Arhiv Za Farmaciju</i> , 2020, 70, 319-331.	0.2	0
1661	The Mediterranean Diet: A Healthy Diet for the Modern Times. , 2020, , 409-434.		0
1662	Nonalcoholic Fatty Liver Disease: A Wide Spectrum Disease. , 2020, , 273-284.		3
1663	The comparison of resting metabolic rate between biopsy-proven non-alcoholic steatohepatitis and non-alcoholic fatty liver patients. <i>Hepatology Forum</i> , 2020, , 14-19.	0.3	2
1665	Comparison of knowledge and awareness between consultant physicians and resident doctors about non-alcoholic fatty liver disease. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 374-383.	0.6	0
1666	Non-alcoholic Fatty Liver Disease: A Global Public Health Issue. , 2020, , 321-333.		2
1667	The Clinical and Histological Characteristics of Patients with Biopsy-Proven Non-alcoholic Fatty Liver Disease in the Absence of Insulin Resistance. <i>Hepatology Forum</i> , 2020, , .	0.3	3
1668	I. Epidemiology of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 11-18.	0.0	1
1670	PNPLA3 and TM6SF2, but Not MBOAT7, Are Associated with Steatosis and HBV Viral Persistence in Pakistani Population. <i>Jundishapur Journal of Microbiology</i> , 2020, 13, .	0.2	0
1671	Imaging methods in the assessment of nonalcoholic fatty liver disease. <i>Radiologia Brasileira</i> , 2020, 53, IX-X.	0.3	1
1673	Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use. <i>Liver International</i> , 2022, 42, 350-362.	1.9	21
1674	Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them. <i>Revista De Gastroenterologia De México (English)</i> Tj ETQq1 1 00784314 r0BT /Over		
1675	Issues regarding NAFLD-From the changes and problems in the pathological diagnosis of NASH to the confusion of nomenclature change. <i>Acta Hepatologica Japonica</i> , 2021, 62, 681-689.	0.0	0
1676	Policosanol alleviates hepatic lipid accumulation by regulating bile acids metabolism in C57BL6/mice through AMPK-FXR-TGR5 cross-talk. <i>Journal of Food Science</i> , 2021, 86, 5466-5478.	1.5	14

#	ARTICLE	IF	CITATIONS
1677	Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. <i>International Journal of Obesity</i> , 2022, 46, 486-493.	1.6	12
1678	Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. <i>Obesity Reviews</i> , 2022, 23, e13367.	3.1	7
1679	Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis. <i>Biomedicines</i> , 2021, 9, 1598.	1.4	18
1680	Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease. <i>Gut and Liver</i> , 2022, 16, 589-598.	1.4	11
1681	Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00420.	1.3	6
1682	A short report on NCM282/aldifermin for the treatment of nonalcoholic steatohepatitis (NASH). <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 889-895.	1.5	6
1683	Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge. <i>World Journal of Gastroenterology</i> , 2020, 26, 4018-4035.	1.4	5
1684	Transcriptome Analysis on the Effect of Tartary Buckwheat Polysaccharide on the Liver of NAFLD-Model Mice. , 2020, , .		0
1689	A Deep Learning Approach for Classifying Nonalcoholic Steatohepatitis Patients from Nonalcoholic Fatty Liver Disease Patients Using Electronic Medical Records. <i>Studies in Computational Intelligence</i> , 2021, , 107-113.	0.7	2
1690	Parallels between non-alcoholic fatty liver disease and non-alcoholic fatty pancreatic disease: looking for points of contact or regard through the lens of metabolic syndrome. <i>Ekspierimental'naya i Klinicheskaya Gastroenterologiya</i> , 2020, 183, 80-101.	0.1	0
1691	Pituitary stalk interruption syndrome and liver changes: From clinical features to mechanisms. <i>World Journal of Gastroenterology</i> , 2020, 26, 6909-6922.	1.4	5
1692	Role of Etiology Therapy in Management of Variceal Hemorrhage in Liver Cirrhosis. , 2021, , 41-51.		0
1693	Pharmacologic Management of Nonalcoholic Steatohepatitis. <i>Gastroenterology and Hepatology</i> , 2018, 14, 582-589.	0.2	4
1694	Pediatric Fatty Liver Disease. <i>Missouri Medicine</i> , 2019, 116, 123-128.	0.3	2
1695	Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. <i>Gastroenterology and Hepatology</i> , 2019, 15, 357-365.	0.2	10
1696	Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?. <i>EXCLI Journal</i> , 2020, 19, 1158-1160.	0.5	0
1697	The association between epicardial adipose tissue and non-alcoholic fatty liver disease: A systematic review of existing human studies. <i>EXCLI Journal</i> , 2021, 20, 1096-1105.	0.5	3
1699	Nonalcoholic steatohepatitis critically rewires the ischemia/reperfusion-induced dysregulation of cardiopins and sphingolipids in mice. <i>Hepatobiliary Surgery and Nutrition</i> , 2023, 12, 3-19.	0.7	2

#	ARTICLE	IF	CITATIONS
1700	Association of serum creatinine-to-cystatin C ratio with skeletal muscle mass and strength in nonalcoholic fatty liver disease in the Iwaki Health Promotion Project. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2022, 70, 273-282.	0.6	6
1701	Exploring the potential mechanism of <i>Rhodomyrtus tomentosa</i> (Ait.) Hassk fruit phenolic rich extract on ameliorating nonalcoholic fatty liver disease by integration of transcriptomics and metabolomics profiling. <i>Food Research International</i> , 2022, 151, 110824.	2.9	39
1702	The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 792667.	1.6	11
1703	High throughput interrogation of human liver stellate cells reveals microenvironmental regulation of phenotype. <i>Acta Biomaterialia</i> , 2022, 138, 240-253.	4.1	14
1704	Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 818-829.	0.4	35
1705	Distribution of subcutaneous and intermuscular fatty tissue of the mid-thigh measured by MRI as a putative indicator of serum adiponectin level and individual factors of cardio-metabolic risk. <i>PLoS ONE</i> , 2021, 16, e0259952.	1.1	7
1706	AMPK/PGC-1 α /GLUT4-Mediated Effect of Icaritin on Hyperlipidemia-Induced Non-Alcoholic Fatty Liver Disease and Lipid Metabolism Disorder in Mice. <i>Biochemistry (Moscow)</i> , 2021, 86, 1407-1417.	0.7	9
1707	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. <i>Digestive and Liver Disease</i> , 2022, 54, 500-508.	0.4	11
1708	Effect of LncPVT1/miR-20a-5p on Lipid Metabolism and Insulin Resistance in NAFLD. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4599-4608.	1.1	13
1709	Gallstone disease and nonalcoholic fatty liver disease in patients with type 2 diabetes: a cross-sectional study. <i>BMC Endocrine Disorders</i> , 2021, 21, 231.	0.9	4
1710	Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 97-107.	1.9	27
1711	Dietary and Lifestyle Inflammation Scores Are Inversely Associated with Metabolic-Associated Fatty Liver Disease among Iranian Adults: A Nested Case-Control Study. <i>Journal of Nutrition</i> , 2022, 152, 559-567.	1.3	10
1712	Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up. <i>International Journal of Colorectal Disease</i> , 2022, 37, 349-356.	1.0	5
1713	ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis. <i>Surgery for Obesity and Related Diseases</i> , 2022, 18, 314-325.	1.0	8
1714	Nonalcoholic liver disease: review with a focus on risks of progression. <i>Ekspertimnaya i Klinicheskaya Gastroenterologiya</i> , 2021, , 167-174.	0.1	0
1715	Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial. <i>BMC Complementary Medicine and Therapies</i> , 2021, 21, 283.	1.2	6
1716	Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults. <i>Nutrients</i> , 2021, 13, 4063.	1.7	7
1717	Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function. <i>Proceedings of the Nutrition Society</i> , 2022, 81, 146-161.	0.4	17

#	ARTICLE	IF	CITATIONS
1718	Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. <i>Nature Reviews Endocrinology</i> , 2022, 18, 55-66.	4.3	82
1719	Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). <i>PLoS ONE</i> , 2021, 16, e0260320.	1.1	10
1720	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	2.4	35
1721	Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. <i>Cells</i> , 2021, 10, 3300.	1.8	25
1722	Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity. <i>Frontiers in Nutrition</i> , 2021, 8, 784354.	1.6	9
1723	Linking liver metabolic and vascular disease via bile acid signaling. <i>Trends in Molecular Medicine</i> , 2022, 28, 51-66.	3.5	16
1724	Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. <i>World Journal of Hepatology</i> , 2021, 13, 1494-1511.	0.8	5
1725	Role of ANGPTL8 in NAFLD Improvement after Bariatric Surgery in Experimental and Human Obesity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12945.	1.8	6
1726	MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. <i>Journal of Hepatology</i> , 2022, 76, 781-787.	1.8	67
1727	The Effects of Butyrate on Induced Metabolic-Associated Fatty Liver Disease in Precision-Cut Liver Slices. <i>Nutrients</i> , 2021, 13, 4203.	1.7	10
1728	Estrogen Receptor α Regulates Metabolic-Associated Fatty Liver Disease by Targeting NLRP3-GSDMD Axis-Mediated Hepatocyte Pyroptosis. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 14544-14556.	2.4	13
1729	Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions. <i>JHEP Reports</i> , 2022, 4, 100411.	2.6	24
1730	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 183-195.	4.5	6
1731	Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, .	1.4	4
1732	Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	5
1733	Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. <i>Chinese Medical Journal</i> , 2021, 134, 2911-2921.	0.9	21
1734	Non-alcoholic fatty liver disease: Current therapeutic options. <i>Current Opinion in Pharmacology</i> , 2021, 61, 98-105.	1.7	15
1735	Protective effects of cerium oxide nanoparticles in non-alcoholic fatty liver disease (NAFLD) and carbon tetrachloride-induced liver damage in rats: Study on intestine and liver. <i>Metabolism Open</i> , 2021, 12, 100151.	1.4	8

#	ARTICLE	IF	CITATIONS
1736	Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2317-2326.e4.	2.4	14
1737	Oxidized Pork Induces Hepatic Steatosis by Impairing Thyroid Hormone Function in Mice. <i>Molecular Nutrition and Food Research</i> , 2022, 66, e2100602.	1.5	11
1738	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. <i>ESMO Open</i> , 2021, 6, 100330.	2.0	25
1739	Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two-dimensional shear wave elastography in non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 102-111.	1.9	13
1740	Relationships among N,N-dimethylformamide exposure, CYP2E1 and TM6SF2 genes, and non-alcoholic fatty liver disease. <i>Ecotoxicology and Environmental Safety</i> , 2021, 228, 112986.	2.9	3
1741	Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). <i>Metabolism Open</i> , 2021, 12, 100149.	1.4	54
1743	Jiang Zhi Granule protects immunological barrier of intestinal mucosa in rats with non-alcoholic steatohepatitis. <i>Pharmaceutical Biology</i> , 2021, 59, 1357-1366.	1.3	3
1744	Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population. <i>Endocrine Journal</i> , 2022, 69, 463-471.	0.7	19
1745	The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110486.	1.1	17
1746	Phloretin attenuation of hepatic steatosis via an improvement of mitochondrial dysfunction by activating AMPK-dependent signaling pathways in C57BL/6J mice and HepG2 cells. <i>Food and Function</i> , 2021, 12, 12421-12433.	2.1	2
1747	NAFLD in type 1 diabetes: overrated or underappreciated?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110555.	1.4	14
1748	Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. <i>Liver International</i> , 2022, 42, 277-287.	1.9	60
1749	Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 230-237.	0.7	15
1750	Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 727-732.	2.2	5
1751	NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. <i>Lipids in Health and Disease</i> , 2022, 21, 3.	1.2	5
1752	Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 824481.	1.1	15
1753	Increasing Risk Factors for Non-Alcoholic Fatty Liver Disease; an Insight into Chronic Periodontitis and Insulin Resistance. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 807-814.	0.6	2
1754	Maternal obesogenic diet regulates offspring bile acid homeostasis and hepatic lipid metabolism via the gut microbiome in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 322, G295-G309.	1.6	9

#	ARTICLE	IF	CITATIONS
1755	De novo lipogenesis in non-alcoholic fatty liver disease: Quantification with stable isotope tracers. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13733.	1.7	8
1756	Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort. <i>Journal of the American Heart Association</i> , 2022, 11, e022576.	1.6	8
1757	The advantages of physical exercise as a preventive strategy against NAFLD in postmenopausal women. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13731.	1.7	8
1758	Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. <i>European Heart Journal</i> , 2022, 43, 2023-2033.	1.0	12
1759	Whole life exposure to low dose cadmium alters diet-induced NAFLD. <i>Toxicology and Applied Pharmacology</i> , 2022, 436, 115855.	1.3	10
1760	Cardiovascular risk factors in patients with NAFLD and its relationship with the gut microbiota. <i>Ukrainian Therapeutical Journal</i> , 2020, .	0.0	0
1761	Possibilities of non-pharmacological correction of intestinal microbiota in patients with non-alcoholic fatty liver disease. <i>Modern Gastroenterology</i> , 2020, .	0.1	1
1762	Analysis of Metabolic Biomarkers in Non-Alcoholic Fatty Liver Disease (NAFLD); A Comprehensive Review. <i>Advanced Journal of Graduate Research</i> , 2020, 9, 46-58.	0.5	1
1763	NAFLD and NASH: The Metabolically Diseased Liver. <i>Handbook of Experimental Pharmacology</i> , 2021, , 253-267.	0.9	5
1764	The Endocrinology of Liver Disease. , 2022, , 1710-1714.		0
1766	Nichtalkoholisch induzierte Fettleber: Wie CD8-T-Zellen das Gewebe schädigen. , 0, , .		0
1767	Experience of using telmisartan, atorvastatin and ursodeoxycholic acid in patients with arterial hypertension in combination with non-alcoholic fatty liver disease. <i>The Siberian Scientific Medical Journal</i> , 2021, 41, 75-82.	0.1	0
1768	Effects of Fish Oil Supplementation on Oxidative Stress Biomarkers and Liver Damage in Hypercholesterolemic Rats. <i>Nutrients</i> , 2022, 14, 426.	1.7	11
1769	Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1102.	1.8	8
1770	Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac003.	0.4	18
1771	Plasma Alkylresorcinol Metabolite, a Biomarker for Whole-Grain Intake, Is Inversely Associated with Risk of Nonalcoholic Fatty Liver Disease in a Case-Control Study of Chinese Adults. <i>Journal of Nutrition</i> , 2022, 152, 1052-1058.	1.3	5
1772	Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review. <i>Hepatology International</i> , 2022, 16, 27-37.	1.9	7
1773	Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-9.	1.0	9

#	ARTICLE	IF	CITATIONS
1774	Gentiana scabra Restrains Hepatic Pro-Inflammatory Macrophages to Ameliorate Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 816032.	1.6	5
1775	Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. <i>Frontiers in Oncology</i> , 2021, 11, 783339.	1.3	4
1776	Vulnerability to alcohol-associated liver disease: A tale of two systems. <i>Hepatology</i> , 2022, 75, 246-247.	3.6	0
1777	Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. <i>Biomedicine</i> , 2022, 10, 249.	1.4	16
1778	Triglyceride and glucose index: a useful tool for non-alcoholic liver disease assessed by liver biopsy in patients with metabolic syndrome?. <i>Romanian Journal of Morphology and Embryology</i> , 2022, 62, 475-480.	0.4	6
1779	Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. <i>World Journal of Gastroenterology</i> , 2022, 28, 310-331.	1.4	29
1780	High-priority liver transplantation and simultaneous sleeve gastrectomy in MELD 32 end-stage liver disease: a case report with long-term follow-up. <i>Obesity Research and Clinical Practice</i> , 2022, 16, 91-94.	0.8	0
1781	Phytochemicals from the Cocoa Shell Modulate Mitochondrial Function, Lipid and Glucose Metabolism in Hepatocytes via Activation of FGF21/ERK, AKT, and mTOR Pathways. <i>Antioxidants</i> , 2022, 11, 136.	2.2	14
1782	Electrophilic thymol isobutyrate from <i>Inula nervosa</i> Wall. (Xiaoheiyao) ameliorates steatosis in HepG2 cells via Nrf2 activation. <i>Journal of Functional Foods</i> , 2022, 88, 104895.	1.6	4
1783	MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. <i>Frontiers in Medicine</i> , 2021, 8, 774079.	1.2	15
1784	Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 589-594.	0.7	7
1785	The adolescent with obesity: what perspectives for treatment?. <i>Italian Journal of Pediatrics</i> , 2022, 48, 9.	1.0	29
1786	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. <i>Journal of Hepatology</i> , 2022, 76, 1013-1020.	1.8	66
1787	The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1042.	1.2	8
1788	Recent insights into the pathogeneses and therapeutic targets of liver diseases: Summary of the 4th Chinese American liver Society/Society of Chinese Bioscientists in America Hepatology Division Symposium in 2021. <i>Liver Research</i> , 2022, 6, 50-57.	0.5	2
1789	Therapeutic efficacy of FASN inhibition in preclinical models of HCC. <i>Hepatology</i> , 2022, 76, 951-966.	3.6	25
1790	Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 356-362.	0.7	6
1791	The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24225.	0.9	14

#	ARTICLE	IF	CITATIONS
1792	Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 367-378.	3.7	92
1793	A sequential approach using the age-adjusted fibrosis index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 994-1007.	1.9	2
1794	Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS). <i>Biomedicines</i> , 2022, 10, 131.	1.4	18
1795	ER Disposal Pathways in Chronic Liver Disease: Protective, Pathogenic, and Potential Therapeutic Targets. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 804097.	1.6	5
1796	Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. <i>Journal of Clinical Medicine</i> , 2022, 11, 753.	1.0	4
1797	NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 409-422.	1.6	12
1798	Visceral adipose tissue quality was associated with nonalcoholic fatty liver disease, independent of its quantity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 973-980.	1.1	4
1799	Nonalcoholic Fatty Liver Disease and Associated Risk Factors in a Community-Based Sample of Mexican-Origin Adults. <i>Hepatology Communications</i> , 2022, 6, 1322-1335.	2.0	11
1800	Biyopsi tanımlanan nonalkolik steatohepatit hastalarında fibrozis evrelerine göre metabolik sendrom komponentlerinin sıklıklarının kararlaştırılması: Metabolik bozukluk sayısındaki artışı fibrozis progresyonunda etkili mi?. <i>Akademik Gastroenteroloji Dergisi</i> , 0, , .		0
1801	The relationship between Lipocalin-2 level and hepatic steatosis in obese patients with NAFLD after bariatric surgery. <i>Lipids in Health and Disease</i> , 2022, 21, 10.	1.2	1
1802	A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 765-767.	1.8	2
1803	Lipid droplets associated perilipins protein insights into finding a therapeutic target approach to cure non-alcoholic fatty liver disease (NAFLD). <i>Future Journal of Pharmaceutical Sciences</i> , 2022, 8, .	1.1	11
1805	Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement. <i>Frontiers in Endocrinology</i> , 2021, 12, 739875.	1.5	11
1806	Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis. <i>Nature Communications</i> , 2022, 13, 578.	5.8	24
1807	Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, , 1-11.	1.4	8
1808	NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 705-721.	1.9	17
1809	Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (<sc>EDICT</sc>). <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 899-907.	2.2	15
1810	Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 553-563.	0.7	9

#	ARTICLE	IF	CITATIONS
1811	Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 733348.	1.8	5
1812	Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. <i>World Journal of Hepatology</i> , 2022, 14, 62-79.	0.8	3
1813	The potential of probiotics in the amelioration of hyperuricemia. <i>Food and Function</i> , 2022, 13, 2394-2414.	2.1	38
1814	Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 580-592.	1.9	12
1815	Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPAR α Signaling Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-15.	0.5	3
1816	Systemic and adipose tissue inflammation in NASH: correlations with histopathological aspects. <i>Romanian Journal of Morphology and Embryology</i> , 2022, 62, 509-515.	0.4	9
1817	Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 469-482.	3.6	41
1818	Low heart rate variability from 10-s electrocardiograms is associated with development of non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, 1062.	1.6	6
1819	Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?. <i>World Journal of Hepatology</i> , 2022, 14, 158-167.	0.8	5
1820	Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00435.	1.3	21
1821	The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. <i>Journal of Digestive Diseases</i> , 2022, 23, 33-43.	0.7	12
1822	Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. <i>British Journal of Pharmacology</i> , 2022, 179, 2054-2077.	2.7	19
1823	Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography. <i>Diabetes Research and Clinical Practice</i> , 2022, 184, 109195.	1.1	6
1824	Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 380-387.e3.	2.4	10
1825	Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis. <i>Endocrine Practice</i> , 2022, 28, 204-213.	1.1	16
1826	Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2022, 13, 830012.	1.5	3
1827	Pdcd4 promotes lipid deposition by attenuating PPAR α -mediated fatty acid oxidation in hepatocytes. <i>Molecular and Cellular Endocrinology</i> , 2022, 545, 111562.	1.6	4
1828	Attractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway. <i>International Journal of Biological Sciences</i> , 2022, 18, 1594-1611.	2.6	25

#	ARTICLE	IF	CITATIONS
1829	Effect of Aerobic Exercise Alone or in Conjunction With Diet on Liver Function, Insulin Resistance and Lipids in Non-Alcoholic Fatty Liver Disease. <i>Biological Research for Nursing</i> , 2022, 24, 259-276.	1.0	6
1830	Fragmented QRS in inferior leads is associated with non-alcoholic fatty liver disease, body-mass index, and interventricular septum thickness in young men. , 2022, 26, 100-104.		1
1831	Nonalcoholic Fatty Liver Disease in Children: where are we?. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
1832	The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 508-521.	1.8	1
1833	Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. <i>Diagnostics</i> , 2022, 12, 407.	1.3	22
1834	Association Between Non-invasive Diagnostic Methods of Liver Fibrosis and Type 2 Diabetes in Pediatric Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Pediatrics</i> , 2022, 10, 825141.	0.9	3
1835	A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease. <i>IScience</i> , 2022, 25, 103890.	1.9	3
1837	Nonalcoholic fatty liver disease shows significant sex dimorphism. <i>World Journal of Clinical Cases</i> , 2022, 10, 1457-1472.	0.3	9
1838	RMRP inhibition prevents NAFLD progression in rats via regulating miR-206/PTPN1 axis. <i>Mammalian Genome</i> , 2022, 33, 480-489.	1.0	8
1839	Effects of Moderate Alcohol Consumption in Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 890.	1.0	7
1840	Risk of hepatic and extrahepatic cancer in <sc>NAFLD</sc>: A populationâ€based cohort study. <i>Liver International</i> , 2022, 42, 820-828.	1.9	29
1841	Perturbation of Wnt/ β -catenin signaling and sexual dimorphism in nonâ€alcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 433-448.	1.8	2
1842	Altered Mitochondrial Quality Control in Rats with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Induced by High-Fat Feeding. <i>Genes</i> , 2022, 13, 315.	1.0	18
1843	Dysregulation of S-adenosylmethionine Metabolism in Nonalcoholic Steatohepatitis Leads to Polyamine Flux and Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1986.	1.8	13
1844	Fluorene-9-bisphenol exposure decreases locomotor activity and induces lipid-metabolism disorders by impairing fatty acid oxidation in zebrafish. <i>Life Sciences</i> , 2022, 294, 120379.	2.0	7
1845	NAFLD and vitamin D: Evidence for intersection of microRNA-regulated pathways. <i>Nutrition Research Reviews</i> , 2021, , 1-20.	2.1	11
1846	The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. <i>Nature Communications</i> , 2021, 12, 7213.	5.8	51
1847	Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 518-525.	1.8	94

#	ARTICLE	IF	CITATIONS
1848	Intestinal Barrier and Permeability in Health, Obesity and NAFLD. <i>Biomedicines</i> , 2022, 10, 83.	1.4	71
1849	Effect of Fetal Exposure to Famine on the Risk of Metabolic Associated Fatty Liver Disease in Adulthood: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1850	Research Progresses for 5-Hydroxytryptamine in Lipid Metabolism. <i>Bioprocess</i> , 2022, 12, 1-9.	0.1	0
1851	Living in the Nonalcoholic Fatty Liver Disease (NAFLD) Silent Epidemic. A Systematic Review of Patientsâ€™ Perspective. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1854	Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210779.	1.1	9
1855	Early Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Advances in Clinical Medicine</i> , 2022, 12, 986-990.	0.0	0
1856	Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease. <i>Methods in Molecular Biology</i> , 2022, 2455, 19-30.	0.4	4
1857	Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	2
1858	Ganoderic acid A ameliorates nonâ€™alcoholic streatohepatitis (NASH) induced by highâ€™fat highâ€™cholesterol diet in mice. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 308.	0.8	5
1859	Novel insights into the effect of Xiaoyao san on corticosterone-induced hepatic steatosis: inhibition of glucocorticoid receptor/perilipin-2 signaling pathway. , 2022, 2, 49-57.		5
1860	Non-alcoholic fatty liver disease (NAFLD): a significant predictor of gestational diabetes mellitus (GDM) and early pregnancy miscarriagesâ€™ prospective study in Rajarata Pregnancy Cohort (RaPCo). <i>BMJ Open Gastroenterology</i> , 2022, 9, e000831.	1.1	7
1861	A robust gene expression signature for NASH in liver expression data. <i>Scientific Reports</i> , 2022, 12, 2571.	1.6	11
1862	The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101896.	0.7	2
1863	Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2668.	1.8	42
1864	Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-19.	1.9	4
1865	Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy. <i>Scientific Reports</i> , 2022, 12, 2996.	1.6	8
1866	Increased Oxygen Desaturation Time During Sleep Is a Risk Factor for NASH in Patients With Obstructive Sleep Apnea: A Prospective Cohort Study. <i>Frontiers in Medicine</i> , 2022, 9, 808417.	1.2	3
1867	Maternal Isocaloric Highâ€™Fat Diet Induces Liver Mitochondria Maladaptations and Homeostatic Disturbances Intensifying Mitochondria Damage in Response to Fructose Intake in Adult Male Rat Offspring. <i>Molecular Nutrition and Food Research</i> , 2022, 66, e2100514.	1.5	5

#	ARTICLE	IF	CITATIONS
1868	Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. <i>Bioengineered</i> , 2022, 13, 5091-5102.	1.4	14
1869	Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH). <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1379-1392.	1.8	7
1870	Itemization difference of patient-reported outcome in patients with chronic liver disease. <i>PLoS ONE</i> , 2022, 17, e0264348.	1.1	2
1871	Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn?. <i>World Journal of Hepatology</i> , 2022, 14, 304-318.	0.8	3
1872	Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2636.	1.8	11
1873	Hepatocyte nuclear factor 4 α in the pathogenesis of non-alcoholic fatty liver disease. <i>Chinese Medical Journal</i> , 2022, 135, 1172-1181.	0.9	13
1874	Gender differences in the association of body composition and biopsy-proved nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2022, , 1.	1.9	3
1875	Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. <i>Biomedicines</i> , 2022, 10, 550.	1.4	16
1876	Histological assessment based on liver biopsy: the value and challenges in NASH drug development. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1200-1209.	2.8	9
1878	The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes. <i>Nature Communications</i> , 2022, 13, 1052.	5.8	23
1879	Assessment of Liver Fibrosis Using Non-invasive Screening Tools in Individuals With Diabetes Mellitus and Metabolic Syndrome. <i>Cureus</i> , 2022, 14, e22682.	0.2	1
1880	Liver biopsy for assessment of chronic liver diseases: a synopsis. <i>Clinical and Experimental Medicine</i> , 2023, 23, 273-285.	1.9	23
1881	Effect of serum vitamin D on metabolic associated fatty liver disease: a large population-based study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-10.	0.6	4
1882	Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 445-455.e2.	2.4	13
1883	Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy. <i>Medicina (Lithuania)</i> , 2022, 58, 290.	0.8	6
1884	Identification of a novel probiotic and its protective effects on <sc>NAFLD</sc> via modulating gut microbial community. <i>Journal of the Science of Food and Agriculture</i> , 2022, 102, 4620-4628.	1.7	4
1885	Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank. <i>Hepatology International</i> , 2022, 16, 325-336.	1.9	9
1886	Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children. <i>Epigenetics</i> , 2022, 17, 1446-1461.	1.3	4

#	ARTICLE	IF	CITATIONS
1887	A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study. <i>PeerJ</i> , 2022, 10, e13022.	0.9	5
1888	Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. <i>BMC Endocrine Disorders</i> , 2022, 22, 63.	0.9	199
1889	The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004. <i>Nutrients</i> , 2022, 14, 1224.	1.7	22
1890	Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease. <i>Hepatology Communications</i> , 2022, 6, 1598-1610.	2.0	6
1891	Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 812030.	1.1	14
1892	Nuclear HMGB1 protects from nonalcoholic fatty liver disease through negative regulation of liver X receptor. <i>Science Advances</i> , 2022, 8, eabg9055.	4.7	7
1893	Relationship Between Greyscale Ultrasound Grading of Hepatic Steatosis and Attenuation Imaging. <i>Cureus</i> , 2022, 14, e23435.	0.2	1
1894	Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control. <i>Nature Communications</i> , 2022, 13, 1259.	5.8	11
1895	Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 377-389.	1.3	22
1896	NAFLD in normal weight individuals. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, 45.	1.2	20
1897	Pathophysiological mechanism between hypopituitarism and nonalcoholic fatty liver disease. , 2022, , .		2
1898	<i>Helicobacter pylori</i> Infection and Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. , 2022, 33, 171-181.		7
1899	Activating Effects of the Bioactive Compounds From Coffee By-Products on FGF21 Signaling Modulate Hepatic Mitochondrial Bioenergetics and Energy Metabolism in vitro. <i>Frontiers in Nutrition</i> , 2022, 9, 866233.	1.6	11
1900	Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2023, 69, .	0.3	5
1901	A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2022, 9, 862879.	1.2	2
1902	Psoralen Suppresses Lipid Deposition by Alleviating Insulin Resistance and Promoting Autophagy in Oleate-Induced L02 Cells. <i>Cells</i> , 2022, 11, 1067.	1.8	4
1903	Editorial: opposite effects of genetic polymorphisms known to induce <sc>NAFLD</sc> on hepatic and cardiovascular outcomes in Chinese population. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 876-877.	1.9	1
1904	Relationship Between Non-Alcoholic Fatty Liver Disease and Degree of Hepatic Steatosis and Bone Mineral Density. <i>Frontiers in Endocrinology</i> , 2022, 13, 857110.	1.5	33

#	ARTICLE	IF	CITATIONS
1905	Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 720.	1.4	5
1906	The Critical and Diverse Roles of CD4 ⁺ CD8 ⁺ Double Negative T Cells in Nonalcoholic Fatty Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1805-1827.	2.3	7
1907	An Open-Label Exploratory Clinical Trial Evaluating the Effects of GLS (Coptidis Rhizoma-Evodiae) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-11.	0.5	3
1908	Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting. <i>Cell Metabolism</i> , 2022, 34, 719-730.e4.	7.2	35
1909	Non-invasive tests for liver fibrosis assessment in patients with chronic liver diseases: a prospective study. <i>Scientific Reports</i> , 2022, 12, 4913.	1.6	7
1910	Translation Reprogramming as a Novel Therapeutic Target in MAFLD. <i>Advanced Biology</i> , 2022, , 2101298.	1.4	1
1911	Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: A population-based study. <i>World Journal of Hepatology</i> , 2022, 14, 551-558.	0.8	3
1912	The association between Dietary Diversity Score and odds of nonalcoholic fatty liver disease: a case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 678-685.	0.8	9
1913	Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population. <i>Postgraduate Medicine</i> , 2022, 134, 435-440.	0.9	13
1914	Developing natural marine products for treating liver diseases. <i>World Journal of Clinical Cases</i> , 2022, 10, 2369-2381.	0.3	3
1915	Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 497-507.	1.8	26
1916	Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3357.	1.8	3
1917	Antioxidant for treatment of diabetic complications: A meta-analysis and systematic review. <i>Journal of Biochemical and Molecular Toxicology</i> , 2022, 36, e23038.	1.4	9
1918	Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from <i>Curcuma longa</i> in Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 368-390.	0.6	10
1919	The association between rs1260326 with the risk of NAFLD and the mediation effect of triglyceride on NAFLD in the elderly Chinese Han population. <i>Aging</i> , 2022, 14, 2736-2747.	1.4	5
1920	Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2022, 77, 312-325.	1.8	49
1921	<i>Porphyromonas gingivalis</i> Induces Increases in Branched-Chain Amino Acid Levels and Exacerbates Liver Injury Through livh/livk. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 776996.	1.8	1
1922	Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 833878.	2.2	22

#	ARTICLE	IF	CITATIONS
1923	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 732	0.8	18
1924	A clinical and pathological update on hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2022, 22, 14-22.	0.3	11
1925	Usefulness of Probiotics in the Management of NAFLD: Evidence and Involved Mechanisms of Action from Preclinical and Human Models. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3167.	1.8	14
1926	Empirically derived dietary pattern and odds of non-alcoholic fatty liver diseases in overweight and obese adults: a case-control study. <i>BMC Gastroenterology</i> , 2022, 22, 158.	0.8	6
1927	Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery. <i>Cells</i> , 2022, 11, 893.	1.8	7
1928	Trends in Prediabetes and Non-Alcoholic Fatty Liver Disease Associated with Abdominal Obesity among Korean Children and Adolescents: Based on the Korea National Health and Nutrition Examination Survey between 2009 and 2018. <i>Biomedicines</i> , 2022, 10, 584.	1.4	12
1929	Empirically-Derived Dietary Patterns in Relation to Non-Alcoholic Fatty Liver Diseases Among Adult Participants in Amol, Northern Iran: A Structural Equation Modeling Approach. <i>Frontiers in Nutrition</i> , 2022, 9, 821544.	1.6	4
1930	Amelioration of hepatic steatosis by dietary essential amino acid-induced ubiquitination. <i>Molecular Cell</i> , 2022, 82, 1528-1542.e10.	4.5	17
1931	Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity. <i>Internal and Emergency Medicine</i> , 2022, 17, 1609-1616.	1.0	3
1932	Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109791.	1.1	10
1933	Advancing Liver Cancer Prevention for American Indian Populations in Arizona: An Integrative Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3268.	1.2	2
1934	High Compliance to Mediterranean Diet Associates with Lower Platelet Activation and Liver Collagen Deposition in Patients with Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 1209.	1.7	5
1935	Effect of rosemary leaf powder with weight loss diet on lipid profile, glycemic status, and liver enzymes in patients with nonalcoholic fatty liver disease: A randomized, double-blind clinical trial. <i>Phytotherapy Research</i> , 2022, 36, 2186-2196.	2.8	2
1936	The monomer TEC of blueberry improves NASH by augmenting tRF-47-mediated autophagy/pyroptosis signaling pathway. <i>Journal of Translational Medicine</i> , 2022, 20, 128.	1.8	10
1937	Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2022, 13, 854674.	1.6	12
1938	The role of microbiota in nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13768.	1.7	22
1939	Relationship between growth hormone deficiency and nonalcoholic fatty liver disease in patients with pituitary stalk interruption syndrome. <i>Clinical Endocrinology</i> , 2022, 97, 612-621.	1.2	2
1940	The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease. <i>Clinics in Liver Disease</i> , 2022, 26, 213-227.	1.0	6

#	ARTICLE	IF	CITATIONS
1941	Methionine cycle in nonalcoholic fatty liver disease and its potential applications. <i>Biochemical Pharmacology</i> , 2022, 200, 115033.	2.0	8
1942	Explore the Mechanism of <i>Astragalus mongholicus</i> Bunge against Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Experimental Verification. <i>Gastroenterology Research and Practice</i> , 2022, 2022, 1-17.	0.7	3
1943	Emerging roles of the Hippo signaling pathway in modulating immune response and inflammation-driven tissue repair and remodeling. <i>FEBS Journal</i> , 2022, 289, 4061-4081.	2.2	11
1944	Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?. <i>Hepatology</i> , 2022, 76, 1423-1437.	3.6	78
1945	Celastrol: An Update on Its Hepatoprotective Properties and the Linked Molecular Mechanisms. <i>Frontiers in Pharmacology</i> , 2022, 13, 857956.	1.6	5
1946	Highly Sensitive Two-Photon Lipid Droplet Tracker for <i>In Vivo</i> Screening of Drug Induced Liver Injury. <i>ACS Sensors</i> , 2022, 7, 1027-1035.	4.0	19
1947	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
1948	Cardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals. <i>PLoS ONE</i> , 2022, 17, e0266505.	1.1	3
1949	Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway. <i>Metabolism: Clinical and Experimental</i> , 2022, 131, 155200.	1.5	33
1950	A non-invasive score for nonalcoholic fatty liver disease (NAFLD) cirrhosis. <i>European Journal of Internal Medicine</i> , 2022, 98, 43-44.	1.0	0
1951	Bariatric Surgery Improves Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. <i>Obesity Surgery</i> , 2022, 32, 1872-1883.	1.1	19
1952	Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis. <i>Archives of Pharmacal Research</i> , 2022, , 1.	2.7	2
1953	Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy. <i>European Radiology</i> , 2022, , 1.	2.3	2
1954	HA-20 prevents hepatocyte steatosis in metabolic-associated fatty liver disease via regulating Ca ²⁺ relative signalling pathways. <i>European Journal of Pharmacology</i> , 2022, 921, 174838.	1.7	1
1955	<i>Inonotus obliquus</i> and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis. <i>European Journal of Pharmacology</i> , 2022, 921, 174841.	1.7	9
1956	NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 823140.	1.6	5
1957	Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease: A 2-Sample Bidirectional Mendelian Randomization Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3497-e3503.	1.8	9
1958	Heat Therapy Can Improve Hepatic Mitochondrial Function and Glucose Control. <i>Exercise and Sport Sciences Reviews</i> , 2022, Publish Ahead of Print, ,	1.6	0

#	ARTICLE	IF	CITATIONS
1959	The Role of Hydrogen Sulfide Regulation of Autophagy in Liver Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4035.	1.8	9
1960	Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. <i>PLoS ONE</i> , 2022, 17, e0265153.	1.1	18
1961	Why are there no strategies for NAFLD?. <i>Journal of Hepatology</i> , 2022, 76, 763-764.	1.8	3
1962	Exosomal miR-181a-2-3p derived from citreoviridin-treated hepatocytes activates hepatic stellate cells through inducing mitochondrial calcium overload. <i>Chemico-Biological Interactions</i> , 2022, 358, 109899.	1.7	5
1963	sSTEAP4 regulates cellular homeostasis and improves high-fat-diet-caused oxidative stress in hepatocytes. <i>Life Sciences</i> , 2022, 296, 120438.	2.0	2
1964	Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF- κ B signaling pathway. <i>Molecular Metabolism</i> , 2022, 59, 101462.	3.0	19
1965	Mitochondrial depletion of glutaredoxin 2 induces metabolic dysfunction-associated fatty liver disease in mice. <i>Redox Biology</i> , 2022, 51, 102277.	3.9	13
1966	Discovery of farnesoid X receptor and its role in bile acid metabolism. <i>Molecular and Cellular Endocrinology</i> , 2022, 548, 111618.	1.6	50
1967	Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2022, 130, 155179.	1.5	2
1968	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2022, 4, 100477.	2.6	31
1969	<i>Gryllus bimaculatus</i> De Geer hydrolysates alleviate lipid accumulation, inflammation, and endoplasmic reticulum stress in palmitic acid-treated human hepatoma G2 cells. <i>Journal of Ethnopharmacology</i> , 2022, 291, 115117.	2.0	3
1970	Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. <i>Surgical Oncology</i> , 2022, 42, 101748.	0.8	2
1971	A Qualitative Analysis of Mexican-Origin Men's Knowledge and Cultural Attitudes Toward Non-Alcoholic Fatty Liver Disease and Interest in Risk Reduction. <i>American Journal of Men's Health</i> , 2021, 15, 155798832110633.	0.7	4
1972	Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 852-862.	0.6	7
1973	Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism. <i>Biomedicines</i> , 2021, 9, 1903.	1.4	16
1974	Fibrosis Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. <i>Hepatology Communications</i> , 2022, 6, 765-779.	2.0	26
1975	A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation. <i>Digestive and Liver Disease</i> , 2022, 54, 614-621.	0.4	11
1976	Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice. <i>Drug Development Research</i> , 2021, , .	1.4	5

#	ARTICLE	IF	CITATIONS
1977	Specificities of lipotoxicity of free fatty acids and cytokine profile in patients with chronic diffuse liver diseases. <i>Regulatory Mechanisms in Biosystems</i> , 2022, 13, 3-9.	0.5	0
1978	New progress in research of intestinal microbiota in fatty liver disease. <i>World Chinese Journal of Digestology</i> , 2021, 29, 1355-1361.	0.0	0
1979	NAFLD Associated Comorbidity. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 5-13.	0.1	3
1980	Dual role of neutrophils in modulating liver injury and fibrosis during development and resolution of diet-induced murine steatohepatitis. <i>Scientific Reports</i> , 2021, 11, 24194.	1.6	11
1981	The Predictive Ability of Hepatic Steatosis Index for Gestational Diabetes Mellitus and Large for Gestational Age Infant Compared with Other Noninvasive Indices Among Chinese Pregnancies: A Preliminary Double-center Cohort Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4791-4800.	1.1	8
1982	Colonic inflammation accelerates the progression of liver disease: A protective role of dipotassium glycyrrhizate. <i>Digestive and Liver Disease</i> , 2022, 54, 1084-1093.	0.4	2
1983	Gender-specific prevalence of metabolic-associated fatty liver disease among government employees in Tianjin, China: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e056260.	0.8	8
1984	Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999–2016. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2838-2847.e7.	2.4	38
1985	Structural and Functional Modulation of Gut Microbiota by Jiangzhi Granules during the Amelioration of Nonalcoholic Fatty Liver Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-18.	1.9	8
1986	Non-alcoholic fatty liver disease and metabolic liver dysfunction in the new coronavirus infection COVID-19. <i>The Siberian Scientific Medical Journal</i> , 2021, 41, 68-75.	0.1	1
1987	Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2021, 9, 1920.	1.4	21
1989	Molecular targets regulating endoplasmic reticulum-mitochondria crosstalk for NAFLD treatment. <i>Exploration of Medicine</i> , 0, , .	1.5	0
1990	Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States. <i>Medicine (United States)</i> , 2021, 100, e28165.	0.4	3
1991	Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF- κ B Signaling in a Rat Non-Alcoholic Steatohepatitis Model. <i>Nutrients</i> , 2022, 14, 42.	1.7	10
1992	Bifidobacterium bifidum Shows More Diversified Ways of Relieving Non-Alcoholic Fatty Liver Compared with Bifidobacterium adolescentis. <i>Biomedicines</i> , 2022, 10, 84.	1.4	14
1993	The Regulatory Effects of Citrus Peel Powder on Liver Metabolites and Gut Flora in Mice with Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Foods</i> , 2021, 10, 3022.	1.9	23
1994	The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis—Systematic Review and Meta-Analysis. <i>Biomedicines</i> , 2021, 9, 1890.	1.4	20
1995	The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease. <i>Biomedicines</i> , 2021, 9, 1853.	1.4	12

#	ARTICLE	IF	CITATIONS
1996	A family history of type 2 diabetes as a predictor of fatty liver disease in diabetes-free individuals with excessive body weight. <i>Scientific Reports</i> , 2021, 11, 24084.	1.6	9
1997	Objectively Measured Physical Activity Is Inversely Associated With Nonalcoholic Fatty Liver Disease: The Rotterdam Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 311-318.	0.2	15
1998	Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan. <i>Bioscience Reports</i> , 2021, 41, .	1.1	3
1999	Gut dysbiosis and systemic inflammation promote cardiomyocyte abnormalities in an experimental model of steatohepatitis. <i>World Journal of Hepatology</i> , 2021, 13, 2052-2070.	0.8	7
2000	Potential Natural Compounds for the Prevention and Treatment of Nonalcoholic Fatty Liver Disease: A Review on Molecular Mechanisms. <i>Current Molecular Pharmacology</i> , 2021, 15, .	0.7	1
2001	New year, new lifestyle. <i>Gastrointestinal Nursing</i> , 2021, 19, S3-S3.	0.0	1
2002	Analysis of N6-Methyladenosine Methylation Modification in Fructose-Induced Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 780617.	1.5	18
2003	Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1516-1524.e2.	2.4	57
2004	Scutellarin ameliorates hepatic lipid accumulation by enhancing autophagy and suppressing XBP1 pathway. <i>Phytotherapy Research</i> , 2022, 36, 433-447.	2.8	17
2005	p62/SQSTM1 in liver diseases: the usual suspect with multifarious identities. <i>FEBS Journal</i> , 2023, 290, 892-912.	2.2	15
2006	Exercise Alleviates the Apolipoprotein A5-Toll-Like Receptor 4 Axis Impairment in Mice With High-Fat Diet-Induced Non-alcoholic Steatohepatitis. <i>Frontiers in Physiology</i> , 2021, 12, 783341.	1.3	4
2007	Advances in liver US, CT, and MRI: moving toward the future. <i>European Radiology Experimental</i> , 2021, 5, 52.	1.7	25
2008	Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?. <i>World Journal of Hepatology</i> , 2021, 13, 2104-2112.	0.8	6
2009	Co-interventions with <i>Clostridium butyricum</i> and soluble dietary fiber targeting the gut microbiota improve MAFLD via the Acly/Nrf2/NF- κ B signaling pathway. <i>Food and Function</i> , 2022, 13, 5807-5819.	2.1	7
2010	Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. <i>Annals of Gastroenterology</i> , 2022, , .	0.4	4
2011	DNA Methylation Patterns According to Fatty Liver Index and Longitudinal Changes from the Korean Genome and Epidemiology Study (KoGES). <i>Current Issues in Molecular Biology</i> , 2022, 44, 1149-1168.	1.0	4
2012	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3.	2.4	9
2013	Annexin A1 treatment prevents the evolution to fibrosis of experimental nonalcoholic steatohepatitis. <i>Clinical Science</i> , 2022, 136, 643-656.	1.8	10

#	ARTICLE	IF	CITATIONS
2014	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 101161ATV0000000000000153.	1.1	167
2015	AAA-ATPase valosin-containing protein binds the transcription factor SREBP1 and promotes its proteolytic activation by rhomboid protease RHBDL4. <i>Journal of Biological Chemistry</i> , 2022, 298, 101936.	1.6	4
2016	Preclinical Long-term Magnetic Resonance Imaging Study of Silymarin Liver-protective Effects. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	0
2017	Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn's disease. <i>BMC Gastroenterology</i> , 2022, 22, 183.	0.8	6
2018	Non-alcoholic fatty liver disease prevalence in Latin America: A systematic review and meta-analysis. <i>Annals of Hepatology</i> , 2022, 27, 100706.	0.6	18
2020	Hepatic Steatosis Is Associated with High White Blood Cell and Platelet Counts. <i>Biomedicines</i> , 2022, 10, 892.	1.4	6
2021	Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review. <i>Frontiers in Nutrition</i> , 2022, 9, 844374.	1.6	5
2022	Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock?. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 5-11.	1.5	2
2023	Lipoprotein Levels in Early Adulthood and NAFLD in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. <i>Journal of Nutrition and Metabolism</i> , 2022, 2022, 1-9.	0.7	0
2024	Potential Therapeutic Targets and Promising Agents for Combating NAFLD. <i>Biomedicines</i> , 2022, 10, 901.	1.4	6
2025	L-theanine prevents progression of nonalcoholic hepatic steatosis by regulating hepatocyte lipid metabolic pathways via the CaMKK β -AMPK signaling pathway. <i>Nutrition and Metabolism</i> , 2022, 19, 29.	1.3	7
2026	Reversal of NAFLD After VSG Is Independent of Weight-Loss but RYGB Offers More Efficacy When Maintained on a High-Fat Diet. <i>Obesity Surgery</i> , 2022, 32, 2010-2022.	1.1	2
2027	Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice. <i>Journal of Biological Chemistry</i> , 2022, 298, 101946.	1.6	7
2028	Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis. <i>Annals of Medicine and Surgery</i> , 2022, 77, .	0.5	4
2029	Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112984.	2.5	2
2058	Liver, NAFLD and COVID-19. <i>Hormone and Metabolic Research</i> , 2022, 54, 522-531.	0.7	11
2059	MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1080-1089.	1.9	19
2060	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. <i>Hypertension</i> , 2022, 79, 1319-1326.	1.3	50

#	ARTICLE	IF	CITATIONS
2064	A predictive model for the diagnosis of non-alcoholic fatty liver disease based on an integrated machine learning method.. American Journal of Translational Research (discontinued), 2021, 13, 12704-12713.	0.0	0
2066	Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer. Advances in Experimental Medicine and Biology, 2022, 1372, 157-168.	0.8	1
2067	Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis. Food and Function, 2022, 13, 6387-6403.	2.1	7
2068	The GR-gp78 Pathway is involved in Hepatic Lipid Accumulation Induced by Overexpression of 11 β -HSD1. International Journal of Biological Sciences, 2022, 18, 3107-3121.	2.6	3
2070	Total cholesterol to high-density lipoprotein ratio and nonalcoholic fatty liver disease in a population with chronic hepatitis B. World Journal of Hepatology, 2022, 14, 791-801.	0.8	1
2071	Receptor-interacting protein kinase-1 ablation in liver parenchymal cells promotes liver fibrosis in murine NASH without affecting other symptoms. Journal of Molecular Medicine, 2022, , 1.	1.7	2
2072	Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 1281-1291.	1.1	7
2073	Styrylpyrones from <i>Phellinus linteus</i> Mycelia Alleviate Non-Alcoholic Fatty Liver by Modulating Lipid and Glucose Metabolic Homeostasis in High-Fat and High-Fructose Diet-Fed Mice. Antioxidants, 2022, 11, 898.	2.2	4
2074	Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis. Biomedicines, 2022, 10, 1015.	1.4	7
2075	Hepatorenal Index by B-mode Ratio Versus Imaging and Fatty Liver Index to Diagnose Steatosis in Alcohol-Related and Nonalcoholic Fatty Liver Disease. Journal of Ultrasound in Medicine, 2022, , .	0.8	5
2076	Burden and Predictors of Non-Alcoholic Fatty Liver Disease in a Retrospective Cohort of Patients With Crohn's Disease. Gastroenterology Research, 2022, 15, 82-90.	0.4	6
2077	Regulatory Roles of Caspase-11 Non-Canonical Inflammasome in Inflammatory Liver Diseases. International Journal of Molecular Sciences, 2022, 23, 4986.	1.8	15
2078	Using Telehealth for Diagnosis and Management of Non-Alcoholic Fatty Liver Disease. Clinical Liver Disease, 2022, 19, 171-175.	1.0	2
2079	Impact of Helicobacter pylori Eradication on the Risk of Incident Nonalcoholic Fatty Liver Disease: A Cohort Study. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2022, 22, 131-138.	0.1	3
2080	The Effect and Mechanism of Sucrose Consumption to Liver Disease – A Systematic Literature Review. Biomolecular and Health Science Journal, 2022, 5, 47-53.	0.1	0
2081	The macrophage-associated microRNA-4715-3p / Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data. Bioengineered, 2022, 13, 11740-11751.	1.4	2
2082	Clinicians' Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study. Journal of Clinical Medicine, 2022, 11, 2707.	1.0	1
2083	Ficus hirta Vahl. Ameliorates Nonalcoholic Fatty Liver Disease through Regulating Lipid Metabolism and Gut Microbiota. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-31.	1.9	9

#	ARTICLE	IF	CITATIONS
2084	Liver Stiffness Measurements by 2D Shear-Wave Elastography: Effect of Steatosis on Fibrosis Evaluation. <i>American Journal of Roentgenology</i> , 2022, , .	1.0	2
2085	Obeticholic Acid Induces Hepatotoxicity Via FXR in the NAFLD Mice. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	3
2086	Clinical Implications of Altered Drug Transporter Abundance/Function and <scp>PBPK</scp> Modeling in Specific Populations: An <scp>ITC</scp> Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 501-526.	2.3	21
2087	Liver Protein Expression in NASH Mice on a High-Fat Diet: Response to Multi-Mineral Intervention. <i>Frontiers in Nutrition</i> , 2022, 9, .	1.6	4
2088	The role of the intestinal permeability in the progression of nonalcoholic fatty liver disease in obese children. <i>Gastroenterologia</i> , 2022, 56, 20-28.	0.0	0
2089	KLF10 promotes nonalcoholic steatohepatitis progression through transcriptional activation of zDHC7. <i>EMBO Reports</i> , 2022, 23, e54229.	2.0	11
2090	Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000861.	1.1	6
2091	High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	7
2092	Polysaccharides and flavonoids from cyclocarya paliurus modulate gut microbiota and attenuate hepatic steatosis, hyperglycemia, and hyperlipidemia in nonalcoholic fatty liver disease rats with type 2 diabetes mellitus. <i>International Journal of Diabetes in Developing Countries</i> , 2023, 43, 317-327.	0.3	1
2093	Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged 40 years. <i>BMC Endocrine Disorders</i> , 2022, 22, 128.	0.9	5
2094	Individuals with Metabolic Syndrome Show Altered Fecal Lipidomic Profiles with No Signs of Intestinal Inflammation or Increased Intestinal Permeability. <i>Metabolites</i> , 2022, 12, 431.	1.3	2
2095	Ethanol extract of <i>Pharbitis nil</i> ameliorates liver fibrosis through regulation of the TGF β 1-SMAD2/3 pathway. <i>Journal of Ethnopharmacology</i> , 2022, 294, 115370.	2.0	5
2096	Prevalence of non-alcoholic fatty liver disease in the Russian Ural Eye and Medical Study and the Ural Very Old Study. <i>Scientific Reports</i> , 2022, 12, 7842.	1.6	5
2097	Loss of mitochondrial ATPase ATAD3A contributes to nonalcoholic fatty liver disease through accumulation of lipids and damaged mitochondria. <i>Journal of Biological Chemistry</i> , 2022, 298, 102008.	1.6	9
2098	Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2022, 24, 515-532.	2.0	18
2099	Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018. <i>Hepatology Communications</i> , 2022, 6, 2253-2261.	2.0	13
2100	Insights from a high-fat diet fed mouse model with a humanized liver. <i>PLoS ONE</i> , 2022, 17, e0268260.	1.1	1
2101	Non-alcoholic fatty liver disease, sleep behaviors, and incident type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1633-1640.	1.4	6

#	ARTICLE	IF	CITATIONS
2102	An examination of eating behavior in patients with non-alcoholic fatty liver disease: A cross-sectional study in a Japanese population. <i>Human Nutrition and Metabolism</i> , 2022, 28, 200150.	0.8	1
2103	The anti-inflammatory effect of Pien Tze Huang in non-alcoholic fatty liver disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113076.	2.5	7
2104	Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. <i>Acta Clinica Croatica</i> , 2021, 60, 36-52.	0.1	0
2105	Risk factors for non-alcoholic fatty liver disease delineate the battlegrounds in optimizing disease prevention. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, .	0.7	0
2106	Network pharmacology analysis on mechanism of Jian Pi Qing Gan Yin decoction ameliorating high fat diet-induced non-alcoholic fatty liver disease and validated in vivo. <i>Journal of Ethnopharmacology</i> , 2022, 295, 115382.	2.0	4
2107	Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Women: Effects of Lifestyle Modifications. <i>Journal of Clinical Medicine</i> , 2022, 11, 2759.	1.0	4
2108	White tea alleviates non-alcoholic fatty liver disease by regulating energy expenditure and lipid metabolism. <i>Gene</i> , 2022, 833, 146553.	1.0	5
2109	Mid-upper arm circumference is associated with liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease: A population based observational study. <i>Hepatology Communications</i> , 2022, 6, 2262-2272.	2.0	2
2110	Non-alcoholic Fatty Liver Disease Is Associated With Aortic Calcification: A Cohort Study With Propensity Score Matching. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	0
2111	Incremental levels of diagnostic information incentivize health-seeking in non-alcoholic fatty liver: a randomized clinical trial. <i>Scientific Reports</i> , 2022, 12, 8272.	1.6	1
2112	Increasing nonalcoholic steatohepatitis overlap in liver transplant recipients: Additive risk for de novo malignancy. <i>Clinical Transplantation</i> , 2022, , e14714.	0.8	0
2113	Renaming from nonalcoholic fatty liver disease to metabolism dysfunction associated fatty liver disease: Pros and cons. <i>Hepatology Research</i> , 2022, 52, 415-416.	1.8	0
2114	Validation of magnetic resonance elastography plus FIB-4 for significant fibrosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	1.4	1
2115	Characterization of diet based nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in rodent models: Histological and biochemical outcomes.. <i>Histology and Histopathology</i> , 2022, , 18462.	0.5	0
2116	Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology. <i>Frontiers in Pharmacology</i> , 2022, 13, 875700.	1.6	4
2117	Ongoing Clinical Trials in Aging-Related Tissue Fibrosis and New Findings Related to AhR Pathways. , 2022, 13, 732.		5
2119	Mendelian Randomization Rules Out Causation Between Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	4
2120	The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00504.	1.3	6

#	ARTICLE	IF	CITATIONS
2121	Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis. <i>Frontiers in Nutrition</i> , 2022, 9, .	1.6	8
2122	High time for common ground in the assessment of steatosis. <i>Liver Transplantation</i> , 2022, 28, 1427-1428.	1.3	1
2123	Premenopausal Syndrome and NAFLD: A New Approach Based on Gender Medicine. <i>Biomedicines</i> , 2022, 10, 1184.	1.4	4
2124	Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena. <i>Liver Research</i> , 2022, 6, 72-83.	0.5	10
2125	Roles of Yes-associated protein and transcriptional coactivator with PDZ-binding motif in non-neoplastic liver diseases. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113166.	2.5	1
2126	Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease. <i>Gene</i> , 2022, 833, 146587.	1.0	7
2127	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. <i>Current Research in Immunology</i> , 2022, 3, 118-127.	1.2	20
2128	The improvement of nonalcoholic steatohepatitis by <i>Poria cocos</i> polysaccharides associated with gut microbiota and NF- κ B/CCL3/CCR1 axis. <i>Phytomedicine</i> , 2022, 103, 154208.	2.3	15
2129	Association between non-alcoholic fatty liver disease and bone turnover markers in southwest China. <i>Journal of Bone and Mineral Metabolism</i> , 0, , .	1.3	2
2130	Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation. <i>Journal of Ethnopharmacology</i> , 2022, 296, 115405.	2.0	15
2131	Saikosaponin D attenuates metabolic associated fatty liver disease by coordinately tuning PPAR α and INSIG/SREBP1c pathway. <i>Phytomedicine</i> , 2022, 103, 154219.	2.3	13
2133	Nonalcoholic Fatty Liver Disease: Current Global Burden. <i>Seminars in Liver Disease</i> , 2022, 42, 401-412.	1.8	17
2135	Hepatocellular carcinoma in Stockholm, Sweden 2003â€“2018: a population-based cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 0, , 1-9.	0.6	0
2136	Association of Oxidized Low-Density Lipoprotein in Nonalcoholic Fatty Liver Disease with High-Risk Plaque on Coronary Computed Tomography Angiography: A Matched Caseâ€“Control Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2838.	1.0	4
2137	Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. , 2022, 19, 834-847.		33
2138	Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 391-401.	1.8	9
2139	Vanadium(IV)-Chlorodipicolinate Protects against Hepatic Steatosis by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammation. <i>Antioxidants</i> , 2022, 11, 1093.	2.2	3
2140	Combined Effects of Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease on the Risk of Cardiovascular Disease in Patients with Diabetes. <i>Biomedicines</i> , 2022, 10, 1245.	1.4	2

#	ARTICLE	IF	CITATIONS
2141	MODERN METHODS OF DIAGNOSIS AND SCREENING OF NON-ALCOHOLIC FATTY LIVER DISEASE AND ITS STAGES: review. <i>Inter Collegas</i> , 2022, 8, 226-231.	0.0	0
2142	Differential Effects of Dietary versus Exercise Intervention on Intrahepatic MAIT Cells and Histological Features of NAFLD. <i>Nutrients</i> , 2022, 14, 2198.	1.7	10
2143	Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. <i>Cureus</i> , 2022, , .	0.2	7
2144	Protective Effects and Mechanisms of Yinchen Linggui Zhugan Decoction in HFD-Induced Nonalcoholic Fatty Liver Disease Rats Based on Network Pharmacology and Experimental Verification. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
2145	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> , 2022, 54, 761-771.	9.4	68
2146	Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	4
2147	Disrupting <i>Osr1</i> expression promoted hepatic steatosis and inflammation induced by high-fat diet in the mouse model. <i>PLoS ONE</i> , 2022, 17, e0268344.	1.1	3
2149	Association between serum uric acid levels and incidence of nonalcoholic fatty liver disease in users of preventive medicine service in southern Brazil: a retrospective study. <i>Bulletin of the National Research Centre</i> , 2022, 46, .	0.7	0
2150	Peripheral endothelial and microvascular damage in liver cirrhosis: a systematic review and meta-analysis. <i>Microcirculation</i> , 0, , .	1.0	0
2151	Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 145-156.	2.8	12
2152	Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 477-496.	1.8	13
2154	Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy. <i>Yonsei Medical Journal</i> , 2022, 63, 619.	0.9	13
2155	Fatty Liver Disease. , 2022, , 265-298.		0
2156	Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: a matched case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 838-843.	0.8	3
2157	Croton urucurana Baill. Ameliorates Metabolic Associated Fatty Liver Disease in Rats. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
2158	La esteatohepatitis no alcoh3lica: una causa emergente de cirrosis en Colombia. <i>Revista Colombiana De Gastroenterologia</i> , 2022, 37, 136-144.	0.1	0
2159	Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. <i>Hepatology</i> , 2023, 77, 558-572.	3.6	17
2160	Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. <i>Seminars in Liver Disease</i> , 2022, 42, 379-400.	1.8	17

#	ARTICLE	IF	CITATIONS
2161	Long noncoding RNA-EN_181 potentially contributes to the protective effects of N-acetylcysteine against non-alcoholic fatty liver disease in mice. <i>British Journal of Nutrition</i> , 0, , 1-42.	1.2	1
2162	The presence of interferon affects the progression of non-alcoholic fatty liver disease. <i>Genes and Immunity</i> , 2022, 23, 157-165.	2.2	2
2164	Exploring the Path of Mediterranean Diet, Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation towards 10-Year Cardiovascular Disease (CVD) Risk: The ATTICA Study 10-Year Follow-Up (2002â€“2012). <i>Nutrients</i> , 2022, 14, 2367.	1.7	5
2165	Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARÎ±/PGC1Î± Signaling Pathway. <i>Journal of Natural Products</i> , 2022, 85, 1738-1750.	1.5	4
2166	Glycation and a Spark of ALEs (Advanced Lipoxidation End Products) â€“ Igniting RAGE/Diaphanous-1 and Cardiometabolic Disease. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	8
2167	Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric Surgery. <i>Disease Markers</i> , 2022, 2022, 1-17.	0.6	4
2168	The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018. <i>Endocrinology and Metabolism</i> , 2022, 37, 455-465.	1.3	9
2169	Hepatocyte nuclear factor 1A suppresses innate immune response by inducing degradation of TBK1 to inhibit steatohepatitis. <i>Genes and Diseases</i> , 2022, , .	1.5	2
2170	Two-dimensional Shear-Wave Elastography and US Attenuation Imaging for Nonalcoholic Steatohepatitis Diagnosis: A Cross-sectional, Multicenter Study. <i>Radiology</i> , 2022, 305, 118-126.	3.6	20
2171	Accurate and generalizable quantitative scoring of liver steatosis from ultrasound images <i>via</i> scalable deep learning. <i>World Journal of Gastroenterology</i> , 2022, 28, 2494-2508.	1.4	10
2172	Prevalence and Risk Factors for Hepatic Steatosis in Children With Perinatal HIV on Early Antiretroviral Therapy Compared to HIV-Exposed Uninfected and HIV-Unexposed Children. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	5
2174	Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 638-651.	8.2	69
2175	Lowering n-6/n-3 Ratio as an Important Dietary Intervention to Prevent LPS-Inducible Dyslipidemia and Hepatic Abnormalities in ob/ob Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6384.	1.8	15
2176	Design, Synthesis, and Biological Evaluation of Novel Pyrrolo [2,3-b] Pyridine Derivatives for Nonalcoholic Fatty Liver Disease. <i>Journal of Chemistry</i> , 2022, 2022, 1-12.	0.9	0
2177	Serum Ferritin and NAFLD in Patients Undergoing Bariatric Surgery. <i>Obesity Surgery</i> , 2022, 32, 2658-2663.	1.1	2
2178	Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
2179	Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD). <i>International Journal of Molecular Sciences</i> , 2022, 23, 6996.	1.8	8
2180	Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. <i>Obesity Reviews</i> , 2022, 23, .	3.1	7

#	ARTICLE	IF	CITATIONS
2181	Prevalence estimation of significant fibrosis because of <sc>NASH</sc> in Spain combining transient elastography and histology. <i>Liver International</i> , 2022, 42, 1783-1792.	1.9	10
2182	Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. <i>Nature Medicine</i> , 2022, 28, 1432-1438.	15.2	23
2183	Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	9
2184	Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. <i>Journal of Hepatology</i> , 2022, 77, 1373-1385.	1.8	60
2185	Crohnâ€™s Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2023, 68, 1006-1015.	1.1	9
2186	Short-term weight loss decreased the risk of chronic kidney disease in men with incident nonalcoholic fatty liver disease. <i>Obesity</i> , 2022, 30, 1495-1506.	1.5	3
2187	Efficacy and safety of oral semaglutide in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. <i>JGH Open</i> , 2022, 6, 503-511.	0.7	10
2188	Deuterium-Reinforced Polyunsaturated Fatty Acids Prevent Diet-Induced Nonalcoholic Steatohepatitis by Reducing Oxidative Stress. <i>Medicina (Lithuania)</i> , 2022, 58, 790.	0.8	0
2189	Identify Functional lncRNAs in Nonalcoholic Fatty Liver Disease by Constructing a ceRNA Network. <i>ACS Omega</i> , 0, , .	1.6	2
2190	Rat liver ECM incorporated into electrospun polycaprolactone scaffolds as a platform for hepatocyte culture. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2022, 110, 2612-2623.	1.6	5
2191	I148M variant of PNPLA3-gene is not associated with metabolic syndrome in patients with NAFLD in the Indian ethnicity. , 2022, 33, 201073.		2
2192	Maternal One-Carbon Supplement Reduced the Risk of Non-Alcoholic Fatty Liver Disease in Male Offspring. <i>Nutrients</i> , 2022, 14, 2545.	1.7	5
2193	Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheepâ€™s Clothing?. <i>Current Oncology</i> , 2022, 29, 4478-4510.	0.9	6
2194	Pro-Neurotensin as a Potential Novel Diagnostic Biomarker for Detection of Nonalcoholic Fatty Liver Disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 1935-1943.	1.1	4
2195	The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties. <i>Expert Reviews in Molecular Medicine</i> , 0, , 1-42.	1.6	3
2196	Alisol B Alleviates Hepatocyte Lipid Accumulation and Lipotoxicity via Regulating RAR α -PPAR β -CD36 Cascade and Attenuates Non-Alcoholic Steatohepatitis in Mice. <i>Nutrients</i> , 2022, 14, 2411.	1.7	17
2197	Synthesis and biological evaluation of tyrosine derivatives as peripheral 5HT $2A$ receptor antagonists for nonalcoholic fatty liver disease. <i>European Journal of Medicinal Chemistry</i> , 2022, 239, 114517.	2.6	3
2198	PM2.5 air pollution exposure and nonalcoholic fatty liver disease in the Nationwide Inpatient Sample. <i>Environmental Research</i> , 2022, 213, 113611.	3.7	22

#	ARTICLE	IF	CITATIONS
2199	Non-alcoholic Fatty Liver Disease and Liver Fibrosis during Aging. , 2022, 13, 1239.		20
2200	Nonalcoholic fatty liver disease: Role of medical colleges in its prevention and control. Indian Journal of Community Medicine, 2022, 47, 302.	0.2	0
2201	Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients. , 2022, 2, 11.		4
2202	Hepatoprotective effect of curcumin against bisphenol A-induced hepatic steatosis via modulating gut microbiota dysbiosis and related gut-liver axis activation in CD-1 mice. Journal of Nutritional Biochemistry, 2022, 109, 109103.	1.9	10
2203	Pharmacological Mechanism of Ganlu Powder in the Treatment of NASH Based on Network Pharmacology and Molecular Docking. Disease Markers, 2022, 2022, 1-12.	0.6	1
2204	Effect of Exercise Training on Serum Transaminases in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Frontiers in Physiology, 0, 13, .	1.3	5
2205	The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. Journal of Clinical Medicine, 2022, 11, 3649.	1.0	19
2206	New Insights into Hippo/YAP Signaling in Fibrotic Diseases. Cells, 2022, 11, 2065.	1.8	29
2207	Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD. Antioxidants, 2022, 11, 1284.	2.2	3
2208	Multiple Mechanisms of Shenqi Pill in Treating Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Molecular Docking. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-9.	0.5	0
2209	External validation and comparison of simple tools to screen for nonalcoholic fatty liver disease in Chinese community population. European Journal of Gastroenterology and Hepatology, 2022, 34, 865-872.	0.8	6
2210	Role of NAFLD on the Health Related QoL Response to Lifestyle in Patients With Metabolic Syndrome: The PREDIMED Plus Cohort. Frontiers in Endocrinology, 0, 13, .	1.5	7
2211	Therapeutic Potential of Artichoke in the Treatment of Fatty Liver: A Systematic Review and Meta-Analysis. Journal of Medicinal Food, 0, , .	0.8	3
2212	Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 0, 13, .	1.6	3
2213	Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD. Developmental Cell, 2022, 57, 1728-1741.e6.	3.1	17
2214	Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC)Ä. Digestive Diseases and Sciences, 0, , .	1.1	2
2215	Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population. BMC Gastroenterology, 2022, 22, .	0.8	7
2216	Targeting fibrosis: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	97

#	ARTICLE	IF	CITATIONS
2217	Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. <i>Nature Reviews Endocrinology</i> , 2022, 18, 638-650.	4.3	18
2218	Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study. <i>Hepatology</i> , 2023, 77, 585-593.	3.6	17
2219	Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000945.	1.1	2
2220	PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo. <i>Diabetes</i> , 0, , .	0.3	2
2221	Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. <i>Journal of Lipid Research</i> , 2022, 63, 100250.	2.0	7
2222	Mechanism and therapeutic strategy of hepatic <i>TM6SF2</i> -deficient non-alcoholic fatty liver diseases via <i>in vivo</i> and <i>in vitro</i> experiments. <i>World Journal of Gastroenterology</i> , 2022, 28, 2937-2954.	1.4	8
2223	microRNA-103a-3p promotes inflammation and fibrosis in nonalcoholic fatty liver disease by targeting HBP1. <i>Immunopharmacology and Immunotoxicology</i> , 2022, 44, 993-1003.	1.1	3
2224	TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	38
2225	Current treatment of non-alcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , 2022, 292, 190-204.	2.7	56
2226	Altered branched-chain β -keto acid metabolism is a feature of NAFLD in individuals with severe obesity. <i>JCI Insight</i> , 2022, 7, .	2.3	16
2227	Inhibition of mPGES2 ameliorates NASH by activating NR1D1 via heme. <i>Hepatology</i> , 2023, 78, 547-561.	3.6	8
2228	Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 570-579.	1.9	9
2229	Nootkatone, a Sesquiterpene Ketone From <i>Alpinia oxyphylla</i> Fructus, Ameliorates Metabolic-Associated Fatty Liver by Regulating AMPK and MAPK Signaling. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
2230	Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. <i>World Journal of Gastroenterology</i> , 2022, 28, 3410-3421.	1.4	7
2231	A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	7
2232	AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. <i>Gastroenterology</i> , 2022, 163, 764-774.e1.	0.6	92
2233	Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7841.	1.8	13
2234	HSPA8 Single-Nucleotide Polymorphism Is Associated with Serum HSC70 Concentration and Carotid Artery Atherosclerosis in Nonalcoholic Fatty Liver Disease. <i>Genes</i> , 2022, 13, 1265.	1.0	1

#	ARTICLE	IF	CITATIONS
2235	Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 751-767.	2.3	21
2236	Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
2237	Editorial: Gastrointestinal and Liver Effects of Fruits and Their Synergism With Drug Therapy: Exploring Possible Mechanisms of Action. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
2238	Prospective dietary polyunsaturated fatty acid intake is associated with trajectories of fatty liver disease: an 8-year follow-up study from adolescence to young adulthood. <i>European Journal of Nutrition</i> , 2022, 61, 3987-4000.	1.8	4
2239	Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2022, 28, 3243-3257.	1.4	16
2240	Berberubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver Disease via Modulating Glucose and Lipid Metabolism and Restoring Gut Microbiota. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	15
2241	Identification of novel targets in adipose tissue involved in non-alcoholic fatty liver disease progression. <i>FASEB Journal</i> , 2022, 36, .	0.2	6
2242	Pathophysiology roles for adenosine 2A receptor in obesity and related diseases. <i>Obesity Reviews</i> , 2022, 23, .	3.1	3
2243	Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. <i>Liver Cancer</i> , 2023, 12, 19-31.	4.2	5
2244	Impact of chronic hepatitis on cardiovascular events among type 2 diabetes patients in Taiwan pay-for-performance program. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
2245	RPA1 controls chromatin architecture and maintains lipid metabolic homeostasis. <i>Cell Reports</i> , 2022, 40, 111071.	2.9	6
2246	Association of Serum Apolipoprotein A5 Concentration with Nonalcoholic Fatty Liver Disease in Ningbo, China. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-5.	0.4	0
2247	SerpineB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
2248	The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1901-1910.	1.4	2
2249	Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study. <i>Nutrients</i> , 2022, 14, 2795.	1.7	11
2250	The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1252-1260.e5.	2.4	6
2251	Non-alcoholic Fatty Liver Disease and Depression: Evidence for Genotype × Environment Interaction in Mexican Americans. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	3
2252	Association of Prenatal Exposure to Endocrine-Disrupting Chemicals With Liver Injury in Children. <i>JAMA Network Open</i> , 2022, 5, e2220176.	2.8	30

#	ARTICLE	IF	CITATIONS
2253	Banting memorial lecture 2022: "Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime". <i>Diabetic Medicine</i> , 2022, 39, .	1.2	9
2254	Sensitivity to thyroid hormones is associated with advanced fibrosis in euthyroid patients with non-alcoholic fatty liver disease: A cross-sectional study. <i>Digestive and Liver Disease</i> , 2023, 55, 254-261.	0.4	6
2255	Fine-tuning of regulatory T cells is indispensable for the metabolic steatosis-related hepatocellular carcinoma: A review. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	12
2256	Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2022, 50, 101534.	3.2	7
2257	Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes. <i>Current Opinion in Pediatrics</i> , 2022, 34, 414-422.	1.0	1
2258	Recent advances in lean NAFLD. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113331.	2.5	34
2259	Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD). <i>Metabolism: Clinical and Experimental</i> , 2022, 134, 155246.	1.5	12
2260	Appendicular Skeletal Muscle Index and HbA1c Evaluate Liver Steatosis in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
2261	Immunological risk factors for nonalcoholic fatty liver disease in patients with psoriatic arthritis: New predictive nomograms and natural killer cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2262	Cutoff Points of Waist Circumference for Predicting Incident Non-Alcoholic Fatty Liver Disease in Middle-Aged and Older Korean Adults. <i>Nutrients</i> , 2022, 14, 2994.	1.7	8
2263	Dietary fatty acids and risk of non-alcoholic steatohepatitis: A national study in the United States. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	1
2264	Improvement in nonalcoholic fatty liver disease through bariatric surgery. <i>Clinical Liver Disease</i> , 2022, 20, 13-17.	1.0	2
2265	Unripe banana flour (<i>Musa cavendishii</i>) promotes increased hypothalamic antioxidant activity, reduced caloric intake, and abdominal fat accumulation in rats on a high-fat diet. <i>Journal of Food Biochemistry</i> , 0, , .	1.2	0
2266	Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia. <i>Biomedicines</i> , 2022, 10, 1770.	1.4	7
2267	A flexible three-dimensional heterophase computed tomography hepatocellular carcinoma detection algorithm for generalizable and practical screening. <i>Hepatology Communications</i> , 2022, 6, 2901-2913.	2.0	5
2268	IRX3 plays an important role in the pathogenesis of metabolic-associated fatty liver disease by regulating hepatic lipid metabolism. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
2269	Regulation of PPAR- β activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2022, 14, 1365-1381.	0.8	3
2270	An improved method for isolation and flow cytometric characterization of intrahepatic leukocytes from fatty and fibrotic liver tissues. <i>Anatomical Record</i> , 2023, 306, 1011-1030.	0.8	4

#	ARTICLE	IF	CITATIONS
2271	Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: A randomized controlled trial. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	20
2272	A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
2273	Metabolic liver disease: A new preventable pandemic. <i>Revista De GastroenterologÃa De MÃ©xico (English)</i> Tj ETQq0.0 0 rgBT/Overlock	0.1	0
2274	Clinical Factors Associated with Non-Obese Nonalcoholic Fatty Liver Disease Detected among US Adults in the NHANES 2017â€“2018. <i>Journal of Clinical Medicine</i> , 2022, 11, 4260.	1.0	0
2275	Noni (<i>Morinda citrifolia</i> L.) fruit phenolic extract supplementation ameliorates NAFLD by modulating insulin resistance, oxidative stress, inflammation, liver metabolism and gut microbiota. <i>Food Research International</i> , 2022, 160, 111732.	2.9	14
2276	Akkermansia Muciniphila Suppressing Nonalcoholic Steatohepatitis Associated Tumorigenesis Through Natural Killer T Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2277	COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD. <i>International Journal of Biological Sciences</i> , 2022, 18, 4756-4767.	2.6	5
2278	The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	10
2279	ç›é...â°æª—çÇ±ç¼¼“è§£ä»»£è°çç›,â...³æ€Sè,,è,è,ç—...çš,,ç”ÿç%©â éçç,1â’ææœª”ç. <i>Chinese Science Bulletin</i> , 2022, , .		0
2280	Genetic variants associated with metabolic dysfunctionâ€“associated fatty liver disease in western China. <i>Journal of Clinical Laboratory Analysis</i> , 0, , .	0.9	8
2281	Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Metabolites</i> , 2022, 12, 664.	1.3	12
2282	Non-Alcoholic Fatty Liver Disease, Heart Failure, and Long-Term Mortality: Insights From the National Health and Nutrition Examination Survey. <i>Current Problems in Cardiology</i> , 2022, 47, 101333.	1.1	10
2283	Therapeutic effects of isosteviol sodium on non-alcoholic fatty liver disease by regulating autophagy via Sirt1/AMPK pathway. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
2284	Impact of duodenal-jejunal bypass liner (DJBL) on NAFLD in patients with obesity and type 2 diabetes mellitus. <i>Nutrition</i> , 2022, 103-104, 111806.	1.1	2
2286	RNA helicase DEADâ€“box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling. <i>Hepatology</i> , 2023, 77, 1670-1687.	3.6	9
2287	A Meta-Analysis of Sleep Disorders and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Nursing</i> , 2022, 45, 354-363.	0.2	0
2288	Autoimmune hepatitis and metabolic syndromeâ€“associated disease development: a U.S. cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1183-1193.	1.9	3
2289	Liver sinusoidal endothelial cell expressed vascular cell adhesion molecule 1 promotes liver fibrosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18

#	ARTICLE	IF	CITATIONS
2290	Targeted Proteomics for Monitoring One-Carbon Metabolism in Liver Diseases. <i>Metabolites</i> , 2022, 12, 779.	1.3	4
2292	The burden of liver cirrhosis in mortality: Results from the global burden of disease study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	37
2293	Association between hepatic steatosis and fibrosis indices and dietary habits, physical activity, and quality of life. <i>Arab Journal of Gastroenterology</i> , 2022, 23, 277-287.	0.4	1
2294	Targeting non-alcoholic fatty liver disease: Design, X-ray co-crystal structure and synthesis of a first-in-kind™ inhibitors of serine/threonine kinase25. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128950.	1.0	3
2295	Liver transplantation for <sc>NAFLD</sc> cirrhosis: Age and recent coronary angioplasty are major determinants of survival. <i>Liver International</i> , 2022, 42, 2428-2441.	1.9	10
2296	Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?. <i>Biology</i> , 2022, 11, 1237.	1.3	23
2297	HBV Reactivation After Bariatric Surgery for HBV-Infected Obese Patients. <i>Obesity Surgery</i> , 2022, 32, 3332-3339.	1.1	2
2298	Discovering Biomarkers for Non-Alcoholic Steatohepatitis Patients with and without Hepatocellular Carcinoma Using Fecal Metaproteomics. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8841.	1.8	4
2299	Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, , 159218.	1.2	6
2300	Application of <i>Weizmannia coagulans</i> in the medical and livestock industry. <i>Annals of Microbiology</i> , 2022, 72, .	1.1	2
2301	Sex-Dependent Hepatoprotective Role of IL-22 Receptor Signaling in Non-Alcoholic Fatty Liver Disease-Related Fibrosis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 1269-1294.	2.3	6
2302	Voluntary physical activity in early life attenuates markers of fatty liver disease in adult male rats fed a high-fat diet. <i>British Journal of Nutrition</i> , 2023, 129, 1667-1676.	1.2	1
2303	The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study. <i>Hepatology</i> , 2023, 77, 949-964.	3.6	58
2304	Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study. <i>Hepatology Research</i> , 2022, 52, 975-984.	1.8	12
2305	Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
2306	Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPAR±/FGF21 Axis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 1003-1023.	2.3	8
2307	Single-cell transcriptome and cell type-specific molecular pathways of human non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
2308	Demographic, clinical and laboratory predictors of hepatic steatosis and fibrosis by elastography. <i>Akademik Gastroenteroloji Dergisi</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
2309	Clinical trials in hepatitis D virus: Measuring success. <i>Hepatology</i> , 2023, 77, 2147-2157.	3.6	4
2310	The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, C387-C400.	1.6	9
2311	Centriole signaling restricts hepatocyte ploidy to maintain liver integrity. <i>Genes and Development</i> , 2022, 36, 843-856.	2.7	5
2312	Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9298.	1.8	2
2313	Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. <i>Journal of Hepatology</i> , 2022, 77, 1482-1490.	1.8	37
2314	Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 3224.	1.7	6
2315	Uncovering the roles of dihydropyrimidine dehydrogenase in fatty-acid induced steatosis using human cellular models. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
2316	Needle-free Nonalcoholic Fatty Liver Disease Prognostication: Moving One Step Closer. <i>Gastroenterology</i> , 2022, 163, 819-822.	0.6	1
2317	Shared Mechanisms between Cardiovascular Disease and NAFLD. <i>Seminars in Liver Disease</i> , 2022, 42, 455-464.	1.8	11
2318	Global Burden of Nonalcoholic Fatty Liver Disease, 1990 to 2019. <i>Journal of Clinical Gastroenterology</i> , 2023, 57, 631-639.	1.1	5
2319	Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3. <i>Hepatology Communications</i> , 2022, 6, 2676-2688.	2.0	4
2320	Modulating hepatic macrophages with annexin A1 in non-alcoholic steatohepatitis. <i>Clinical Science</i> , 2022, 136, 1111-1115.	1.8	1
2321	Transient Elastography and Serum-Based Tests for Diagnosis of Fatty Liver and Advanced Fibrosis in a Community Cohort: A Cross-Sectional Analysis. <i>Digestive Diseases</i> , 2023, 41, 767-779.	0.8	4
2322	Noncoding RNAs and RNA-binding proteins: emerging governors of liver physiology and metabolic diseases. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C1003-C1017.	2.1	8
2323	Sarcopenia, healthy living, and mortality in patients with chronic liver diseases. <i>Hepatology Communications</i> , 2022, 6, 3140-3153.	2.0	16
2324	A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity. <i>Metabolites</i> , 2022, 12, 732.	1.3	6
2325	Rats with high aerobic capacity display enhanced transcriptional adaptability and upregulation of bile acid metabolism in response to an acute high-fat diet. <i>Physiological Reports</i> , 2022, 10, .	0.7	2
2326	Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2022, 12, S5-S14.	0.1	0

#	ARTICLE	IF	CITATIONS
2327	Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
2328	Parathyroid hormone alleviates non-alcoholic liver steatosis via activating the hepatic cAMP/PKA/CREB pathway. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
2329	The role of SPARC (secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease. <i>Journal of Physiology and Biochemistry</i> , 2023, 79, 815-831.	1.3	5
2330	Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 425-434.	1.2	17
2331	Diagnosis of hepatic steatosis based on ultrasound attenuation imaging is not influenced by liver fibrosis. <i>Hepatology Research</i> , 0, , .	1.8	1
2332	Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study. <i>BMC Medicine</i> , 2022, 20, .	2.3	10
2333	Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 2148-2151.	0.8	9
2334	New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis. <i>Life</i> , 2022, 12, 1189.	1.1	14
2335	Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease. <i>Metabolites</i> , 2022, 12, 718.	1.3	7
2336	Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. <i>Cells</i> , 2022, 11, 2511.	1.8	35
2337	Periodontal Treatment and Usual Care for Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized Controlled Trial. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00520.	1.3	7
2338	The prevalence of metabolic dysfunction-associated fatty liver disease and its association on adverse pregnancy outcomes in women with gestational diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2022, 191, 110038.	1.1	0
2339	Exploring the antioxidant effects of Aloe vera: Potential role in controlling liver function and lipid profile in high fat and fructose diet (HFFD) fed mice. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 4, 100150.	0.5	5
2340	Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease. <i>IScience</i> , 2022, 25, 104949.	1.9	12
2341	A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPAR α) and farnesoid X receptor (FXR). <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113577.	2.5	17
2342	Untargeted metabolomics reveals the role of AQP9 in nonalcoholic fatty liver disease in a mice model. <i>International Journal of Biological Macromolecules</i> , 2022, 219, 864-875.	3.6	4
2343	Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis. <i>Metabolism: Clinical and Experimental</i> , 2022, 136, 155292.	1.5	5
2344	Polarity-sensitive and lipid droplet-specific red emission fluorophore for identifying fatty liver of living mice through in vivo imaging. <i>Biosensors and Bioelectronics</i> , 2022, 216, 114618.	5.3	19

#	ARTICLE	IF	CITATIONS
2345	NAFLD: genetics and its clinical implications. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 102003.	0.7	14
2347	Nutrient patterns and non-alcoholic fatty liver disease in Iranian Adult: A case-control study. Frontiers in Nutrition, 0, 9, .	1.6	5
2348	Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial Based on the Theory of Planned Behavior. BioMed Research International, 2022, 2022, 1-10.	0.9	9
2349	Chaihu Shugan powder alleviates liver inflammation and hepatic steatosis in NAFLD mice: A network pharmacology study and in vivo experimental validation. Frontiers in Pharmacology, 0, 13, .	1.6	5
2350	Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China. Frontiers in Endocrinology, 0, 13, .	1.5	10
2351	Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. Pharmacological Research, 2022, 184, 106426.	3.1	6
2352	Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD. Annals of Hepatology, 2022, 27, 100756.	0.6	2
2353	Vitality, mental health and role-physical mediate the influence of coping on depressive symptoms and self-efficacy in patients with non-alcoholic fatty liver disease: A cross-sectional study. Journal of Psychosomatic Research, 2022, 162, 111045.	1.2	3
2354	Mineral metabolism and ferroptosis in non-alcoholic fatty liver diseases. Biochemical Pharmacology, 2022, 205, 115242.	2.0	20
2355	Using a Machine Learning Model to Risk Stratify for the Presence of Significant Liver Disease in a Primary Care Population. SSRN Electronic Journal, 0, , .	0.4	0
2356	The global battle against SARS-CoV-2 and COVID-19 at the third year. International Journal of Biological Sciences, 2022, 18, 4792-4794.	2.6	0
2357	Non-Alcoholic Fatty Liver Disease and Steatohepatitis. , 2023, , 610-621.		2
2358	Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies. International Journal of Biological Sciences, 2022, 18, 5681-5697.	2.6	12
2359	Bariatrische Operation. , 2022, , 323-334.		0
2360	Plasma MicroRNA (miRNA)s as Novel Markers of Nonalcoholic Fatty Liver Disease. Biomarkers in Disease, 2022, , 1-18.	0.0	0
2361	Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series. Clinics, 2022, 77, 100097.	0.6	0
2362	Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211001.	1.4	5
2363	Pathophysiologie: Genetik. , 2022, , 75-92.		0

#	ARTICLE	IF	CITATIONS
2364	Serum 25-hydroxyvitamin D levels and the risk of non-alcoholic fatty liver: A two-sample Mendelian randomization study. <i>Saudi Journal of Gastroenterology</i> , 2023, 29, 39.	0.5	1
2365	Association between Melatonin Value and Interleukins1B, -18, and -33 Levels in Patients with Different Stages of Non-Alcoholic Fatty Liver Disease. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 110-117.	0.2	1
2366	Long non-coding RNA in Non-alcoholic fatty liver disease. <i>Advances in Clinical Chemistry</i> , 2022, , 1-35.	1.8	4
2367	Associations between Abnormal Iron Metabolism and Elevated Alanine Aminotransferase in Adults. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2368	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. <i>Choonpa Igaku</i> , 2022, 49, 385-396.	0.0	0
2370	Stepwise Evaluation for the Risk of Metabolic Unhealthiness and Significant Non-Alcoholic Fatty Liver Disease in the Community of a Lower Income Country. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2371	Endpunkte klinischer Studien. , 2022, , 395-401.		0
2372	Obesity, inflammation, and diseases of the gastrointestinal tract. , 2023, , 101-118.		0
2373	A novel matrine derivative, WM130, inhibits activation and movement of human hepatic stellate LX-2 cells by targeting cofilin 1. <i>Cytotechnology</i> , 2022, 74, 613-622.	0.7	3
2374	Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. <i>Biomedicines</i> , 2022, 10, 2101.	1.4	4
2375	African genetic ancestry and protection against fatty liver disease. <i>Liver International</i> , 2022, 42, 2122-2123.	1.9	4
2376	The Role of STAMP2 in Pathogenesis of Chronic Diseases Focusing on Nonalcoholic Fatty Liver Disease: A Review. <i>Biomedicines</i> , 2022, 10, 2082.	1.4	0
2377	ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2/ERK signaling pathways. <i>Journal of Advanced Research</i> , 2023, 47, 41-56.	4.4	11
2378	Effect of theaflavin-3,3-digallate on leptin-deficient induced nonalcoholic fatty liver disease might be related to lipid metabolism regulated by the Fads1/PPAR α /Fabp4 axis and gut microbiota. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
2379	Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus – From Prevalence to Diagnostic Approach and Treatment Strategies. <i>Journal of Clinical Medicine</i> , 2022, 11, 5144.	1.0	8
2380	Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	8
2381	Investigation of the Potential Mechanism of Danggui Shaoyao San for the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) with Network Pharmacology and Molecular Docking. <i>Current Computer-Aided Drug Design</i> , 2022, 18, 258-270.	0.8	4
2382	Neutrophil α lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non α alcoholic fatty liver disease. <i>Cancer Medicine</i> , 2023, 12, 3589-3600.	1.3	5

#	ARTICLE	IF	CITATIONS
2383	Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	25
2384	Prognostic Role of Neutrophil to Lymphocyte Ratio in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-10.	0.8	6
2385	Establishment and evaluation of a risk-prediction model for hypertension in elderly patients with NAFLD from a health management perspective. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
2386	The Efficacy of Oligonol in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blinded Placebo-Controlled Trial. , 2022, 28, 904-908.		1
2387	Analysis of time-dependent changes in the FIB4 index in patients with obesity receiving weight reduction therapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
2388	Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes. <i>Biomedicines</i> , 2022, 10, 2375.	1.4	5
2389	Association between the fatty liver index and chronic kidney disease: the population-based KORA study. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.4	2
2390	Risk Predictors of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2022, 12, 2136.	1.3	1
2391	Pharmacological effects of Chinese medicine modulating NLRP3 inflammasomes in fatty liver treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
2392	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 841-850.	4.5	62
2394	Geographical similarity and differences in the burden and genetic predisposition of NAFLD. <i>Hepatology</i> , 2023, 77, 1404-1427.	3.6	43
2395	Liver stiffness (Fibroscan®) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease. <i>Liver International</i> , 2023, 43, 90-99.	1.9	16
2396	Molecular Advances in MAFLD—A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11380.	1.8	1
2397	Missing-view completion for fatty liver disease detection. <i>Computers in Biology and Medicine</i> , 2022, 150, 106097.	3.9	3
2398	Therapies for non-alcoholic fatty liver disease: A 2022 update. <i>World Journal of Hepatology</i> , 0, 14, 1718-1729.	0.8	4
2399	Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1700-1716.	1.4	17
2400	Clinical Usefulness of Non-Invasive Metabolic-Associated Fatty Liver Disease Risk Assessment Methods in Patients with Full-Blown Polycystic Ovary Syndrome in Relation to the MRI Examination with the Ideal IQ Sequence. <i>Biomedicines</i> , 2022, 10, 2193.	1.4	0
2402	Micronutrients and Plant Food Bioactive Compounds against Obesity Related Diseases. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, .	0.6	0

#	ARTICLE	IF	CITATIONS
2403	All Roads Lead to Cathepsins: The Role of Cathepsins in Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma. <i>Biomedicines</i> , 2022, 10, 2351.	1.4	1
2404	Communication in non-communicable diseases (NCDs) and role of immunomodulatory nutraceuticals in their management. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	0
2405	Cardiometabolic index: A new predictor for metabolic associated fatty liver disease in Chinese adults. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	7
2406	Primary Care Providers and Nonalcoholic Fatty Liver Disease: A Needs Assessment Survey. <i>Digestive Diseases and Sciences</i> , 2023, 68, 434-438.	1.1	7
2407	Association between arterial hypertension and liver outcomes using polygenic risk scores: a population-based study. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
2408	Gut Microbiota Regulation of AHR Signaling in Liver Disease. <i>Biomolecules</i> , 2022, 12, 1244.	1.8	9
2409	Racial/ethnic differences in fibrosis prevalence and progression in biopsy-proven steatosis: A focus on the Asian American population. <i>Hepatology Communications</i> , 2022, 6, 3024-3035.	2.0	1
2410	Investigation of the effects of wet cupping therapy on some inflammatory factors in patients affected by non-alcoholic fatty liver disease (NAFLD): A quasi-experimental trial study with self-controls. <i>Qeios</i> , 0, , .	0.0	0
2412	Liver Fibrosis is Associated with Clinical Outcomes in Patients with Intracerebral Hemorrhage. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 2021-2030.	1.0	0
2413	NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 513-520.	3.2	30
2414	How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4651.	1.7	14
2415	Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	16
2416	Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 0, , .	1.9	3
2417	Bichromatic Imaging with Hemicyanine Fluorophores Enables Simultaneous Visualization of Non-alcoholic Fatty Liver Disease and Metastatic Intestinal Cancer. <i>Analytical Chemistry</i> , 2022, 94, 13556-13565.	3.2	11
2418	Non-alcoholic fatty liver disease and the risk of fibrosis in Italian primary care services. <i>Liver International</i> , 2022, 42, 2632-2645.	1.9	2
2419	Curcumin-loaded nanocomplexes ameliorate the severity of nonalcoholic steatohepatitis in hamsters infected with <i>Opisthorchis viverrini</i> . <i>PLoS ONE</i> , 2022, 17, e0275273.	1.1	1
2420	Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection—a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1581-1590.	1.9	8
2422	Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1622-1636.	0.8	6

#	ARTICLE	IF	CITATIONS
2424	Tanshinone IIA Ameliorates Nonalcoholic Steatohepatitis in Mice by Modulating Neutrophil Extracellular Traps and Hepatocyte Apoptosis. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-13.	0.5	3
2425	Investigation of the effects of wet cupping therapy on some inflammatory factors in patients affected by non-alcoholic fatty liver disease (NAFLD): A quasi-experimental trial study with self-controls. Qeios, 0, , .	0.0	0
2426	Liver fat content assessed by conventional B-mode ultrasound and metabolic profile in non-diabetic patients: Implications for clinical practice. Ultrasound, 0, , 1742271X2211225.	0.3	1
2427	The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005-2010 and 2017-2018. Liver International, 2022, 42, 2646-2661.	1.9	8
2428	Key hepatic signatures of human and mouse nonalcoholic steatohepatitis: A transcriptome-proteome data meta-analysis. Frontiers in Endocrinology, 0, 13, .	1.5	0
2429	Correlation between Liver Fat Indices and Ultrasonography to Determine Non-alcoholic Fatty Liver Disease among Diabetic Patients in Sri Lanka. , 0, 17, 15.		0
2430	Fatty liver disease in overweight and obese Iranian Children: Comprehensive systematic review and meta-analysis. Obesity Medicine, 2022, 35, 100455.	0.5	1
2431	Validation and Comparison of Two Dietary Indexes for Predicting Nonalcoholic Fatty Liver Disease in US Adults. Journal of Nutrition, 2022, 152, 2865-2876.	1.3	7
2432	Î±-D-1,3-glucan from Radix Puerariae thomsonii improves NAFLD by regulating the intestinal flora and metabolites. Carbohydrate Polymers, 2023, 299, 120197.	5.1	20
2433	Effect of cumulative body mass index exposure and long-term related change on incident non-alcoholic fatty liver disease. Liver International, 2023, 43, 345-356.	1.9	2
2434	Advances in Anti-metabolic Disease Treatments Targeting CD47. Current Pharmaceutical Design, 2022, 28, 3720-3728.	0.9	1
2435	Homocysteine, folate, and nonalcoholic fatty liver disease: a systematic review with meta-analysis and Mendelian randomization investigation. American Journal of Clinical Nutrition, 2022, 116, 1595-1609.	2.2	12
2436	Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. Expert Opinion on Therapeutic Targets, 2022, 26, 697-705.	1.5	4
2437	Interaction Between Increasing Body Mass Index and Spinal Cord Injury to the Probability of Developing a Diagnosis of Nonalcoholic Fatty Liver Disease. Obesity Science and Practice, 0, , .	1.0	0
2438	A comparison of magnetic resonance elastography (MRE) to biomarker testing for staging fibrosis in non-alcoholic fatty liver disease (NAFLD). Translational Gastroenterology and Hepatology, 0, 8, 7-7.	1.5	1
2439	The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019. JMIR Public Health and Surveillance, 2022, 8, e34809.	1.2	12
2440	Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. Journal of Atherosclerosis and Thrombosis, 2022, , .	0.9	1
2441	Update on genetics and epigenetics in metabolic associated fatty liver disease. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882211321.	1.4	7

#	ARTICLE	IF	CITATIONS
2442	Plasma MicroRNA (miRNA)s as Novel Markers of Nonalcoholic Fatty Liver Disease. <i>Biomarkers in Disease</i> , 2022, , 517-534.	0.0	0
2443	Association between physical activity and serum liver aminotransferases in Southwestern Iran: A Cross-sectional study. <i>Journal of Research in Medical Sciences</i> , 2022, 27, 79.	0.4	1
2444	The Challenging Ethical Landscape of Non-alcoholic Fatty Liver Disease. <i>European Medical Journal Hepatology</i> , 0, , .	1.0	2
2445	Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liverâ€”A Single Centre Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 5802.	1.0	3
2446	Ethyl Acetate Extract of <i>Dracocephalum heterophyllum</i> Benth Ameliorates Nonalcoholic Steatohepatitis and Fibrosis via Regulating Bile Acid Metabolism, Oxidative Stress and Inhibiting Inflammation. <i>Separations</i> , 2022, 9, 273.	1.1	1
2448	Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States. <i>Hepatology International</i> , 2023, 17, 225-236.	1.9	4
2449	Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). <i>Livers</i> , 2022, 2, 264-282.	0.8	3
2450	The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2022, 4, 132-141.	0.0	0
2451	Association between triglycerideâ€”glucose index and nonalcoholic fatty liver disease in type 2 diabetes mellitus. <i>BMC Endocrine Disorders</i> , 2022, 22, .	0.9	4
2452	Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, singleâ€”blind, placeboâ€”controlled study in F2/F3 NASH. <i>Hepatology Communications</i> , 2022, 6, 3379-3392.	2.0	9
2453	Are Ingested or Inhaled Microplastics Involved in Nonalcoholic Fatty Liver Disease?. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 13495.	1.2	12
2454	Hypothalamic orexin prevents non-alcoholic steatohepatitis and hepatocellular carcinoma in obesity. <i>Cell Reports</i> , 2022, 41, 111497.	2.9	8
2455	Pathological connections between non-alcoholic fatty liver disease and chronic kidney disease. <i>Kidney Diseases (Basel, Switzerland)</i> , 0, , .	1.2	0
2457	Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers. <i>Hepatology Communications</i> , 2022, 6, 3299-3310.	2.0	6
2458	Measurement and projection of the burden of disease attributable to population aging in 188 countries, 1990-2050: A population-based study. <i>Journal of Global Health</i> , 0, 12, .	1.2	9
2459	The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway. <i>Pharmaceuticals</i> , 2022, 15, 1241.	1.7	2
2460	Effect of foetal exposure to famine on the risk of nonalcoholic fatty liver disease in adulthood: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2022, , .	0.4	0
2461	The effectiveness of web-based interventions on non-alcoholic fatty liver disease (NAFLD) in obese children: A study protocol for a randomized controlled trial. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0

#	ARTICLE	IF	CITATIONS
2462	Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13045.	1.8	5
2463	Deciphering the role of aberrant DNA methylation in NAFLD and NASH. <i>Heliyon</i> , 2022, 8, e11119.	1.4	8
2464	Low levels of osteocalcin, but not CTX or P1NP, are associated with nonalcoholic hepatic steatosis and steatohepatitis. <i>Diabetes and Metabolism</i> , 2023, 49, 101397.	1.4	2
2465	Accuracy of FIB-4 to Detect Elevated Liver Stiffness Measurements in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Referral Centers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12489.	1.8	7
2466	The effects of conjugated linoleic acid supplementation on liver function enzymes and malondialdehyde in adults: A GRADE-assessed systematic review and dose-response meta-analysis. <i>Pharmacological Research</i> , 2022, 186, 106518.	3.1	7
2467	Wnt/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2023, 22, 333-345.	0.6	7
2468	Circulating THBS1: A Risk Factor for Nonalcoholic Fatty Liver Disease in Obese Children. <i>Annals of Nutrition and Metabolism</i> , 2023, 79, 16-28.	1.0	5
2469	New insights into the characteristics of DRAK2 and its role in apoptosis: From molecular mechanisms to clinically applied potential. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
2470	Determining the temporal, dose, and composition effects of nutritional substrates in an in vitro model of intrahepatocellular triglyceride accumulation. <i>Physiological Reports</i> , 2022, 10, .	0.7	2
2471	Healthy Diet, Grape Phytochemicals, and Vitamin D: Preventing Chronic Inflammation and Keeping Good Microbiota. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2023, 23, 777-800.	0.6	2
2472	Hepatic Lipid Homeostasis in NAFLD. , 0, , .		0
2473	Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis. <i>Journal of Clinical Gastroenterology</i> , 0, Publish Ahead of Print, .	1.1	1
2474	Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2023, 43, 089-099.	1.8	2
2475	Interleukin-18 in metabolism: From mice physiology to human diseases. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	13
2476	Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents. <i>Medicine (United States)</i> , 2022, 101, e31164.	0.4	16
2477	Incidence and Impact of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent. <i>World Journal of Surgery</i> , 2023, 47, 227-235.	0.8	0
2478	Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study. <i>Cancers</i> , 2022, 14, 5002.	1.7	3
2479	Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies. <i>Diagnostics</i> , 2022, 12, 2608.	1.3	2

#	ARTICLE	IF	CITATIONS
2480	Triglyceride: A mediator of the association between waist-to-height ratio and non-alcoholic fatty liver disease: A second analysis of a population-based study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
2481	Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2482	Elevated Serum Low-Density Lipoproteins-Cholesterol Levels and B1B2/B2B2 <i><i>CETP</i></i> Genotype Are Positively Associated with Nonalcoholic Fatty Liver Disease in Women with Gallstone Disease. <i>Metabolic Syndrome and Related Disorders</i> , 0, , .	0.5	1
2483	Prevalence and risk factors of nonalcoholic fatty liver disease in a general population, the HUNT study. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 505-511.	0.6	1
2484	Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	13
2485	A soy-yoghurt-honey product as a therapeutic functional food: mode of action and narrative review. <i>Heliyon</i> , 2022, 8, e11011.	1.4	4
2486	Myeloid- and hepatocyte-specific deletion of group VIA calcium-independent phospholipase A2 leads to dichotomous opposing phenotypes during MCD diet-induced NASH. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166590.	1.8	2
2487	Mouse models of nonalcoholic steatohepatitis and their application to new drug development. <i>Archives of Pharmacal Research</i> , 2022, 45, 761-794.	2.7	5
2488	Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation. <i>Molecular Cell</i> , 2022, 82, 4099-4115.e9.	4.5	20
2489	High Sodium Intake, as Assessed by Urinary Sodium Excretion, Is Associated with Nonalcoholic Fatty Liver Disease or Sarcopenia. <i>Gut and Liver</i> , 2023, 17, 456-465.	1.4	2
2490	The hepatoprotective effects of n3-polyunsaturated fatty acids against non-alcoholic fatty liver disease in diabetic rats through the FOXO1/PPAR α /GABARAPL1 signalling pathway. <i>Life Sciences</i> , 2022, 311, 121145.	2.0	5
2491	Leptin increases hepatic triglyceride export via a vagal mechanism in humans. <i>Cell Metabolism</i> , 2022, 34, 1719-1731.e5.	7.2	17
2492	Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2023, 53, 184-195.	1.8	3
2493	Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 269-273.	1.4	11
2494	The gut microbiota metabolite glycochenodeoxycholate activates TFR-ACSL4-mediated ferroptosis to promote the development of environmental toxin-linked MAFLD. <i>Free Radical Biology and Medicine</i> , 2022, 193, 213-226.	1.3	21
2495	Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 3829-3845.	2.0	8
2496	Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	18
2498	Estrogen as a key regulator of energy homeostasis and metabolic health. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113808.	2.5	21

#	ARTICLE	IF	CITATIONS
2499	Creatine supplementation protects against diet-induced non-alcoholic fatty liver but exacerbates alcoholic fatty liver. <i>Life Sciences</i> , 2022, 310, 121064.	2.0	1
2500	In vivo identification of the pharmacodynamic ingredients of <i>Polygonum cuspidatum</i> for remedying the mitochondria to alleviate metabolic dysfunction-associated fatty liver disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113849.	2.5	3
2501	Modulation of gut microbiota by glycyrrhizic acid may contribute to its anti-NAFLD effect in rats fed a high-fat diet. <i>Life Sciences</i> , 2022, 310, 121110.	2.0	4
2502	Zinc normalizes hepatic lipid handling via modulation of ADA/XO/UA pathway and caspase 3 signaling in highly active antiretroviral therapy-treated Wistar rats. <i>Chemico-Biological Interactions</i> , 2022, 368, 110233.	1.7	10
2503	Federated-Learning-based Hierarchical Diagnosis of Liver Fibrosis. , 2022, , .		0
2504	Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemaibrate Treatment for NAFLD. <i>Biomedicines</i> , 2022, 10, 2806.	1.4	1
2505	LINC01468 drives NAFLD-HCC progression through CUL4A-linked degradation of SHIP2. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	12
2506	The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 233-240.	0.4	3
2507	Glucose metabolism status modifies the relationship between lipoprotein(a) and carotid plaques in individuals with fatty liver disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
2508	Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	3
2509	The environmental pollutant, polychlorinated biphenyl 126, alters liver function in a rodent model of alcohol-associated liver disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2023, 47, 60-75.	1.4	3
2510	The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
2511	Plasma phospholipid arachidonic acid in relation to non-alcoholic fatty liver disease: Mendelian randomization study. <i>Nutrition</i> , 2023, 106, 111910.	1.1	5
2512	Sex and age differences in the association of fatty liver index-defined non-alcoholic fatty liver disease with cardiometabolic risk factors: a cross-sectional study. <i>Biology of Sex Differences</i> , 2022, 13, .	1.8	10
2513	Insulin-like growth factor binding protein 5: Diverse roles in cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
2514	Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2023, 78, 493-500.	1.8	20
2515	Hepatocyte Kctd17 Inhibition Ameliorates Glucose Intolerance and Hepatic Steatosis Caused by Obesity-induced Chrebp Stabilization. <i>Gastroenterology</i> , 2023, 164, 439-453.	0.6	5
2516	Mechanosensing in macrophages and dendritic cells in steady-state and disease. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	13

#	ARTICLE	IF	CITATIONS
2517	Genuine selective caspase-2 inhibition with new irreversible small peptidomimetics. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	2
2518	Chromosome-level genome assembly of the Muscovy duck provides insight into fatty liver susceptibility. <i>Genomics</i> , 2022, 114, 110518.	1.3	2
2519	The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
2520	Epigenetics and mitochondrial dysfunction insights into the impact of the progression of nonalcoholic fatty liver disease. <i>Cell Biochemistry and Function</i> , 2023, 41, 4-19.	1.4	6
2521	Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	22
2522	Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD). <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 709-722.	1.9	13
2523	Lycopene Improves Metabolic Disorders and Liver Injury Induced by a High-Fat Diet in Obese Rats. <i>Molecules</i> , 2022, 27, 7736.	1.7	2
2524	Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
2525	Radiofrequency coil design for improving human liver fat quantification in a portable single-side magnetic resonance system. <i>NMR in Biomedicine</i> , 2023, 36, .	1.6	2
2526	The Association of Sarcopenia and Visceral Obesity with Lean Nonalcoholic Fatty Liver Disease in Chinese Patients with Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-8.	1.0	6
2527	Proton Pump Inhibitor Pantoprazole Modulates Intestinal Microbiota and Induces TLR4 Signaling and Fibrosis in Mouse Liver. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13766.	1.8	1
2528	NAFLD as the metabolic hallmark of obesity. <i>Internal and Emergency Medicine</i> , 2023, 18, 31-41.	1.0	5
2529	Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein. <i>Oncogenesis</i> , 2022, 11, .	2.1	8
2530	Effect of Structured Phenolic Lipids with EPA/DHA and Gallic Acid against Metabolic-Associated Fatty Liver Disease (MAFLD) in Mice. <i>Molecules</i> , 2022, 27, 7702.	1.7	1
2531	Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH. <i>Journal of Nutritional Biochemistry</i> , 2023, 112, 109217.	1.9	4
2532	Ameliorative effect of <i>Lactobacillus rhamnosus</i> Fmb14 from Chinese yogurt on hyperuricemia. <i>Food Science and Human Wellness</i> , 2023, 12, 1379-1390.	2.2	4
2533	High-starchy carbohydrate diet aggravates NAFLD by increasing fatty acids influx mediated by NOX2. <i>Food Science and Human Wellness</i> , 2023, 12, 1081-1101.	2.2	6
2534	Emerging pharmacological treatment options for MAFLD. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211424.	1.4	4

#	ARTICLE	IF	CITATIONS
2535	The Treatment Progression of Obeticholic Acid in Non-Alcoholic Fatty Liver Disease. <i>Advances in Clinical Medicine</i> , 2022, 12, 11399-11404.	0.0	0
2536	Structural elucidation and anti-non-alcoholic fatty liver disease activity of <i>Polygonatum cyrtoneum</i> Hua polysaccharide. <i>Food and Function</i> , 2022, 13, 12883-12895.	2.1	9
2537	Utility of Indices Obtained During Medical Checkups for Predicting Fatty Liver Disease in Non-obese People. <i>Internal Medicine</i> , 2023, , .	0.3	2
2538	Residential greenness associated with decreased risk of metabolic-dysfunction-associated fatty liver disease: Evidence from a large population-based epidemiological study. <i>Ecotoxicology and Environmental Safety</i> , 2023, 249, 114338.	2.9	2
2539	Side effect profile of pharmacologic therapies for liver fibrosis in non-alcoholic fatty liver disease: a systematic review and network meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 1-14.	0.8	5
2540	Decreased autophagosome biogenesis, reduced NRF2, and enhanced ferroptotic cell death are underlying molecular mechanisms of non-alcoholic fatty liver disease. <i>Redox Biology</i> , 2023, 59, 102570.	3.9	16
2541	Cardiac abnormalities in patients with non-alcoholic fatty liver disease. <i>Revista Da Associação Médica Brasileira</i> , 2022, 68, 1394-1399.	0.3	0
2542	Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes. <i>Gastroenterology and Hepatology</i> , 2023, 46, 682-691.	0.2	1
2543	Duodenal mucosal resurfacing for non-alcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2022, 20, 166-169.	1.0	2
2544	The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Non-alcoholic Steatohepatitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2023, 384, 406-416.	1.3	5
2545	Fibrosis-4 index efficiently predicts chronic hepatitis and liver cirrhosis development based on a large-scale data of general population in Japan. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
2546	The Diagnostic and Prognostic Value of the Triglyceride-Glucose Index in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Meta-Analysis. <i>Nutrients</i> , 2022, 14, 4969.	1.7	20
2547	Diagnostic performance of novel inflammatory biomarkers based on ratios of laboratory indicators for non-alcoholic fatty liver disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
2548	Molecular and cellular mechanisms underlying the hepatoprotective role of ghrelin against NAFLD progression. <i>Journal of Physiology and Biochemistry</i> , 2023, 79, 833-849.	1.3	4
2549	Approbation of a Model of Fat Liver Disease Induced by Orotic Acid. <i>Drug Development and Registration</i> , 2022, 11, 240-245.	0.2	1
2550	Crosstalk between liver macrophages and gut microbiota: An important component of inflammation-associated liver diseases. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
2551	Consumption of the cell-free or heat-treated fractions of a pitched kefir confers some but not all positive impacts of the corresponding whole kefir. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
2552	ASCO update: hepatocellular and cholangiocellular carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 259-263.	0.3	1

#	ARTICLE	IF	CITATIONS
2553	Characterization of signature trends across the spectrum of non-alcoholic fatty liver disease using deep learning method. <i>Life Sciences</i> , 2023, 314, 121195.	2.0	7
2554	Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III. <i>BMJ Open</i> , 2022, 12, e067203.	0.8	5
2555	Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2496-2507.e5.	2.4	17
2558	Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful. <i>Journal of Viral Hepatitis</i> , 2023, 30, 148-159.	1.0	2
2559	HORMONAL AND METABOLIC FEATURES OF PUBERTY IN ADOLESCENTS WITH ULTRASOUND SIGNS OF FATTY HEPATOSIS (ON THE EXAMPLE OF ARKHANGELSK). <i>Ekologiya Cheloveka (Human Ecology)</i> , 0, , .	0.2	0
2560	Liver-derived metabolites as signaling molecules in fatty liver disease. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	8
2562	Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15489.	1.8	43
2563	Poor Outcomes of Patients With NAFLD and Moderate Renal Dysfunction or Short-Term Dialysis Receiving a Liver Transplant Alone. <i>Transplant International</i> , 0, 35, .	0.8	0
2564	Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration. <i>Nutrients</i> , 2022, 14, 5340.	1.7	0
2565	Altered serotonin metabolism in Takeda G protein-coupled receptor 5 knockout mice protects against diet-induced hepatic fibrosis. <i>Liver Research</i> , 2022, , .	0.5	1
2566	Fetal pulmonary artery Doppler parameters in pregnancies complicated with intrahepatic cholestasis of pregnancy: a prospective case-control study. <i>Journal of the Turkish German Gynecology Association</i> , 2022, 23, 249-254.	0.2	0
2567	Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16063.	1.8	0
2568	<i>Terminalia bellirica</i> ethanol extract ameliorates nonalcoholic fatty liver disease in mice by amending the intestinal microbiota and faecal metabolites. <i>Journal of Ethnopharmacology</i> , 2023, 305, 116082.	2.0	5
2569	Short sleep duration and the risk of nonalcoholic fatty liver disease/metabolic associated fatty liver disease: a systematic review and meta-analysis. <i>Sleep and Breathing</i> , 2023, 27, 1985-1996.	0.9	3
2570	Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15791.	1.8	17
2571	Improved prediction of 10-year risk of severe liver disease in the general population using commonly available biomarkers. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 418-425.	1.9	8
2572	Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
2573	Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 210.	1.8	9

#	ARTICLE	IF	CITATIONS
2574	Single-cell transcriptomics of hepatic stellate cells uncover crucial pathways and key regulators involved in non-alcoholic steatohepatitis. <i>Endocrine Connections</i> , 2023, 12, .	0.8	2
2575	The Triangle of Nonalcoholic Fatty Liver Disease, Metabolic Dysfunction, and Periodontitis: Analysis of the Dental, Oral, Medical and Epidemiological (DOME) Records-Based Nationwide Research. <i>Metabolites</i> , 2022, 12, 1212.	1.3	4
2576	Association between <i>Helicobacter pylori</i> infection and non-alcoholic fatty liver disease for Asian and non-Asian population: A systematic review and meta-analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
2577	Effects of metabolic traits, lifestyle factors, and pharmacological interventions on liver fat: mendelian randomisation study. , 2022, 1, e000277.		2
2579	A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 304-312.	1.9	15
2580	Effects of homocysteine on nonalcoholic fatty liver related disease: A mendelian randomization study. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
2581	Galic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade. <i>European Journal of Pharmacology</i> , 2023, 940, 175457.	1.7	6
2582	Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	5
2583	A healthy liver will always deliver: development of a NAFLD awareness comic. <i>Health Promotion International</i> , 2022, 37, .	0.9	4
2584	The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 454-467.	0.4	9
2585	Therapeutic role of Artemether in the prevention of hepatic steatosis through miR-34a/PPAR γ pathway. <i>Drug Development Research</i> , 2023, 84, 156-171.	1.4	1
2586	<i>Akkermansia muciniphila</i> suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
2587	Lower serum PRL is associated with the development of non-alcoholic fatty liver disease: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	4
2588	The Role of Non-Alcoholic Fatty Liver Disease in Infections. <i>Life</i> , 2022, 12, 2052.	1.1	3
2589	Differential methylation patterns in lean and obese non-alcoholic steatohepatitis-associated hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
2590	T lymphocyte-mediated pyroptosis: A new regulatory mechanism in non-viral liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102070.	0.7	1
2591	Real-world assessment of SmartExam, a novel FibroScan computational method: A retrospective single-center cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 321-329.	1.4	5
2592	Global incidence and prevalence of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S32-S42.	4.5	67

#	ARTICLE	IF	CITATIONS
2593	The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S319-S332.	4.5	4
2594	Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease. <i>Gut</i> , 2023, 72, 573-580.	6.1	9
2595	Development and validation of a new nomogram to screen for MAFLD. <i>Lipids in Health and Disease</i> , 2022, 21, .	1.2	5
2596	Editorial: <i>“Talis pater, talis filius”</i> ™. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 171-172.	1.9	0
2597	METTL16-mediated translation of <i>CIDEA</i> promotes non-alcoholic fatty liver disease progression <i>via</i> m6A-dependent manner. <i>PeerJ</i> , 0, 10, e14379.	0.9	8
2598	NAFLD and NASH biomarker qualification in the LITMUS consortium “Lessons learned. <i>Journal of Hepatology</i> , 2023, 78, 852-865.	1.8	14
2599	Association between ultra-processed foods consumption and risk of non-alcoholic fatty liver disease: a population-based analysis of NHANES 2011–2018. <i>British Journal of Nutrition</i> , 2023, 130, 996-1004.	1.2	2
2600	Efficacy and safety of Yinchenwuling Powder for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis of randomized controlled trials. <i>Medicine (United States)</i> , 2022, 101, e32088.	0.4	0
2601	Dual-Channel Fluorescent Probe for Detecting Viscosity and ONOO [•] without Signal Crosstalk in Nonalcoholic Fatty Liver. <i>Analytical Chemistry</i> , 2022, 94, 17439-17447.	3.2	37
2602	Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 273-302.	0.4	16
2603	Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	12
2604	Factors Associated with Awareness and Knowledge of Nonalcoholic Fatty Liver Disease, a Liver Cancer Etiological Factor, Among Chinese Young Adults. <i>Journal of Cancer Education</i> , 2023, 38, 1177-1186.	0.6	2
2605	Osr1 Regulates Macrophage-mediated Liver Inflammation in Nonalcoholic Fatty Liver Disease Progression. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 1117-1133.	2.3	1
2606	Associations between life’s essential 8 and non-alcoholic fatty liver disease among US adults. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	11
2607	Serum Uric Acid but Not Ferritin Level Is Associated with Hepatic Fibrosis in Lean Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease: A Community-Based Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 2009.	1.1	0
2608	Hepatocyte Smoothed Activity Controls Susceptibility to Insulin Resistance and Nonalcoholic Fatty Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 949-970.	2.3	4
2609	Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
2610	Positive Association Between the Chinese Visceral Adiposity Index and Nonalcoholic Fatty Liver Disease in Lean Adults. <i>Digestive Diseases and Sciences</i> , 2023, 68, 656-664.	1.1	2

#	ARTICLE	IF	CITATIONS
2611	Systematic review and meta-analysis of the effect of garlic in patients with non-alcoholic fatty liver disease. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 548-557.	0.7	4
2612	Increased plasma genistein after bariatric surgery could promote remission of NAFLD in patients with obesity. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
2613	Intermittent Protein Diets Alter Hepatic Lipid Accumulation by Changing Tryptophan Metabolism in a Fast-Response Manner. <i>Journal of Agricultural and Food Chemistry</i> , 0, , .	2.4	0
2614	Effect of Metabolic Dysfunction-Associated Fatty Liver Disease on Left Ventricular Deformation and Atrioventricular Coupling in Patients With Metabolic Syndrome Assessed by <sc>MRI</sc>. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 1098-1107.	1.9	1
2615	Rhinacanthin C Ameliorates Insulin Resistance and Lipid Accumulation in NAFLD Mice via the AMPK/SIRT1 and SREBP-1c/FAS/ACC Signaling Pathways. <i>Evidence-based Complementary and Alternative Medicine</i> , 2023, 2023, 1-14.	0.5	8
2616	Psychiatric Aspects of Obesity in Transplantation. , 2022, , 65-72.		0
2617	Impact of Thyroid Function on the Prevalence and Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, e434-e443.	1.8	7
2618	Increased Hepatic ATG7 mRNA and ATG7 Protein Expression in Nonalcoholic Steatohepatitis Associated with Obesity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1324.	1.8	1
2619	Alleviation of Hepatic Steatosis by 4-azidophlorizin via the Degradation of Geranylgeranyl Diphosphate Synthase by the Ubiquitin-Proteasome Pathway in Vivo and in Vitro. <i>Advanced Biology</i> , 0, , 2200150.	1.4	0
2620	Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 433-452.	4.5	14
2621	The effect of 12 weeks of combined training on hepatic fat content and metabolic flexibility of individuals with non-alcoholic fatty liver disease: Protocol of an open-label, single-center randomized control trial. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	0
2622	Programmed cell death and lipid metabolism of macrophages in NAFLD. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
2623	Therapeutic Potential of Herbal medicine against Non-alcoholic Fatty Liver Disease. <i>Current Drug Targets</i> , 2023, 24, .	1.0	0
2624	The Role of Oxidative Inactivation of Phosphatase PTEN and TCPTP in Fatty Liver Disease. <i>Antioxidants</i> , 2023, 12, 120.	2.2	4
2625	Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	3
2626	Nonalcoholic fatty liver disease and insulin resistance in children. <i>Clinical and Experimental Pediatrics</i> , 2023, 66, 512-519.	0.9	6
2628	Nonalcoholic fatty liver disease and non-liver comorbidities. <i>Clinical and Molecular Hepatology</i> , 2023, 29, s86-s102.	4.5	10
2629	Pathophysiology of obesity and its associated diseases. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 2403-2424.	5.7	27

#	ARTICLE	IF	CITATIONS
2630	Resveratrol in disease prevention and health promotion: A role of the gut microbiome. <i>Critical Reviews in Food Science and Nutrition</i> , 0, , 1-18.	5.4	4
2631	Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome. <i>European Journal of Pharmacology</i> , 2023, 942, 175504.	1.7	6
2632	Serum glycolipids mediate the relationship of urinary bisphenols with NAFLD: analysis of a population-based, cross-sectional study. <i>Environmental Health</i> , 2022, 21, .	1.7	4
2633	Regression of Hepatic Fibrosis After Endoscopic Gastric Plication in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 983-990.	0.2	5
2634	IL-1 β neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
2636	The diagnostic value of novel ultrasound attenuation analysis in detecting liver steatosis identified by the controlled attenuation parameter: a diagnostic accuracy study. <i>Annals of Translational Medicine</i> , 2023, 11, 38-38.	0.7	3
2637	Rising incidence, progression and changing patterns of liver disease in Wales 1999-2019. <i>World Journal of Hepatology</i> , 0, 15, 89-106.	0.8	3
2639	New Insights into the Basic and Translational Aspects of AMPK Signaling. <i>Cells</i> , 2023, 12, 206.	1.8	1
2640	Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
2641	Exploring the mechanism of Cassiae semen in regulating lipid metabolism through network pharmacology and experimental validation. <i>Bioscience Reports</i> , 0, , .	1.1	0
2642	Protective Effect of Vegan Microbiota on Liver Steatosis Is Conveyed by Dietary Fiber: Implications for Fecal Microbiota Transfer Therapy. <i>Nutrients</i> , 2023, 15, 454.	1.7	1
2643	Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake. <i>Phytomedicine</i> , 2023, 111, 154661.	2.3	7
2644	High prevalence of periodontal disease in patients with NASH- possible association of poor dental health with NASH severity. <i>Annals of Hepatology</i> , 2023, 28, 100887.	0.6	2
2645	Concordance of Non-Alcoholic Fatty Liver Disease and Associated Factors among Older Married Couples in China. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1426.	1.2	1
2646	Digital imaging software versus the "eyeball" method in quantifying steatosis in a liver biopsy. <i>Liver Transplantation</i> , 2023, 29, 268-278.	1.3	3
2647	The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study. <i>Hepatology</i> , 2023, 77, 2063-2072.	3.6	9
2648	Estimates and trends of the global burden of NASH-related liver cancer attributable to high fasting plasma glucose in 1990–2019: analysis of data from the 2019 Global Burden of Disease Study. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	1.2	4
2649	Genetic polymorphisms of Ca ²⁺ transport proteins and molecular chaperones in mitochondria-associated endoplasmic reticulum membrane and non-alcoholic fatty liver disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0

#	ARTICLE	IF	CITATIONS
2651	Medical infrared thermal image based fatty liver classification using machine and deep learning. Quantitative InfraRed Thermography Journal, 2024, 21, 102-119.	2.1	5
2652	Chronic liver diseases and erectile dysfunction. Frontiers in Public Health, 0, 10, .	1.3	2
2653	Si-Ni-San reduces lipid droplet deposition associated with decreased YAP1 in metabolic dysfunction-associated fatty liver disease. Journal of Ethnopharmacology, 2023, 305, 116081.	2.0	3
2654	Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences. European Medical Journal Hepatology, 0, , 74-83.	1.0	0
2655	Metabolic Diffusion in Neuropathologies: The Relevance of Brain-Liver Axis. Frontiers in Physiology, 0, 13, .	1.3	6
2656	Development and application of a novel model to predict the risk of non-alcoholic fatty liver disease among lean pre-diabetics with normal blood lipid levels. Lipids in Health and Disease, 2022, 21, .	1.2	3
2657	HÃgado graso (parte 1): aspectos generales, epidemiologÃa, fisiopatologÃa e historia natural. Revista Colombiana De Gastroenterologia, 2022, 37, 420-433.	0.1	1
2658	STATE OF THE GUT MICROBIOTA IN PATIENTS WITH METABOLIC-ASSOCIATED FATTY LIVER DISEASE WITH TYPE 2 DIABETES MELLITUS. Proceedings of the Shevchenko Scientific Society Medical Sciences, 2022, 69, .	0.0	1
2659	Self-Management and Associated Factors among Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2023, 20, 667.	1.2	0
2661	Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. Nutrients, 2023, 15, 178.	1.7	4
2662	The improvement of treatment and prevention of non-alcoholic fatty liver disease progression against the background of metabolic disorders. Modern Gastroenterology, 2022, , 17-23.	0.1	0
2663	Gender differences in the ideal cutoffs of visceral fat area for predicting MAFLD in China. Lipids in Health and Disease, 2022, 21, .	1.2	2
2664	Utility of 99mTc-Sestamibi Heart/Liver Uptake Ratio in Screening Nonalcoholic Fatty Liver Disease During Myocardial Perfusion Imaging. Cancer Biotherapy and Radiopharmaceuticals, 0, , .	0.7	0
2665	Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up. Wiener Klinische Wochenschrift, 2023, 135, 420-428.	1.0	1
2666	Interaction between the PNPLA3 Gene and Nutritional Factors on NAFLD Development: The Korean Genome and Epidemiology Study. Nutrients, 2023, 15, 152.	1.7	1
2667	Mucosal-Associated Invariant T Cells in the Digestive System: Defender or Destroyer?. Cellular and Molecular Gastroenterology and Hepatology, 2023, 15, 809-819.	2.3	1
2668	The role of intestinal microbiome in the progression of non-alcoholic fatty liver disease. Modern Gastroenterology, 2019, , 92-99.	0.1	0
2669	Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses. Hypertension Research, 2023, 46, 1110-1121.	1.5	8

#	ARTICLE	IF	CITATIONS
2670	Effect of Metabolic Surgery on Non-Alcoholic Steatohepatitis. , 2023, , 1005-1011.		0
2671	Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase. <i>Nutrients</i> , 2023, 15, 577.	1.7	5
2673	Natural compounds with aldose reductase (AR) inhibition: A class of medicative agents for fatty liver disease.. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, .	0.6	0
2674	Acute liver injury in a non-alcoholic fatty liver disease patient with chloroform exposure: a case report. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
2675	The interaction of T2DM and BMI with NASH in recipients of liver transplants: an SRTR database analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 0, , 1-9.	1.4	0
2676	Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. <i>Hepatology</i> , 2023, 78, 1625-1653.	3.6	2
2677	Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
2678	Baicalein alleviates non-alcoholic fatty liver disease in mice by ameliorating intestinal barrier dysfunction. <i>Food and Function</i> , 2023, 14, 2138-2148.	2.1	2
2679	The Connection between Non-Alcoholic Fatty-Liver Disease, Dietary Behavior, and Food Literacy in German Working Adults. <i>Nutrients</i> , 2023, 15, 648.	1.7	1
2680	Epigenetics of NAFLD and NASH. , 2023, , 423-445.		0
2681	Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 985-999.	2.3	18
2682	Integration of transcriptomics and metabolomics revealed the protective effects of hemp seed oil against methionineâ€“choline-deficient diet-induced non-alcoholic steatohepatitis in mice. <i>Food and Function</i> , 2023, 14, 2096-2111.	2.1	3
2683	Bioactive Compounds from Brown Algae Alleviate Nonalcoholic Fatty Liver Disease: An Extensive Review. <i>Journal of Agricultural and Food Chemistry</i> , 2023, 71, 1771-1787.	2.4	5
2684	Genetic variation in TBC1 domain family member 1 gene associates with the risk of lean NAFLD via high-density lipoprotein. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2685	Colonic permeability is increased in non-cirrhotic patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2023, 55, 614-621.	0.4	1
2686	Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression. <i>Hepatology</i> , 2023, 78, 1492-1505.	3.6	5
2687	Inflammatory processes involved in NASH-related hepatocellular carcinoma. <i>Bioscience Reports</i> , 2023, 43, .	1.1	8
2688	Metabolic-associated Fatty Liver Disease regulation through Nutri Epigenetic Methylation. <i>Mini-Reviews in Medicinal Chemistry</i> , 2023, 23, .	1.1	0

#	ARTICLE	IF	CITATIONS
2689	Circulating chemerin level and the risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Journal of Diabetes and Metabolic Disorders</i> , 0, , .	0.8	0
2690	TBC1D25 alleviates nonalcoholic steatohepatitis by inhibiting abnormal lipid accumulation and inflammation. <i>Journal of Cellular Physiology</i> , 0, , .	2.0	2
2692	Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	7
2693	Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH. <i>Scientific Reports</i> , 2023, 13, .	1.6	10
2694	Causal effect of lower birthweight on nonalcoholic fatty liver disease and mediating roles of insulin resistance and metabolites. <i>Liver International</i> , 2023, 43, 829-839.	1.9	6
2695	Global Epidemiology and Genetics of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2023, 164, 766-782.	0.6	67
2696	Changes in the Prevalences of Obesity, Abdominal Obesity, and Non-Alcoholic Fatty Liver Disease among Korean Children during the COVID-19 Outbreak. <i>Yonsei Medical Journal</i> , 2023, 64, 269.	0.9	5
2697	Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis. <i>Medicine (United States)</i> , 2023, 102, e32734.	0.4	12
2698	Prevalence and Factors Associated with Hepatic Steatosis in Patients with Metabolic Syndrome in Cameroon: Cases of 4 Reference Hospitals. <i>Open Journal of Gastroenterology</i> , 2023, 13, 99-110.	0.1	0
2699	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. <i>Choonpa Igaku</i> , 2023, , .	0.0	0
2700	Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease. <i>World Journal of Clinical Cases</i> , 0, 11, 1236-1244.	0.3	5
2701	Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials. <i>Aging Cell</i> , 2023, 22, .	3.0	1
2702	Adherence to oxidative balance scores and lower odds of non-alcoholic fatty liver disease: a case-control study. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
2703	Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019. <i>Hepatology</i> , 2023, 78, 1168-1181.	3.6	7
2704	Musclin attenuates lipid deposition in hepatocytes through SIRT7/autophagy-mediated suppression of ER stress. <i>Biochemical and Biophysical Research Communications</i> , 2023, 658, 62-68.	1.0	5
2705	Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness. <i>Clinics in Liver Disease</i> , 2023, 27, 173-186.	1.0	6
2706	Type 2 diabetes complications are associated with liver fibrosis independent of hemoglobin A1c. <i>Annals of Hepatology</i> , 2023, 28, 101087.	0.6	0
2707	Multi-model in silico characterization of 3-benzamidobenzoic acid derivatives as partial agonists of Farnesoid X receptor in the management of NAFLD. <i>Computers in Biology and Medicine</i> , 2023, 157, 106789.	3.9	1

#	ARTICLE	IF	CITATIONS
2708	Nonalcoholic Fatty Liver Disease in Asia, Africa, and Middle East Region. <i>Clinics in Liver Disease</i> , 2023, 27, 287-299.	1.0	4
2709	Chlorogenic acid ameliorated non-alcoholic steatohepatitis via alleviating hepatic inflammation initiated by LPS/TLR4/MyD88 signaling pathway. <i>Chemico-Biological Interactions</i> , 2023, 376, 110461.	1.7	5
2710	Association between liver fibrosis and decreased myocardial mechano-energetic efficiency in individuals with different degree of glucose tolerance. <i>Diabetes Research and Clinical Practice</i> , 2023, 199, 110639.	1.1	1
2711	Changings and Challenges in Liver Transplantation for Nonalcoholic Fatty Liver Disease/Steatohepatitis. <i>Clinics in Liver Disease</i> , 2023, 27, 225-237.	1.0	0
2712	Neferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway. <i>Phytomedicine</i> , 2023, 114, 154798.	2.3	4
2713	A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease. <i>Life Sciences</i> , 2023, 322, 121626.	2.0	1
2714	Creatine ameliorates high-fat diet-induced obesity by regulation of lipolysis and lipophagy in brown adipose tissue and liver. <i>Biochimie</i> , 2023, 209, 85-94.	1.3	1
2715	Study protocol for a randomized, controlled trial using a novel, family-centered diet treatment to prevent NAFLD in Hispanic children. <i>Contemporary Clinical Trials</i> , 2023, 129, 107170.	0.8	0
2716	Betulin prevents high fat diet-induced non-alcoholic fatty liver disease by mitigating oxidative stress and upregulating Nrf2 and SIRT1 in rats. <i>Life Sciences</i> , 2023, 322, 121688.	2.0	2
2718	Stepwise evaluation for the risk of metabolic unhealthiness and significant non-alcoholic fatty liver disease in India. , 2023, , 100142.		1
2719	The therapeutic aspects of non-alcoholic fatty liver disease. <i>L'ki Ukraïni</i> , 2022, , 18-21.	0.0	1
2720	Screening of Biomarkers in Liver Tissue after Bariatric Surgery Based on WGCNA and SVM-RFE Algorithms. <i>Disease Markers</i> , 2023, 2023, 1-23.	0.6	7
2721	Targeting negative energy balance with calorie restriction and mitochondrial uncoupling in db/db mice. <i>Molecular Metabolism</i> , 2023, 69, 101684.	3.0	4
2722	<i>Helicobacter pylori</i> infection increases the risk of nonalcoholic fatty liver disease in diabetic population. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	1
2723	Replacing Foods with a High-Glycemic Index and High in Saturated Fat by Alternatives with a Low Glycemic Index and Low Saturated Fat Reduces Hepatic Fat, Even in Isocaloric and Macronutrient Matched Conditions. <i>Nutrients</i> , 2023, 15, 735.	1.7	3
2724	Prospective study of a case-finding algorithm to detect NAFLD with advanced fibrosis in primary care patients. <i>Hepatology Communications</i> , 2023, 7, e0024-e0024.	2.0	1
2725	Effect of Dietary Intervention, with or without Cointerventions, on Inflammatory Markers in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Advances in Nutrition</i> , 2023, 14, 475-499.	2.9	4
2726	The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease. <i>Life</i> , 2023, 13, 419.	1.1	8

#	ARTICLE	IF	CITATIONS
2727	Physical Activity Intensity, Genetic Predisposition, and Risk of Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 3444-3447.e2.	2.4	0
2728	Identifying High-Risk Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 0, Publish Ahead of Print, .	1.1	0
2729	Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 320-331.	4.5	13
2730	Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 783-793.	0.4	3
2731	Vsig4+ resident single-Kupffer cells improve hepatic inflammation and fibrosis in NASH. <i>Inflammation Research</i> , 2023, 72, 669-682.	1.6	0
2732	Effects of differential regional PM2.5 induced hepatic steatosis and underlying mechanism. <i>Environmental Pollution</i> , 2023, 323, 121220.	3.7	2
2733	The Role of the Stress Response in Metabolic Dysfunction-Associated Fatty Liver Disease: A Psychoneuroendocrineimmunology-Based Perspective. <i>Nutrients</i> , 2023, 15, 795.	1.7	0
2734	Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In Vivo. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3217.	1.8	2
2735	Adipose-targeted SWELL1 deletion exacerbates obesity- and age-related nonalcoholic fatty liver disease. <i>JCI Insight</i> , 2023, 8, .	2.3	2
2736	Unraveling the Potential Role of <i>Tecomella undulata</i> in Experimental NASH. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3244.	1.8	2
2737	Association between hemoglobin glycation index and non-alcoholic fatty liver disease. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
2739	The liver-kidney axis: Is serum leptin a potential link in non-alcoholic fatty liver disease-associated chronic kidney disease?. <i>Arab Journal of Gastroenterology</i> , 2023, 24, 52-57.	0.4	0
2740	The Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Peripheral Arterial Disease in the Chinese Population. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 16, 373-384.	1.1	0
2741	Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway. <i>Hepatology Communications</i> , 2023, 7, e0045-e0045.	2.0	9
2742	Non-alcoholic fatty liver disease in diabetes mellitus patients on chronic hemodialysis – A case series addressing cardiovascular and mortality risks. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 0, 4, .	0.3	0
2743	<i>In Vivo</i> Imaging of Lipid Droplets and Oxygen Status in Hepatic Tissues of Nonalcoholic Fatty Liver Model Mice Using a Lipophilic Ir(III) Complex. <i>Analytical Chemistry</i> , 2023, 95, 3729-3735.	3.2	3
2744	Benzyl isothiocyanate attenuates activation of the NLRP3 inflammasome in Kupffer cells and improves diet-induced steatohepatitis. <i>Toxicology and Applied Pharmacology</i> , 2023, 462, 116424.	1.3	3
2745	Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	3

#	ARTICLE	IF	CITATIONS
2746	CS27109, A Selective Thyroid Hormone Receptor- β Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models. <i>International Journal of Endocrinology</i> , 2023, 2023, 1-11.	0.6	2
2747	The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	13
2749	Adiponectin β -leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance. <i>Annals of Medicine</i> , 2023, 55, 634-642.	1.5	4
2750	Cordycepin β -Loaded Macrophage Vesicles for Targeted Nonalcoholic Steatohepatitis Attenuation. <i>Advanced Functional Materials</i> , 0, , 2214059.	7.8	0
2751	Effects of lifestyle intervention on adults with metabolic associated fatty liver disease: A systematic review and meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	12
2752	An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. <i>Biomedicines</i> , 2023, 11, 586.	1.4	2
2753	A New In Vivo Zebrafish Bioassay Evaluating Liver Steatosis Identifies DDE as a Steatogenic Endocrine Disruptor, Partly through SCD1 Regulation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3942.	1.8	3
2754	Association of aspirin with all-cause and cardiocerebrovascular mortality in patients with metabolic associated fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 908-914.	0.6	0
2755	Association between smoking cessation and non-alcoholic fatty liver disease using NAFLD liver fat score. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	7
2756	Significant Dose-Response Association of Physical Activity and Diet Quality With Mortality in Adults With Suspected NAFLD in a Population Study. <i>American Journal of Gastroenterology</i> , 2023, 118, 1576-1591.	0.2	5
2757	A metagenomic study identifies a <i>Prevotella copri</i> enriched microbial profile associated with non β -alcoholic steatohepatitis in subjects with obesity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 791-799.	1.4	5
2758	NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. <i>Internal and Emergency Medicine</i> , 2023, 18, 993-1006.	1.0	10
2759	DMF-Activated Nrf2 Ameliorates Palmitic Acid Toxicity While Potentiates Ferroptosis Mediated Cell Death: Protective Role of the NO-Donor S-Nitroso-N-Acetylcysteine. <i>Antioxidants</i> , 2023, 12, 512.	2.2	3
2760	Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. <i>Cancers</i> , 2023, 15, 1308.	1.7	3
2761	MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2570-2577.e1.	2.4	7
2762	Involvement of <i>eNAMPT</i> / <i>TLR4</i> inflammatory signaling in progression of non β -alcoholic fatty liver disease, steatohepatitis, and fibrosis. <i>FASEB Journal</i> , 2023, 37, .	0.2	6
2763	Diet was less significant than physical activity in the prognosis of people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: Analysis of the National Health and Nutrition Examination Survey III. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	4
2764	Metabonomics application on screening serum biomarkers of golden hamsters with nonalcoholic steatohepatitis induced by high-fat diet. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, .	0.6	0

#	ARTICLE	IF	CITATIONS
2765	The association of dietary inflammatory index (DII) and central obesity with non-alcoholic fatty liver disease (NAFLD) in people with diabetes (T2DM). <i>Heliyon</i> , 2023, 9, e13983.	1.4	4
2766	Weigh change across adulthood is related to the presence of NAFLD: results from NHANES III. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	4
2767	TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a "Prudent" Dietary Pattern on Serum Triglyceride Levels. <i>Nutrients</i> , 2023, 15, 1112.	1.7	0
2768	Patients with High Cardiovascular Risk in the Practice of a Primary Care Physician. , 2022, , 56-62.		0
2769	The complex function of macrophages and their subpopulations in metabolic injury associated fatty liver disease. <i>Journal of Physiology</i> , 2023, 601, 1159-1171.	1.3	2
2770	Alignment of Physician-Stated vs Clinically Derived Reference Fibrosis Score in Patients with Non-Alcoholic Steatohepatitis: A Real-World European Survey. <i>Journal of Pragmatic and Observational Research</i> , 0, Volume 14, 13-27.	1.1	0
2771	Effect of portulaca oleracea (purslane) extract on inflammatory factors in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial. <i>Journal of Functional Foods</i> , 2023, 102, 105465.	1.6	1
2772	Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study. <i>Chinese Medical Journal</i> , 2023, 136, 341-350.	0.9	1
2773	Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4583.	1.8	7
2774	The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 414-416.	4.5	0
2775	Global burden of common cancers attributable to metabolic risks from 1990 to 2019. <i>Med</i> , 2023, 4, 168-181.e3.	2.2	1
2776	Novel NF- κ B reporter mouse for the non-invasive monitoring of inflammatory diseases. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
2777	Correlation between CT Abdominal Anthropometric Measurements and Liver Density in Individuals with Non-Alcoholic Fatty Liver Disease. <i>Medicina (Lithuania)</i> , 2023, 59, 500.	0.8	1
2778	Machine learning classifiers for screening nonalcoholic fatty liver disease in general adults. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
2779	Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	6
2780	What Do NAFLD, Liver Fibrosis, and Inflammatory Bowel Disease Have in Common? Review of the Current Literature. <i>Metabolites</i> , 2023, 13, 378.	1.3	0
2781	Initial outcomes of a dedicated multidisciplinary non-alcoholic fatty liver disease clinic: a retrospective cohort study. <i>Internal Medicine Journal</i> , 2023, 53, 2065-2072.	0.5	1
2782	Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications. , 2023, 244, 108372.		6

#	ARTICLE	IF	CITATIONS
2783	Role of targeting TLR4 signaling axis in liver-related diseases. <i>Pathology Research and Practice</i> , 2023, 244, 154410.	1.0	3
2784	Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. <i>Journal of Hepatology</i> , 2023, 79, 538-551.	1.8	27
2785	The essential effect of mTORC1-dependent lipophagy in non-alcoholic fatty liver disease. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
2786	Pathobiology of Metabolic-Associated Fatty Liver Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 405-416.	1.2	3
2787	Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 381-383.	4.5	1
2788	Nanodrug delivery systems for metabolic chronic liver diseases: advances and perspectives. <i>Nanomedicine</i> , 2023, 18, 67-84.	1.7	4
2789	Experimental mouse models for translational human cancer research. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
2790	Associations between dietary flavonoid intake with hepatic steatosis and fibrosis quantified by VCTE: Evidence from NHANES and FNDDS. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, 33, 1179-1189.	1.1	20
2791	Lipid metabolism, BMI and the risk of nonalcoholic fatty liver disease in the general population: evidence from a mediation analysis. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	8
2792	Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	10
2793	Multifaceted involvements of Paneth cells in various diseases within intestine and systemically. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
2794	Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 693-704.	4.5	3
2795	Sex differences in cardiovascular and all-cause mortality in nonalcoholic fatty liver disease in the US population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, 33, 1349-1357.	1.1	1
2796	Azonal steatosis correlates with disease severity and poor outcome of nonalcoholic fatty liver disease. <i>Journal of Digestive Diseases</i> , 0, , .	0.7	0
2797	Prediction of the mechanisms of action of Qutan Huoxue decoction in non-alcoholic steatohepatitis (NASH): a network pharmacology study and experimental validation. <i>Pharmaceutical Biology</i> , 2023, 61, 520-530.	1.3	0
2798	The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
2799	Association of nonalcoholic fatty liver disease and liver fibrosis detected by transient elastography with serum retinol in American adults. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	0
2800	Uncovering the NAFLD burden in people living with HIV from high and middle income nations: a meta-analysis with a data gap from Sub-Saharan Africa. <i>Journal of the International AIDS Society</i> , 2023, 26, .	1.2	4

#	ARTICLE	IF	CITATIONS
2802	Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2023, 6, e233513.	2.8	22
2803	Microbiome-liver crosstalk: A multihit therapeutic target for liver disease. <i>World Journal of Gastroenterology</i> , 0, 29, 1651-1668.	1.4	4
2804	Non-Alcoholic Fatty Liver Disease and Vitamin D in the UK Biobank: A Two-Sample Bidirectional Mendelian Randomisation Study. <i>Nutrients</i> , 2023, 15, 1442.	1.7	2
2805	Design and Discovery of Novel Cyclic Peptides as EDPsâ€™EBP Interaction Inhibitors for the Treatment of Liver Fibrosis. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4689-4702.	2.9	1
2806	BIOCHEMICAL MARKERS FOR STEATOSIS: A NECESSITY. BUT FOR NOW, BE SATISFIED WITH THE BIOPSY. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 0, 36, .	0.5	0
2807	Prediction of Fatty Liver Disease in a Chinese Population Using Machine-Learning Algorithms. <i>Diagnostics</i> , 2023, 13, 1168.	1.3	2
2808	Immunotherapies for advanced hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
2809	Comparison of Magnetic Resonance-Based Elastography and Ultrasound Shear Wave Elastography in Patients With Suspicion of Nonalcoholic Fatty Liver Disease. <i>Ultrasound Quarterly</i> , 0, Publish Ahead of Print, .	0.3	2
2810	Racial difference in the association between non-alcoholic fatty liver disease and incident type 2 diabetes: findings from the CARDIA study. <i>Diabetologia</i> , 2023, 66, 1235-1246.	2.9	3
2811	Emerging role of engineered exosomes in nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 0, 15, 386-392.	0.8	1
2812	Perirenal fat thickness and liver fat fraction are independent predictors of MetS in adults with overweight and obesity suspected with NAFLD: a retrospective study. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	1.2	1
2813	Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective. <i>Obesity Reviews</i> , 2023, 24, .	3.1	2
2814	Associations of physical activity domains and muscle strength exercise with non-alcoholic fatty liver disease: a nation-wide cohort study. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
2815	The interplay between herbal medicines and gut microbiota in metabolic diseases. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	5
2816	Oleanolic Acid Inhibits SCD1 Gene Expression to Ameliorate Fructoseâ€™Induced Hepatosteatosis through SREBP1câ€™Dependent and â€™Independent Mechanisms. <i>Molecular Nutrition and Food Research</i> , 2023, 67, .	1.5	2
2817	Global burden of liver disease: 2023 update. <i>Journal of Hepatology</i> , 2023, 79, 516-537.	1.8	141
2818	Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals. <i>JHEP Reports</i> , 2023, 5, 100744.	2.6	3
2819	The combination of the enhanced liver fibrosis and FIBâ€™4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 1417-1422.	1.9	4

#	ARTICLE	IF	CITATIONS
2820	A UPLC-Q-TOF/MS and network pharmacology method to explore the mechanism of Anhua fuzhuan tea intervention in nonalcoholic fatty liver disease. <i>Food and Function</i> , 2023, 14, 3686-3700.	2.1	2
2821	Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis. <i>JHEP Reports</i> , 2023, 5, 100746.	2.6	6
2823	Non-alcoholic fatty liver disease. <i>Medicine</i> , 2023, , .	0.2	1
2824	Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study. <i>Hepatology</i> , 2023, 78, 258-271.	3.6	4
2825	Current, emerging, and potential therapies for non-alcoholic steatohepatitis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	6
2826	Relationship between obesity related indicators and non-alcoholic fatty liver disease in children: a systematic review and meta-analysis. <i>Translational Pediatrics</i> , 2023, 12, 429-444.	0.5	0
2827	Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis. <i>Hepatology</i> , 0, Publish Ahead of Print, .	3.6	5
2828	The potential of integrating human and mouse discovery platforms to advance our understanding of cardiometabolic diseases. <i>ELife</i> , 0, 12, .	2.8	3
2829	Uncarboxylated Osteocalcin Decreases SCD1 by Activating AMPK to Alleviate Hepatocyte Lipid Accumulation. <i>Molecules</i> , 2023, 28, 3121.	1.7	4
2830	Association between nonalcoholic fatty liver disease and atrial fibrillation and other clinical outcomes: a meta-analysis. <i>Journal of Investigative Medicine</i> , 2023, 71, 591-602.	0.7	5
2831	Development and validation of a novel non-invasive test for diagnosing nonalcoholic fatty liver disease in Chinese children. <i>World Journal of Pediatrics</i> , 0, , .	0.8	2
2832	Tussilagone ameliorates high-fat diet-induced hepatic steatosis by enhancing energy metabolism and antioxidant activity. <i>Phytotherapy Research</i> , 0, , .	2.8	0
2833	Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
2834	New murine model of alcoholic hepatitis in obesity-induced metabolic-associated fatty liver disease. <i>Experimental Animals</i> , 2023, 72, 389-401.	0.7	1
2835	Dysregulation of murine long non-coding single cell transcriptome in non-alcoholic steatohepatitis and liver fibrosis. <i>Rna</i> , 0, , rna.079580.123.	1.6	2
2836	The future of hepatology. <i>Hepatology</i> , 2023, 78, 637-648.	3.6	1
2837	Serum Cardiotrophin-1 Concentration Is Negatively Associated with Controlled Attenuation Parameters in Subjects with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 2741.	1.0	0
2838	Expansion of macrophage and liver sinusoidal endothelial cell subpopulations during non-alcoholic steatohepatitis progression. <i>IScience</i> , 2023, 26, 106572.	1.9	3

#	ARTICLE	IF	CITATIONS
2839	Comorbidities and Malignancy among NAFLD Patients Compared to the General Population, A Nation-Based Study. <i>Biomedicines</i> , 2023, 11, 1110.	1.4	1
2840	Fatty Liver Disease. , 2024, , 330-401.		1
2841	Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes. <i>JHEP Reports</i> , 2023, 5, 100753.	2.6	5
2842	Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. <i>Journal of Hepatology</i> , 2023, 79, 287-295.	1.8	43
2843	Curcumin preconditioned mesenchymal stem cells derived exosomes transplantation ameliorate and protect against non- alcoholic steatohepatitis by regulation the expression of key genes of inflammation and oxidative stress. <i>Transplant Immunology</i> , 2023, 78, 101837.	0.6	6
2844	Fatty Liver Disease in Patients with Prediabetes and Overweight or Obesity. <i>Metabolites</i> , 2023, 13, 531.	1.3	1
2845	Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression. <i>Hepatology</i> , 2023, 78, 1209-1222.	3.6	2
2846	The complex link between non-alcoholic fatty liver disease and type 2 diabetes mellitus. <i>Medic Ro</i> , 2023, 1, 32.	0.0	0
2847	Association of serum folate with prevalence of non-alcoholic fatty liver disease among adults (NHANES 2011â€“2018). <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	3
2848	A transcriptomic intratumour heterogeneity-free signature overcomes sampling bias in prognostic risk classification for hepatocellular carcinoma. <i>JHEP Reports</i> , 2023, 5, 100754.	2.6	2
2849	In vitro to in vivo extrapolation and high-content imaging for simultaneous characterization of chemically induced liver steatosis and markers of hepatotoxicity. <i>Archives of Toxicology</i> , 0, , .	1.9	1
2850	Tilianin alleviates lipid deposition and fibrosis in mice with nonalcoholic steatohepatitis by activating the PPAR α /Nnat axis. <i>Drug Development Research</i> , 0, , .	1.4	0
2851	FXR and NASH: an avenue for tissue-specific regulation. <i>Hepatology Communications</i> , 2023, 7, .	2.0	8
2852	EFFECT OF INTERMITTENT FASTING ON CARBOHYDRATE, LIPID AND ULTRASONOGRAPHIC PARAMETERS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND PREDIABETES. <i>WiadomoÅci Lekarskie</i> , 2023, 76, 520-526.	0.1	0
2854	Higher intakes of lysine, threonine and valine are inversely associated with non-alcoholic fatty liver disease risk: a community-based case-control study in the Chinese elderly. , 2024, 13, 191-197.		3
2855	Identification of Ubr1 as an amino acid sensor of steatosis in liver and muscle. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2023, 14, 1454-1467.	2.9	1
2856	Circulating Interlukin-32 and Altered Blood Pressure Control in Individuals with Metabolic Dysfunction. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7465.	1.8	4
2857	Gene Therapy Based on Mesenchymal Stem Cells Derived from Adipose Tissue for the Treatment of Obesity and Its Metabolic Complications. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7468.	1.8	5

#	ARTICLE	IF	CITATIONS
2858	Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL). <i>Molecular Metabolism</i> , 2023, 73, 101728.	3.0	6
2859	Evaluation of the registry DIALYREG for the assessment of continuous renal replacement techniques in the critically ill patient. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
2860	Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes. <i>World Journal of Hepatology</i> , 0, 15, 477-496.	0.8	2
2861	Association between hypertension and the prevalence of liver steatosis and fibrosis. <i>BMC Endocrine Disorders</i> , 2023, 23, .	0.9	1
2862	Postprandial dysfunction in fatty liver disease. <i>Physiological Reports</i> , 2023, 11, .	0.7	4
2863	Low Normal Thyroid Function Is Not Associated with Either Non-Alcoholic Fatty Liver Disease or with Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Life</i> , 2023, 13, 1048.	1.1	0
2864	Dihydrotrichodimerol Purified from the Marine Fungus <i>Acremonium citrinum</i> Prevents NAFLD by Targeting PPAR α . <i>Journal of Natural Products</i> , 0, , .	1.5	1
2865	Nutritional and Lifestyle Therapy for NAFLD in People with HIV. <i>Nutrients</i> , 2023, 15, 1990.	1.7	1
2866	Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	4
2867	Labeled breath tests in patients with NASH: Octanoate oxidation relates best to measures of glucose metabolism. <i>Frontiers in Physiology</i> , 0, 14, .	1.3	0
2868	Effect of Exercise on Liver Function and Insulin Resistance Markers in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2023, 12, 3011.	1.0	1
2869	Schisandra lignans ameliorate nonalcoholic steatohepatitis by regulating aberrant metabolism of phosphatidylethanolamines. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 3545-3560.	5.7	1
2882	Nonalcoholic Steatohepatitis (NASH). , 2023, , 95-103.		0
2950	<i>Endocrine</i> . , 2023, , 107-203.		0
2956	Editorial: Reviews in gastroenterology. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
2967	Meta-analysis of the association between major foods with added fructose and non-alcoholic fatty liver disease. <i>Food and Function</i> , 2023, 14, 5551-5561.	2.1	1
2971	The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities. <i>Hepatology</i> , 2023, 78, 1020-1022.	3.6	0
3002	Editorial: Herbal medicines for gastrointestinal and hepatic diseases - novel pharmacological and toxicological approaches, Volume I. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0

#	ARTICLE	IF	CITATIONS
3018	Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approaches. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
3050	Zwitterionic mesoporous engineering aids peptide-dependent pattern profiling for identification of different liver diseases. <i>Chemical Communications</i> , 0, , .	2.2	1
3079	Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia. <i>Sports Medicine</i> , 2023, 53, 2347-2371.	3.1	2
3113	Fatty acid composition but not quantity is an important indicator of non-alcoholic fatty liver disease: a systematic review. <i>European Journal of Clinical Nutrition</i> , 2023, 77, 1113-1129.	1.3	1
3115	A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials. <i>Journal of Endocrinological Investigation</i> , 2024, 47, 761-776.	1.8	1
3120	Nonalcoholic Fatty Liver Disease Versus Metabolic Associated Fatty Liver Disease. , 2023, , 9-17.		0
3123	Practical Clinical Cases in Nonalcoholic Fatty Liver Disease. , 2023, , 255-267.		0
3127	Extracellular Vesicles and Fatty Liver. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 129-141.	0.8	1
3132	Editorial: Metabolism in nonalcoholic fatty liver disease. <i>Frontiers in Physiology</i> , 0, 14, .	1.3	0
3154	Metabolomics of Gastrointestinal Cancers. , 2023, , .		0
3185	Non-alcoholic Fatty Liver Disease. , 2023, , 1-17.		0
3190	Data-Driven Classification of Fatty Liver From 3D Unenhanced Abdominal CT Scans. <i>Lecture Notes in Computer Science</i> , 2024, , 264-272.	1.0	0
3246	Quantitative imaging through the production chain: from idea to application. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2023, 36, 851-855.	1.1	0
3298	22.ÂChronic Liver Disease. , 2023, , .		0
3310	Combined Weights LSTM-Based Deep Learning System for Predicting CVDS in NAFLD Patients. , 2023, , .		0
3323	Functional Food Chemical Ingredient Strategies for Non-alcoholic Fatty Liver Disease (NAFLD) and Hepatic Fibrosis: Chemical Properties, Health Benefits, Action, and Application. <i>Current Nutrition Reports</i> , 2024, 13, 1-14.	2.1	0
3354	Assessment of a liver graft. , 2024, , 91-100.		0
3373	Non-alcoholic Fatty Liver Disease. , 2023, , 567-583.		0

#	ARTICLE	IF	CITATIONS
3394	Editorial: New Perspectives on Hepatic Steatosis. Journal of Clinical and Experimental Hepatology, 2024, 14, 101359.	0.4	0